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ABSTRACT
A number o f mouse genetic mutants develop neural tube defects (NTDs). In some cases, defects can 
be prevented by administration of folic acid during pregnancy, whereas in other mutants there is no 
response. This parallels the human situation in which a proportion of NTDs appear resistant to folic 
acid therapy. Curly tail is the best characterised mouse model o f folic acid-resistant NTDs. 
Previously it was shown that the incidence o f spina bifida in curly tail mice can be reduced by 
administration o f inositol during embryonic development. In this thesis, I compared the 
effectiveness of two isomers, myo- and D-chiro-inositol, with administration either directly to 
embryos in vitro, or to pregnant females by subcutaneous or oral routes. Although both inositols 
exerted a preventive effect on spina bifida, by all routes o f administration, D-chiro-inositol 
consistently exhibited greater potency than myo-inositol. The protective effect o f inositol has been 
shown previously to be mediated through the activity of the inositol/lipid cycle and to depend on 
downstream activation of protein kinase C (PKC). In the studies decscribed in this thesis, I 
examined the role of PKC in more detail. The expression o f PKC isoforms was first examined by 
immunohistochemistry, Broad spectrum chemical inhibitors were then used in whole embryo 
culture to confirm that one or more PKC isoforms are indispensable for normalisation o f neural tube 
closure by inositol. Specific peptide inhibitors were then applied, and revealed that PKC beta I, 
gamma and zeta are most important in the protective pathway. Finally, I demonstrated that inositol 
stimulates cell proliferation in the hindgut of curly tail embryos, reversing the imbalance of cell 
proliferation that is known to lead, via enhanced ventral curvature of the caudal region, to delay or 
failure o f neural tube closure.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 INTRODUCTION
The formation of the vertebrate nervous system begins at gastrulation when, during neural 
induction, a subset of ectodermal cells segregates and thickens to form the neural plate. 
Soon afterwards, the neural plate undergoes a series of morphogenetic events that ends 
with the formation o f a hollow neural tube characteristic of the chordate phylum, this 
process being known as neurulation. Impairment of neurulation leads to a range of 
anomalies known as neural tube defects (NTDs) that are among the commonest 
congenital malformations in humans.
The embryonic process of neurulation has been well characterised morphologically in 
different animal systems (Schoenwolf, 1985,Shum and Copp, 1996;Colas and 
Schoenwolf, 2001). Some of the genetic pathways controlling this programme have been 
identified from the large number of mouse mutants that display NTDs (Juriloff and 
Harris, 2000;Copp et al., 2003). However, the underlying molecular mechanisms are still 
largely unknown.
1.2 THE NORMAL PROCESS OF NEURULATION
Neurulation is divided into two parts: primary and secondary neurulation. Primary 
neurulation results in the formation of the cranial neural tube and the upper spinal cord 
rostral to the mid-sacral region, through a process that involves the specification and 
shaping of the neural plate, followed by the elevation and fusion o f the neural folds 
(Criley, 1969). Initially, the neural plate becomes specified by the underlying mesoderm 
and is transformed into a pseudo-stratified columnar epithelium that thickens 
apicobasally. The edges of the columnar epithelium elevate to form the neural folds that
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converge in the dorsal midline and fuse, forming the neural tube. Once primary 
neurulation has occurred and the neural tube has closed, secondary neurulation takes 
place caudally to the mid-sacral region. At this axial level, the neural tube forms by 
condensation of mesenchymal cells within the tail bud region which forms an epithelium 
that subsequently cavitates, forming the secondary neural tube (Schoenwolf, 1984;Copp 
and Brook, 1989). Secondary neurulation is a separate autonomous process in relation to 
primary neurulation, at least in the chick embryo, where if  primary neurulation is 
disrupted experimentally secondary neurulation still occurs normally (Costanzo et al., 
1982).
1.2.1 Primary neurulation occurs in a cranio-caudal sequence
During primary neurulation in the mouse embryo, closure o f the neural tube starts at three 
different initiation sites, in a cranio-caudal sequence along the body axis (Fig 1.1) 
(MacDonald et al., 1989;Copp et al., 1990;Golden and Chemoff, 1993). The first 
initiation site, Closure 1, occurs in the mouse embryo at the 4-6 somite stage with closure 
occurring at the cervical/hindbrain region and continuing in a zippering-like fashion 
caudally along the future spine and rostrally into the hindbrain. By the 12 somite stage, a 
second site of closure, Closure 2, occurs at the forebrain/midbrain boundary and proceeds 
caudally into the midbrain and rostrally into the forebrain. At about the same somite 
stage, a third site of closure, Closure 3, occurs at the rostral extremity of the 
prosencephalon, and proceeds caudally towards the midbrain. As a result of these three de 
novo sites of closure, three neuropores become apparent. The anterior neuropore (within 
the forebrain, formed by closure progression from Closures 2 and 3) closes at 
approximately the 17 somite stage. Soon afterwards, the hindbrain neuropore (formed by 
progression from Closures 1 and 2) closes, and the zippering mechanism initiated at
24
Closure 1 spreads caudally, resulting in the closure o f the posterior neuropore at the 29 
somite stage.
The developmental stage and exact position in which the events of neurulation take place 
vary between mouse strains (Juriloff et al., 1991). Hence, the site of Closure 2 is 
polymorphic between mouse strains and its position confers susceptibility to cranial 
neural tube defects (Fleming and Copp, 2000).
Hindbrain
neuropore
Anterior neurflpore
Posterior
Neuropore
Closure 1
Figurel.l Initiation sites of neural tube closure
Diagram to illustrate the three sites of the neural tube closure and the three neuropores 
during primary neurulation. From Copp (1994)
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1.2.2 The spectrum of NTDs depends on which of the events of neurulation fail to be 
completed
The spectrum o f NTDs depends on which of the de novo closure sites or neuropore 
closures fail to be completed (Fig. 1.2)(Copp and Bemfield, 1994). Hence, failure of 
initiation of Closures 2 and 3 or incomplete closure o f the anterior or hindbrain 
neuropores leads to an open cranial neural tube termed exencephaly. The second type of 
NTD, lumbosacral spina bifida results from failure of the posterior neuropore to complete 
closure. The size and severity o f the lesion depends upon the axial level where closure 
failed. Hence if  closure stops at a more rostral level these results in a more severe 
phenotype. Cranial NTDs and spina bifida can occur independently or in combination, in 
humans and in mouse. Failure o f initiation of Closure 1 causes craniorachischisis, the 
most severe form of NTD, in which the hindbrain and spinal neural tube remain open 
(Fig. 1.2). In the mouse models that display craniorachischisis, Closures 2 and 3 occur, 
and development of the forebrain and rostral midbrain appear normal (Greene et al., 
1998;Murdoch et al., 2001). These observations indicate that the genetic regulation of 
Closure 1 differs from that of Closures 2 and 3.
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Exencephaly  ----------------
ct/cL
Lumbosacral spina bifida’
Closure 2
Hindbrain
neuroporeAnterior
neuropore
Closure 3 Closure 1
Posterior
Craniorachischisis
Figure 1.2 The three main subtypes of NTDs
Diagram to illustrate exencephaly, craniorachischisis and lumbosacral spina bifida, which 
result from failure of closure initiation events or from failure of each neuropore to 
complete closure (arrows). The embryo on the left shows exencephaly (E) and 
lumbosacral spina bifida (S) whilst the embryo on the right shows craniorachischisis 
(diagram modified from A. (Copp and Bemfield, 1994)).
The neural folds form by elevation and bending of the lateral edges of the neural plate at 
either side of the midline. The morphology that the neural plate acquires during closure 
differs in the cranial and spinal neural tube. In the midbrain region of the cranial neural 
tube, the neural folds initially adopt a biconvex shape as they elevate. Subsequently, the 
lateral edges bend inwards to form the dorsolateral hinge points (DLHPs), which bring 
the apices of the neural folds into apposition at the dorsal midline (Morriss-Kay, 
1981;Morriss-Kay et al., 1994).
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1.3 Morphological changes during primary neurulation: convergent-extension, 
elevation, bending and apposition
(A-B) Oblique and dorsal images of a 6-8-somite-stage embryo showing the initiation 
neural tube closure (Closure 1) at the level of the future hindbrain-cervical junction 
(arrows). (C-E) Three views of the head of a 12 to 16-somite-stage embryo showing the 
second point of closure (Closure 2) at the level of the forebrain-midbrain junction (arrow) 
and a third point of closure (Closure 3) at the rostral end of the neural tube (arrowhead). 
(F) The posterior neuropore at the caudal extremity of the neural tube. Closure of the 
spinal neural tube proceeds from the hindbrain-cervical junction caudally and eventually 
closes the posterior neuropore at the 29 somite-pair stage, (h) heart. (Photography by Dr 
K Tosney)
As the wave of spinal neural tube closure spreads down the body axis, the morphology of 
the neural plate at the spinal cord region changes in a stereotypic fashion (Shum and 
Copp, 1996). Three distinct morphologies (named Modes of neurulation) have been
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reported, from the cross-sectional appearance of the neural plate at different axial levels 
(Fig. 1.3; 1.4). In Mode 1 spinal neurulation, which is seen in the closing posterior 
neuropore at the 7-15 somite stage, the neural plate bends medially forming the median 
hinge point (MHP), whilst the lateral edges elevate with straight sides and the neural folds 
approach each other in the dorsal midline, closing the neural tube to form a slit-like 
lumen.
At the 16-24 somite stage, when Mode 2 spinal neurulation occurs, the neural plate bends 
not only at the midline, forming the MHP, as in Mode 1, but the dorsal region of each 
neural fold also bends forming the dorso-lateral hinge points (DLHPs). DLHPs cause the 
tips o f the neural folds to appose in the dorsal midline yielding a closed neural tube with a 
diamond shaped lumen. At the 25-30 somite stage, in Mode 3 of spinal neurulation, the 
neural plate does not form a MHP, whereas DLHPs are prominent, closing the neural tube 
to form a circular shaped lumen. These stereotypical changes in morphology o f the spinal 
neuroepithelium as it closes to form the neural tube have been observed in mouse 
neurulation. In other systems, such as the chick, DLHP formation occurs in the hindbrain 
region, but apparently not in the caudal neural tube, demonstrating differences between 
these species (Schoenwolf, 1985)
1.3 NTDS IN HUMANS 
1.3.1Types of NTDs in humans
NTDs are among the commonest congenital malformation in humans with an average 
prevalence o f 1:1000 live births worldwide (Edmonds and James, 1993). Human NTDs 
can be divided into open and closed defects. Open NTDs result from failure of the neural 
tube to close during primary neurulation, whilst closed NTDs result from aberrant
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secondary neurulation and abnormal axial skeleton development (Lemire, 1988). As in 
mouse, open NTDs can be grouped depending on which event of closure fails to occur 
(Van Allen et al., 1993). Exencephaly, open neural tube in the cranial region, can be sub­
grouped into three classes. Rostrally, failure of closure 3 at the forebrain region with 
facial clefting leads to anencephaly. Failure of Closure 2, results in an open midbrain- 
hindbrain and is named holocrania, whilst failure of closure of the hindbrain neuropore 
results in merocrania.
As in mouse, spina bifida results from failure o f closure of the PNP resulting in an open 
caudal neural tube that can be exposed (myelocele) or covered by meninges 
(myelomeningocele). Craniorachischisis is the most severe NTD, and the neural tube 
remains open along almost the entire rostro-caudal axis.
Neurulation in humans starts at 17-18 days post fertilisation and ends by 26-28 days after 
fertilisation with closure of the PNP (Campbell et al., 1986). In humans, as in mouse, the 
initiation of neural tube closure is discontinuous (Van Allen et al., 1993), and sites of 
initiation equivalent to Closure 1 and Closure 3 have been described (Golden and 
Chemoff, 1995;Juriloff and Harris, 2000), although some studies do not identify Closure 
2 (O'Rahilly and Muller, 2002). Humans undergo secondary neurulation in the low sacral 
and coccygeal regions. Despite failure in neural tube closure, neural differentiation and 
nerve connections can occur (Campbell et al., 1986). However tissue exposure to the 
amniotic fluid results in degeneration of the open neural tube leading to musculoskeletal, 
gastrointestinal and urinary dysfunction often associated with NTDs in patients (Stark, 
1977).
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Figure 1.4 Diagram to illustrate the morphology of the neural plate during
progressive closure of the posterior neuropore
Mode 1 is characterised by formation of a MHP with straight neural folds apposing each 
other. In Mode 2 of neurulation the neural plate bends medially to form the MHP and, 
dorsally, the neural folds bend bilaterally to form the DLHPs. In Mode 3 of neurulation, 
closure is solely dependent on DLHPs. Diagram modified from Ybot-Gonzalez (2001)
As in mouse, spina bifida results from failure of closure of the PNP resulting in an open 
caudal neural tube that can be exposed (myelocele) or covered by meninges
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(myelomeningocele). Craniorachischisis is the most severe NTD, and the neural tube 
remains open along almost the entire rostro-caudal axis.
1.3.2 Multifactorial aetiology of human NTDs
Human NTDs have multifactorial aetiology, involving genetic and environmental factors 
(Campbell et al., 1986;Copp and Bemfield, 1994;Juriloff et al., 2001). The most 
important environmental factors are geography, maternal age, socio-economic class, 
maternal diet and illness (Campbell et al., 1986).
The relationship between prevalence of NTDs and geography is noticeable. For instance, 
prevalence of NTDs is higher in the north west of England than in the south east (Carter, 
1974). A correlation has also been found between the month of conception and 
prevalence of NTDs. Maternal age is also important in prevalence of NTDs since the 
majority of affected children are bom to mothers under 20 years or over 35 years of age. 
Several studies have shown an association between socio-economic class and the 
prevalence o f NTDs, the prevalence being higher in poor socio-economic backgrounds. 
This observation prompted investigations of the effects of diet in relation to the 
prevalence of NTDs. Indeed, supplementing mothers with folic acid or multivitamins has 
been shown to lead to a reduction in the prevalence of NTDs (Wald et al., 1991;Czeizel 
and Dudas, 1992). A correlation has also been found between maternal illness, including 
higher fever, during the first month of pregnancy and an increase in the risk of NTDs.
The genetic component of NTDs is supported by family studies showing that siblings of 
affected individuals have a ten times greater risk of NTDs than the background 
prevalence (Campbell et al., 1986). In addition, an increased risk is observed in offspring 
of affected parents (Blatter et al., 1997). However, the inheritance of NTDs does not
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follow a pattern of single-gene inheritance, but rather suggests multigenic inheritance 
with strong environmental influence (Campbell et al., 1984;Juriloff and Harris, 2000). 
These factors have made the identification of genes for human NTDs difficult. In some 
cases a mutation in a gene that could be responsible for the NTD phenotype has been 
found in a patient but also in unaffected relatives, indicating that the mutation may confer 
susceptibility but is not causative for NTDs. Moreover some of the genetic studies do not 
take into consideration the phenotypical spectrum of NTDs, and look for linkage or 
causative mutations within a group o f heterogeneous NTDs: spina bifida, exencephaly 
and craniorachischisis, without considering that specific genes may regulate just one 
aspect of neural tube closure. For instance, targeted disruption of Msx2 has been shown to 
cause exencephaly in mice (Liu et al., 1995) and this prompted an investigation to 
determine whether mutations in MSX2 in humans could also cause NTDs (Stegmann et 
al., 2001). The study concluded that, despite identifying one deletion in one patient from 
204 NTD cases, there was no statistical significance for the implication of MSX2 in 
human NTDs. However from the 204 patients with NTD analysed, only 13 displayed 
cranial NTDs (also including craniorachischisis). Hence, this study included only a very 
small cranial NTD sample (Stegmann et al., 2001), despite this phenotype being most 
likely A/sx2-related based on the mouse studies.
Mutations in the PAX3 gene have been found in patients with NTDs (Hoi et al., 1995). 
However, a second population study using 194 people including 50 NTD cases failed to 
find an association between the PAX3 and NTDs (Chatkupt et al., 1995). A mutation in 
SLUG, a zinc finger transcription factor involved in neural crest development, was found 
in a patient with NTD. Moreover, the mutation was not present in unaffected individuals 
raising the possibility that SLUG could be causative of the NTD observed in this patient
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(Stegmann et al., 1999). A mutation in PAX1 was detected in a single patient with spina 
bifida, suggesting that this gene can also act as a susceptibility factor (Joosten et al., 
1998).
Further genetic studies have centred on identifying mutations in enzymes that act in the 
folic acid pathway. The importance of folic acid in NTDs comes from studies indicating a 
protective effect o f folic acid administration during the periconceptional period (Wald et 
a l, 1991). This prompted studies to identify mutations in genes that participate in the 
biochemical pathways involving folic acid, which may confer susceptibility to NTDs. A 
polymorphism in the 5,10-methylene-tetrahydrofolate reductase gene (MTHFR) has been 
found to confer a two-fold increased risk of NTDs in some populations (Van der Put et 
al., 1995) (Botto and Mastroiacovo, 1998), although there is no association with NTDs in 
other populations. MTHFR encodes an enzyme that catalyses the conversion of 5,10- 
methyl-tetrahydrofolate to 5-methylene-tetrahydrofolate. Homozygous individuals for the 
C677T polymorphism are predisposed to mild hyperhomocysteinemia when their folate 
status is low. The precise mechanism that confers susceptibility to NTDs in individuals 
homozygous for C677T is unknown.
1.4 THE EMBRYONIC PROCESS OF SPINAL NEURULATION
After Closure 1 has occurred at the cervical-hindbrain region, closure of the spinal neural 
tube continues caudally forming the posterior neuropore. Failure o f the posterior 
neuropore to complete closure leads to spina bifida. The embryonic mechanism that 
controls closure of the posterior neuropore can be autonomous to the neural plate 
(intrinsic forces) or non-autonomous to the neural plate (extrinsic forces) (Smith and 
Schoenwolf, 1997;Colas and Schoenwolf, 2001;Copp et al., 2003).
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1.4.1 Intrinsic forces control morphogenesis of the neural plate
As spinal neurulation progresses along the body axis the neural plate bends at specific 
dorsoventral locations (Fig. 1.4). The MHP forms in contact with the notochord and the 
DLHPs form bilaterally in contact with the surface ectoderm (Shum and Copp, 
1996;Ybot-Gonzalez et al., 2002). Bending in these regions has been suggested to be 
mediated by intrinsic forces so that the behaviour of neuroepithelial cells changes 
compared to those in the non-bending regions. Indeed, morphological studies in the chick 
revealed that the neuroepithelial cells can adopt one of three types of morphology: 
spindle-shape, wedge-shape and inverted wedge-shape (Smith et al., 1994). In the MHP 
and DLHP, the majority of cells acquire a wedge-shape morphology which results from 
an expansion o f the basal surface of the cell compared to its apical surface. In contrast, in 
the non-bending regions, spindle-shape cells and inverse-wedge (apically expanded)cells 
are in the majority (Smith et al., 1994). Two different mechanisms have been proposed 
that result in cell wedging: constriction of apical microfilaments and changes in the cell 
cycle.
1.4.1.1 Constriction of apical microfilaments
A pseudostratified epithelium will bend if its apical surface area is reduced with respect to 
its basal surface area. The reduction in apical surface area has been proposed to be 
mediated through the constriction of apical containing microfilaments in a purse-string 
fashion (see Fig. 1.5)(Karfunkel, 1974;Nagele and Lee, 1980;Sadler et al., 1982). Indeed, 
microfilaments and cytoskeleton-associated proteins, such as actin, MARCKS, vinculin, 
spectrin and Shroom are localised apically during neural plate morphogenesis (Nagele 
and Lee, 1980;Sadler et al., 1982;Stumpo et al., 1995b;Xu et al., 1998;Ybot-Gonzalez and 
Copp, 1999;Hildebrand and Soriano, 1999;Haigo et al., 2003).
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To test experimentally the function of the cytoskeleton in neurulation, actin microfilament 
polymerisation was disrupted in embryo culture using cytochalasins and calcium 
chelating agents (Morriss-Kay and Tuckett, 1985;Ybot-Gonzalez and Copp, 1999). In 
these experiments cranial neural tube closure was inhibited, whilst spinal neural tube 
closure occurred relatively normally, indicating that cytoskeletal integrity is required for 
cranial neurulation whilst its loss is not prohibitive for spinal neural tube closure (Ybot- 
Gonzalez and Copp, 1999). However treatment of embryos with cytochalasin D prior to 
Closure 1 inhibited this closure site, resulting in a craniorachischisis-like phenotype 
(Ybot-Gonzalez and Copp, 1999). It appears then that initiation of closure is dependent 
on the actin cytoskeleton but once Closure 1 has occurred, disruption of the actin 
cytoskeleton does not affect the continuation and completion of spinal neural tube 
closure.
0 0 0
o
Apical constriction
Figure 1.5 Constriction of apical filaments and bending of neural plate
Diagram to illustrate how constriction of apical microfilaments could generate bending of 
the neuroepithelium by constricting the apical surface area with respect to the basal 
surface area.
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This observation is partially supported by the finding that mouse mutants for cystokeletal 
or putative cytoskeletal dynamics proteins exhibit exencephaly but generally not spina 
bifida (Copp et al., 2003). For instance, null embryos for MARCKS, the actin-binding 
protein vinculin, compound mutants for the Abl and Arg tyrosine kinases or for the 
protein kinase a subunits CalCfil all display exencephaly but not spina bifida (Stumpo et 
al., 1995b;Koleske et al., 1998;Xu et al., 1998;Huang et al., 2002). This supports the idea 
that cytoskeletal integrity is more important for cranial neurulation than spinal 
neurulation. However, it could also indicate that these genes are not expressed in the 
lower spinal regions, which would explain the lack of spina bifida in these mutants. 
Indeed, two mutants for cytoskeleton-related proteins, Shroom and MARKS-related (also 
called MacMARCKS) protein, develop spina bifida at low frequency (Wu et al., 
1996;Hildebrand and Soriano, 1999). Interestingly, Shroom has been shown to be 
required for apical microfilament constriction in polarised epithelial cells and to regulate 
hinge point formation in Xenopus (Haigo et al., 2003). More studies are required to rule 
out a critical role for the actin cytoskeleton during mouse spinal neurulation and to 
establish whether the cytoskeleton functions simply to stabilise the neural plate once 
bending has occurred.
1.4.1.2 Cell wedging mediated through changes in the cell cycle
The neuroepithelium consist of a single pseudostratified cell layer in which the nucleus of 
each cell migrates from the basal surface to the apical surface and back to the basal 
surface, a phenomenon known as interkinetic nuclear cell migration (Langman et al., 
1967). Studies in chick embryos have shown that the positioning of the nucleus, from 
basal to apical, is linked to the cell cycle (Smith and Schoenwolf, 1987). Hence, during 
mitosis, nuclei are localised at the apical surface generating inverse wedge-shape cells,
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during G1 and G2 phases they are located between the apical and basal surfaces, creating 
a spindle-shape, and in S phase, they are located basally, generating wedge-shape cells. If 
a sizeable subset of cells have their nuclei in a basal position, this can potentially generate 
a neuroepithelial bend, by increasing the basal surface^rca respective to the apical 
surface area. Indeed, cells that form the MHP are mostly wedge-shaped and have a longer 
cell cycle S phase and a shorter M phase than cells outside the MHP (Smith and 
Schoenwolf, 1987;Smith and Schoenwolf, 1988). Hence, localised changes in the 
neuroepithelial cell cycle can generate specific sites of bending of the neural plate (see 
Fig. 1.6). These observations have been shown for the MHP in chick and mouse embryos. 
A similar mechanism could account for bending at the DLHP, although this has not been 
proven yet.
1.4.2 Extrinsic forces drive spinal neurulation
During neurulation the neuroepithelium is in contact with the surface ectoderm, the 
endoderm and the mesoderm. Changes in cell shape and/or cell number in these tissues 
could provide extrinsic forces that might assist neural plate folding (Schoenwolf, 1985). 
To test this hypothesis tissue isolation experiments in chick and mouse embryos, where 
the lateral mesoderm and endoderm tissues are removed, have been performed and result 
in normal folding o f the spinal neural plate (Alvarez and Schoenwolf, 1992; Van Straaten 
et al., 1993;Ybot-Gonzalez et a l , 2002). However, if  the surface ectoderm is removed, 
the neural plate fails to bend dorsolaterally in both chick and mouse resulting in an open 
neural tube (Alvarez and Schoenwolf, 1992;Ybot-Gonzalez et al., 2002). This indicates 
that, o f all the lateral tissues, only the surface ectoderm is necessary for formation o f 
DLHPs. One hypothesis to explain the extrinsic role of the surface ectoderm has been 
formulated from experiments in chick embryos, which suggested that medial expansion of
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the surface ectoderm through convergent extension movements could potentially provide 
the force that brings the paired neural folds together (Alvarez and Schoenwolf, 1992).
However, if the neural folds are dissected from the mesoderm and endoderm and only a 
small fragment of the surface ectoderm is left intact in contact with the neural fold, 
closure of the neural tube still occurs with the presence of DLHPs (Ybot-Gonzalez et al., 
2002). Therefore, whilst the surface ectoderm could mediate a pushing force at early 
stages, it seems unlikely that this process functions during Mode 2 and Mode 3 of 
neurulation, and rather the surface ectoderm may be required to signal to the underlying 
neural folds to form the DLHPs.
DLHP
MHP
Figure 1.6. Diagram to illustrate the cell cycle-dependent position of the nucleus in 
formation of bending regions in a transverse section through the PNP
In the neural plate, cells undergo interkinetic nuclear migration, such that the nucleus is 
located apically during mitosis (M) and basally during S-phase (S). When the nucleus is 
in a basal or apical position the cell acquires a wedge or inverted wedge shape
%
respectively. In the median hinge point (MHP), an increased proportion of cells is in S- 
phase with basally located nuclei. The increase in number of wedge shaped cells in the
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ventral midline of the neural plate appears to create the MHP. Cell cycle variations 
resulting in cell wedging could also regulate DLHPs, although this has not studied in 
detail.
Whilst the mesoderm and endoderm are not required for DLHP formation, these tissues 
are nevertheless important for neurulation, since an imbalance of cell proliferation within 
these tissues can affect spinal neural tube closure. For example, an increase in axial 
curvature is seen in affected curly tail mutant embryos due to an imbalance in cell 
proliferation in the hindgut endoderm and notochord, which results in increased axial 
curvature and delay or failure of posterior neuropore closure (Brook et al., 1991c;Van 
Straaten et al., 1993). In curly tail, bending at the DLHPs and MHP occurs normally, 
whereas the increase in axial curvature results in strain on the neural folds that impedes 
meeting at the dorsal midline. This has also been observed in the chick, where delay in 
closure was achieved by culturing embryos on a convex surface which led to an increase 
in axial curvature (Van Straaten et a l , 1993).
1.4.3 Fusion of the neural folds
After apposition, the neural folds fuse in the dorsal midline to form the neural tube. The 
surface ectoderm of each neural fold loses its continuity with the neuroepithelium, and 
closes over the top of the neural tube to form the epidermis. Fusion of the neural folds has 
been proposed to be mediated by cell protrusions, lamelipodia, extending from the 
apposing cells (Geelen and Langman, 1979). Lamelipodia structures have been observed 
by scanning electron microscopy on the luminal surface of the neural plate and at the 
edges of the surface ectoderm (Geelen and Langman, 1979). However, the molecules 
involved in cell to cell recognition have not been studied during closure of the spinal 
neural tube. Carbohydrate-rich material localised at the tips of the neural folds has been
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suggested to assist fusion by increasing the adhesiveness of the neural folds (Moran and 
Rice, 1975) (Sadler, 1978). Indeed, embryos cultured with phospholipase C to remove 
carbohydrate material exhibit delayed neural tube closure (O'Shea and Kaufman, 1980). 
However, the observed phenotype could be due to enzymatic removal of 
glycosylphophatidylinositol-anchored (GPI) proteins, including cell adhesion molecules. 
More studies are needed to understand the role of adhesion molecules in spinal 
neurulation.
1.5 MOUSE GENETIC MODELS OF NEURAL TUBE DEFECTS
To date more than 80 genes that cause NTDs in mice have been identified by positional 
cloning, gene targeting or gene trap screens (Juriloff and Harris, 2000;Copp et al., 
2003;Harris and Juriloff, 2007a). Despite the identification of a large number of genes 
required for neurulation, in most cases the embryonic mechanisms leading to NTDs in 
each individual mutant are not well characterised. The number of mouse mutants that 
display exencephaly is greater than the number with spina bifida, perhaps indicating 
greater complexity of genetic regulation of cranial neural tube closure. The identification 
of these “NTDs genes” provides a tool to determine the molecular pathways that regulate 
neurulation. For instance, the planar cell polarity pathway is now known to regulate 
Closure 1 (review). In this section I will explain the importance of using mouse models for 
the study of NTDs and I will concentrate on some pathways for which information is 
available from mouse mutants that display spina bifida. The wide range of defects seen in 
the NTD mutants is also found in humans; it is possible, therefore, that each phenotypic 
category o f mutants mimics a subtype o f human NTDs. Today a large number of mouse 
mutants that produce NTDs have been identified ' ' '  (Juriloff and
Harris, 2000;Harris and Juriloff, 2007b).
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1.5.1 Use of mouse models to investigate NTDs
Mouse models offer an alternative to direct study of human NTDs, which is hampered by 
several factors. Human NTDs appear to have a multigenic complex aetiology, with strong 
influence o f environmental factors, such as lifestyle and diet (Campbell et al., 1986;Copp 
and Bemfield, 1994). Moreover, the identification of causative genes for NTDs by 
linkage analysis requires large families, and this represents a difficulty since families with 
large numbers of NTDs are rare. In addition to this, embryological studies using human 
embryos can raise serious ethical issues.
The use o f the mouse represents an excellent model to elucidate the genetic programmes 
controlling NTDs. With the sequence of the mouse genome completed and the 
availability of microsatellite markers for genetic mapping, the identification of the 
mutated genes responsible for NTD phenotypes has become quicker. Moreover, several 
mutagenesis strategies, particularly using chemical mutagenesis, gene trap strategies or 
gene targeting, have begun to make a major contribution to the list o f known NTDs 
genes. Phenotype-driven mutagenesis programmes using chemical mutagens such as 
ethylnitrosourea (ENU) or chlorambucil are available to the scientific community (Justice 
et al., 1999;Nolan et al., 2000;Justice, 2000). This approach, allows the identification of 
new mouse mutations that have a particular phenotype, for instance NTDs. The mutated 
gene must then be identified by positional cloning.
Another type o f mutagenesis is the “gene-trap” strategy, where genes are disrupted by 
vector insertion in ES cells, generating ES-cell clones containing a disrupted gene. This 
strategy has the advantages that large numbers o f genes can be disrupted and then 
identified by a forward-genetic strategy, prior to implantation of ES cells to generate the
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mouse mutant (Skames et al., 1992;Mitchell et al., 2001). The disadvantages of this 
technique include the unpredictable nature of the phenotype caused by the gene trap and 
the necessity for germ-line transmission of the mutated gene in order to generate a mouse 
mutant line.
A further mutagenesis approach is gene targeting that allows precision design o f the type 
of mutation. Hence, deletions, point mutations or insertions can all be achieved. The 
advantage o f gene targeting is that mapping o f the mutated gene is not required. However 
the resulting phenotype is unpredictable and knowledge of the gene structure is required 
to generate the targeted mutant mouse.
The mouse also represents a good experimental tool to investigate the cellular and 
embryological bases o f neurulation. Mouse embryos are easily accessible and can be 
cultured for up to 48 hours in vitro (Copp et al., 1999). Neurulation in mouse takes place 
from the 5 to 29 somite stage during a 48 hour period. Therefore, mouse embryos can be 
cultured throughout the entire neurulation process, allowing experimental manipulation. 
This is important in the study of the effects of teratogenic substances on closure of the 
neural tube as well as the analysis o f vitamin supplementation to prevent NTDs.
1.5.2 Genes in the planar cell polarity pathway regulate Closure 1
Recently, mutations in the planar cell polarity (PCP) pathway genes have been found to 
be responsible for the craniorachischisis phenotype observed in three different mouse 
mutants, loop tail, circletail and crash (Kibar et al., 2001;Murdoch et al., 2001;Curtin et 
al., 2003;Murdoch et al., 2003). Embryos that are homozygous for mutation in Vangl2 
{loop-tail), Scribble {circletail) and Celsrl {crash) display failure of Closure 1 leading to 
craniorachischisis. The other mouse mutants known to display craniorachischisis is the
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Dishevelled 1/2 double knockout (Dshl/2) (Hamblet et al., 2002) and the frizzled 3,6 
double knockout. Embryonic examination shows that at least three of these mutants, loop- 
tail, circletail and Dshl/2 have a similar phenotype to that of Xenopus embryos where 
convergent-extension has been disrupted (Wallingford et al., 2000;Wallingford and 
Harland, 2002). Embryos display shorter body axis, with a broad floor plate and failure of 
the neural tube to close.
Convergent extension movements occur during gastrulation and consist of the migration 
o f cells from a lateral position towards the midline, where they intercalate, resulting in 
lengthening o f the anterior-posterior axis and extension of midline cells anteriorly (Keller 
et al., 1992;Davidson and Keller, 1999). Disruption o f convergent-extension movements 
has not yet been reported in mouse mutants with craniorachischisis but initial studies 
using Dil labelling suggest that convergent extension is disrupted in homozygous loop- 
tail (Lp) embryos ((Ybot-Gonzalez et al., 2007b)). The embryonic mechanism of 
convergent-extension has been studied in Xenopus, where disruption in the PCP pathway 
in the midline results in a broader floor plate or MHP, with formation of the neural folds 
far apart that prevent fusion (Wallingford and Harland, 2002).
Genes that control the PCP pathway, a non canonical-Wnt pathway, have been identified 
in Drosophila to control the polarisation of cells in the plane of the epithelium. This is 
required for example, for the unidirectional array of bristles on the wing and for the 
arrangement of ommatidia in the compound eye (Kiihl et al., 2000;Mlodzik, 2002). The 
PCP pathway shares components of the Wnt pathway, such as the transmembrane 
receptor Frizzled and the downstream effector Dishevelled. However, unlike the Wnt 
pathway, the PCP pathway does not result in stabilisation and nuclear translocation of /3-
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catenin by Dishevelled to control cell proliferation and cell fate decisions. Rather, 
Dishevelled is thought to signal through small GTPases such as RhoA and Rac to regulate 
cytoskeleton assembly and cell motility (Mlodzik, 2002) (Keller, 2002). In support of this 
idea are the experiments in which mouse embryos treated with cytochalasin D before the 
onset of Closure 1 resulted in failure of this closure site, indicating that cell 
rearrangements that control Closure 1 are cytoskeleton-dependent. It is unknown how 
Vangl2, Scribble and Celsrl are related to each other within the PCP pathway.
1.5.3 Sonic hedgehog (Shh) pathway and neural tube closure
The Shh pathway has been implicated in neural tube closure, specifically in regulating the 
formation of DLHPs (Ybot-Gonzalez et a l , 2002). Shh is an extracellular signalling 
protein that regulates a number of embryological processes, such as patterning of the 
neural tube and limbs, cell proliferation and cell-fate determination. Postnatally, aberrant 
Shh signalling pathway has been linked to basal cell carcinomas and medulloblastoma 
tumours (Chiang et al., 1996;Goodrich et al., 1997;Fan et al., 1997;Wechsler-Reya and 
Scott, 1999). The molecular mechanisms underlying the Shh signalling pathway have 
been principally determined by studies in Drosophila (Ruiz i Altaba, 1999). The 
preliminary pathway involves binding of HH to its transmembrane receptor Patched (Ptc), 
which prevents the inhibition of Smoothened (Smo), a transmembrane protein that forms 
part of the HH receptor complex. De-inhibtion of Smo allows signalling to a 
cytoplasmatic protein complex formed by Fused, Costal-2 and Cubitus Interruptus (Cl) 
(Tabin and McMahon, 1997). When Shh is not present, proteolytic processing of Cl 
results in the generation of the shorter Cl N-terminal form that functions as a 
transcriptional repressor of HH downstream genes. Binding of HH to its receptor inhibits 
the Cl proteolysis resulting in the stable full length Cl that functions as a transcriptional 
activator of HH downstream genes. In mouse, Shh, Patched and Gli are the vertebrate
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homologues of Drosophila HH, Patched and CI. In mouse three Gli proteins have been 
identified, Glil, Gli2 and Gli3 that code for zinc finger domain (ZFD) transcription 
factors. In mouse Glil and Gli2 displays a similar function to the full length CI, and acts 
as a transcriptional activator of Shh downstream genes. However, Gli3 has a repressive 
function similar to that of the N-terminal CI (Marigo et al., 1996).
During neurulation, Shh emanating from the notochord functions as a morphogen, to 
pattern the neural tube so that progenitor cells in the ventral region acquire ventral fates 
and become ventral neural types including motor neurons. Mice that are null for Shh 
display a dorsalised neural tube, and dorsal markers such as Pax3 become expressed in 
ventral regions (Chiang et al., 1996). In contrast over-expression of Shh results in loss of 
dorsal fates and a ventralised neural tube.
Several mice that carry mutations in Shh pathway genes display NTDs, for example two 
mutant alleles of Open brain (opb), one spontaneous and the second ENU-induced. 
Embryos homozygous for either mutant allele display exencephaly, spina bifida, 
polydactyly and poorly developed eyes (Sporle et al., 1996). Analysis of opb'1' mutant 
embryos shows a lack of dorsal neuronal cell types, a phenotype that resembles mice with 
partial loss of function of Patched or over-expression of Shh (Milenkovic et al., 1999). 
The gene mutated in opb was identified as Rab23, encoding a member o f the Rab family 
o f GTPases, which controls vesicle transport. How this protein participates in Shh 
signalling remains unknown but, since opb phenocopies GH3 and Patchedl mutant 
embryos, Rab23 may antagonistically regulate the Shh pathway.
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Interestingly, null embryos for Patchedl (Ptchl) and double homozygotes for protein 
kinase a subunit Ca/C/31 {Prkaca, Prkacb), display cranial NTDs that may also be caused 
by excessive Shh signalling. In Drosophila, protein kinase A phosphorylates CI, a process 
that is required for protein cleavage to yield the N-terminal transcriptional repressor form 
of CI (Chen et al., 1999). In vertebrates, a similar mechanism has been proposed (Ruiz i 
Altaba, 1999). Double homozygote embryos for Prkaca and Prkacb have excess Shh 
signalling, possibly because pKA cannot phosphorylate Gli proteins (Huang et al., 2002).
Further evidence for the importance o f regulation of the Shh pathway in neurulation 
comes from the Extra-toesJ mouse (Xt1), that carries a deletion in Gli3, and also displays 
cranial NTDs (Hui and Joyner, 1993). Lack of Gli3, which acts as a repressor of Shh 
downstream targets, results in excessive Shh signalling and exencephaly.
The information obtained from mouse mutants indicates that the Shh pathway is 
necessary for cranial and spinal neurulation. However, the embryonic mechanisms 
leading to NTDs in these mutants have not been characterised. One hypothesis to explain 
the exencephalic phenotype could be the loss of dorsal structures due to excessive Shh 
signalling resulting in a ventralised neural tube. In the spinal neural tube, the role of Shh 
has been studied in more detail (Ybot-Gonzalez et al., 2002). Shh signalling was found to 
inhibit DLHP formation. Indeed, homozygous null embryos for Shh develop DLHPs at an 
earlier stage of neurulation, during Mode 1, compared to the wild type embryos. DLHP 
formation can also be inhibited by local release of Shh peptide using implanted beads 
next to the neural folds, resulting in straight neural folds. In normal development, the 
inhibitory action of Shh on DLHPs formation declines at more caudal levels. Shh is 
expressed in the notochord at progressively lower intensity as spinal neurulation
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progresses, allowing DLHPs to appear and so enabling the transition to Mode 2 and Mode 
3. Therefore, Shh controls the timing of DLHP development by inhibiting its formation.
A hypothetical model of DLHP regulation has been postulated (see Fig. 1.6)(Ybot- 
Gonzalez et ah, 2002). In this model, the balance between positive (inducing) and 
negative (inhibiting) signals regulates DLHP formation. An unknown inducing signal 
from the surface ectoderm stimulates bending of the neural plate, perhaps through 
regulation of the cell cycle of the adjacent tissue. Early in neurulation, at Mode 1, Shh is 
expressed at high levels in the notochord and antagonises the positive signal from the 
surface ectoderm resulting in straight neural folds. However, as neurulation progresses 
(Mode 2 and Mode 3 of neurulation) the expression of Shh decreases, reducing the 
inhibitory effect and resulting in bending of the neural folds that are under the influence 
of the inducing signal.
This model is supported by experimental observations and the analysis of mouse mutants. 
Once Closure 1 has occurred, the MHP is not required for closure of the neural tube. 
Thus, mouse mutants for HNF3(3, Gli2, Shh and GU1/GU2 double mutants do not form a 
floor plate (MHP) and yet close their neural tube successfully in a Mode 3 morphology 
(Ang and Rossant, 1994;Chiang et al., 1996;Motoyama et al., 1998;Matise et al., 
1998;Park et al., 2000).
Removal o f the surface ectoderm abolishes DLHPs formation (Ybot-Gonzalez et a l , 
2002) showing that the surface ectoderm must signal to the underlying neural folds to 
induce the formation of DHLPs. Initially, BMP2 expressed from the surface ectoderm, 
was thought to be a good candidate molecule to induce DLHP. However recent
48
examination of embryos that lack BMP2 revealed that DLHP are actually formed 
prematurely in these embryos, as in Shh" embryos ((Ybot-Gonzalez et al., 2007a)). 
Recently, it was found that BMP2 from the surface ectoderm induces noggin expression 
in the dorsal neural fold.
Surface
ectoderm
Neural
folds
Notochord
Mode 1 Mode 2 Mode 3
Figure 1.7 Diagram to illustrate the proposed regulation of DLHPs in three 
progressive stages of mouse neurulation
Strong expression of Shh from the notochord in Mode 1 of neurulation inhibits DLHPs, 
whilst an unknown signal from the notochord induces the MHP (blue arrow). In Mode 2, 
Shh expression declines and its inhibitory action is lost. An unknown inducing signal 
from the surface ectoderm (red arrows) induces bending of the underlying neural fold 
(green arrows). In Mode 3, the MHP inducing signal is lost and closure of the neural tube 
depends only on DLHPs. Diagram modified from Ybot-Gonzales (2002).
Bending of the neural plate at the DLHPs regions ensures apposition of the neural folds 
prior to their fiision in the dorsal midline. However, determining how DLHPs are 
regulated has been hampered by the lack of mouse mutants that fail to develop DLHPs. A 
mouse mutant that lacked DLHPs would provide an opportunity to understand the
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molecular mechanisms required for DLPHs formation and neural tube closure in the low 
spinal region (Ybot-Gonzalez et al., 2007a).
1.5.4 Wnt signalling pathway
The Wnts are a family of secreted proteins that regulate many biological processes 
(Cadigan and Nusse, 1997). Functional analyses in Xenopus suggest that the Wnt family 
can be divided into two functionally distinct groups. The first group of Wnts induces a 
secondary axis when ectopically expressed in embryos. They activate the canonical 
Wnt/p-catenin pathway and induce the transcription of target genes such as siamois and 
Xnr3 ((Brannon and Kimelman, 1996); (Camac et al., 1996); McKendry etal. 1997). The 
second group of Wnts, which includes Xwnt5aand X w ntll, activates the noncanonical 
Wnt signaling pathway that controls morphogenetic cell movements (Kuhl 2002; Tadaet 
al. 2002). It was shown in zebrafish that mutations in Wntl 1/silberblick and 
Wnt5a/pipetail inhibit normal gastrulation movements (Rauch et al., 1997); (Heisenberg 
et al., 2000). The noncanonical Wnt pathway branches into two cascades. One is the 
Wnt/JNK pathway, which involves c-Jun N-terminal kinase (JNK); (Boutros et al., 1998); 
(Yamanaka et al., 2002). The other is the Wnt/Ca2+ pathway (Kuhl et al. 2000). In 
Drosophila, the Wnt/JNK pathway is called the planer cell polarity (PCP) pathway, and it 
specifies cell polarities in epithelial cells and other types of cells (Adler, 2002).
The Wnt signaling pathway is mediated by a seven-transmembrane Wnt receptor, 
Frizzled, and the signal is transmitted through a cytoplasmic protein, Dishevelled (Dsh), 
which plays pivotal roles in both the canonical and noncanonical Wnt pathways (Boutros 
and Mlodzik, 1999); (Rousset et al., 2002). In Drosophila, Dsh localizes to the membrane, 
and this localization is required for Dsh function (Axelrod, 2001). Xenopus Dsh (Xdsh) is 
also translocated from the cytoplasm to the plasma membrane in response to a signal
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generated by Frizzled receptors (Yang-Snyder et al., 1996); (Axelrod et al., 1998). One 
such receptor is Xenopus Frizzled7 (Xfz7), which is involved in the noncanonical Wnt 
pathway (Djiane et al., 2000); (Medina and Steinbeisser, 2000); (Medina et al., 2000). 
However, the mechanism of this translocation and the activation of Dishevelled are not 
known. The signal transduction of the canonical pathway seems to be different from that 
of the noncanonical pathway, because the membrane translocation of Xdsh is not required 
for the activation o f the canonical Wnt pathway (Rothbacher etal. 2000).
Protein kinase C (PKC) is thought to be involved in the noncanonical Wnt signaling 
pathway, particularly in the Wnt/Ca pathway, for several reasons. Xwnt5a and rat 
Frizzled2 activate the phosphatidylinositol pathway and increase the intracellular Ca2+ 
levels in zebrafish embryos (Slusarski et al., 1997). The phosphatidylinositol pathway and 
Ca levels are closely related to PKC activation. In fact, overexpression of Frizzled 
causes the translocation of epitope-tagged PKCa from the cytoplasm to the plasma 
membrane in Xenopus embryos (Sheldahl et al., 1999); (Medina et al., 2000). Kuhl et al., 
(2001) showed that PKCa phosphorylated Dsh in vitro. In addition, the loss of Xfz7 
function leads to a defect in tissue separation during Xenopus gastrulation, which is 
rescued by the overexpression of PKCa (Winkbauer et al., 2001). PKC is also implicated 
in the X w ntll signaling pathway for Xenopus cardiogenesis (Pandur et al., 2002) and in 
the Dwnt4 pathway for Drosophila ovarian morphogenesis (Cohen, Jr. and Shiota, 2002).
Although much evidence suggests that PKC is involved in the Wnt signaling pathway, the 
molecular roles of PKC in this pathway are not well understood.
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1.5.5 MARCKS signalling pathway
As previously described the neural tube is formed by morphogenetic movements largely 
dependent on cytoskeletal dynamics. Actin and many of its associated proteins have been 
proposed as important mediators of neurulation. For instance, mice deficient in 
Myristoylated Alanine-Rich C Kinase Substrate (MARCKS), an actin cross-linking 
membrane-associated protein that is regulated by PKC and other kinases, present severe 
developmental defects, including failure of cranial neural tube closure. MARCKS is a 
ubiquitous protein substrate for different PKC family kinases and proline directed kinases 
such as MAPK and Cdks (Aderem, 1992b).Its PKC-phosphorylation domain or PSD 
(Phosphorylation Site Domain) is highly conserved and it is also the site for interaction 
with other molecules, such as calcium-calmodulin, negatively charged membrane 
phospholipids and F-actin (Aderem, 1992a). Binding to calcium-calmodulin and the 
plasma membrane, as well as actin filament cross-linking activity, are antagonized by 
PSD phosphorylation (Laux, 2000). Conversely, calcium-calmodulin binding inhibits 
PSD phosphorylation and actin crosslinking. In addition to neural tube closure, MARCKS 
and MacMARCKS have been implicated in several other events related to the actin 
cytoskeleton, such as cell motility, cell spreading, membrane ruffling, phagocytosis, 
exocytosis and neurite outgrowth (Laux, 200).
1.6 DIETARY DEFICIENCY AND NTDs
The role of dietary deficiency during pregnancy has been studied in various animal models 
including the hamster (Mooij et al., 1993), rat (Miller et al., 1994) and mouse (Heid et al., 
1992). No association has been found in any of these models between folate deficiency 
and increased incidence of offspring affected by NTDs. The question of dietary deficiency 
has also been addressed using the in vitro whole embryo culture system. Cockcroft (1988)
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showed that specifically omitting folate from dialysed serum cultures reduces embryonic 
growth but does not yield NTDs, in contrast to myo-inositol whose omission leads to the 
development of cranial NTDs. In other studies, embryos have been cultured under sub- 
optimal conditions to produce NTDs in non-mutant strains. Such conditions produce a 
range of defects that can be ameliorated by various supplements. Rat embryos cultured in 
cow serum (Coelho et al., 1989) or canine serum (Flynn et al., 1987) develop cranial 
NTDs which can be prevented by supplementation with methionine. Culturing rodent 
embryos in human serum produces NTDs which can be prevented by supplementation 
with L-homocysteine (VanAerts et al., 1994). However, these studies do not provide a 
satisfactory model for the human condition for a number of reasons. Firstly, the original 
culture conditions are sub-optimal since embryos exhibited growth retardation as well as 
NTDs, which does not appear to mirror the human situation where pregnancies resulting in 
NTDs have not been shown to be sub-optimal. Secondly, the administration of methionine 
or homocysteine, but not folic acid, prevents NTDs whereas homocysteine is a risk factor 
for human NTDs. Moreover, although these agents are related to folate metabolism, a 
model for the human condition would have to be preventable by folic acid itself.
1.7 THE curly tail MUTANT MOUSE
Figure 1.8 curly tail mouse. (Photograph from (Catherine Chalmers, 2007)
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1.7.1 The curly tail mutant as a model for NTDs in humans
Although no animal model has been convincingly established as the equivalent of human 
NTDs, many aspects of the curly tail mouse mutant appear to parallel the malformations 
in humans (Embury et al., 1979). Lesions occur at both ends of the central nervous 
system, resulting in exencephaly and spina bifida. Exencephaly occurs in 1-2 % of 
embryos, spina bifida in around 15 % and tail flexion defects in around 50 % (Anatomy 
and Embryology review). There is a marked female excess both in exencephalic mice and 
anencephalic humans where the female:male ratios are 4:1 and 3:1 respectively (Carter, 
1974); (Embury et al., 1979). Polyhydramnios, which usually occurs in human 
anencephalic pregnancies, is also found in association with curly tail mouse fetuses with 
open lesions and is especially significant in the exencephalics. Large numbers of rapidly 
adherent cells, with distinctive morphology, in the amniotic fluid is another common 
characteristic in humans (Wald et al., 1977); (Brock and Sutcliffe, 1972), and curly tail 
(Embury et al., 1979) NTD pregnancies. Hydrocephaly sometimes occurs in conjunction 
with NTDs in both the curly tail mouse and humans. Furthermore, raised 
alphafetolprotein levels in the amniotic fluid can be detected in affected fetuses of both 
mouse and human (Adinolfi et al., 1976); (Brock and Sutcliffe, 1972).
1.7.2 The curly tail defect at the genetic level
The curly tail mouse arose as a spontaneous mutation in 1950 in the inbred GFF stock at 
the Glaxo Laboratories. The founder female was subsequently mated to a CBA/Gr male 
and then the mice were bred as a closed colony (Griinberg, 1954). As described above, 
around 60 % of curly tail mice exhibit NTDs which have variable expression: 
exencephaly, lumbo-sacral spina bifida, a coiled or kinked tail. These mice are referred to 
as ‘affected’ and symbolized by CT. The rest of the mice are morphologically normal and
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are referred to as ‘unaffected’, symbolized by ST. Whatever their phenotype, it is believed 
that all curly tail mice are homozygous for a recessive genetic mutation (<ct/ct), the 
expression of which is modified by the genetic background (Griineberg 1954); (Seller et 
al., 1979); (Estibeiro and Copp, 1990). Evidence for recessivity came from out-crossing 
CT mice to BALB/c, A/Strong, C57BL/6 and DBA/2 strains which produced no offspring 
with neurovertebral abnormalities in the FI generation; NTDs reappeared in the back- 
cross generation. However, there was a significant deviation from the expected 50 % CT 
in the backcross offspring, and the actual expression differed according to the inbred strain 
used: 24 % of offspring were CT in the BALB/c cross, 8 % in the A/Strong cross, 22.5 % 
in the C57BL/6 cross and 0.4 % in the DBA/2 cross, suggesting that genetic background 
has a modifying effect on the expression of the gene (Embury et al., 1979). Selective 
breeding experiments provided further evidence that all mice, irrespective of their 
phenotype, are homozygous recessive with the gene having variable penetrance and 
expressivity (Embury et al., 1979).
1.7.2.1 Grainyhead (Grhl-3)
The Grainyhead, drosophila, Homolog of, or 3 sister of mammalian grainyhead (sister of 
MGR); SOM or Grainyhead like 3 (Grhl3) belongs to a family of transcription factors 
related to the Drosophila grainyhead (grh) protein. The Drosophila gene grainyhead is the 
founding member of a large family of genes that are highly conserved from fly to human. 
The family consists of two main branches, with grainyhead as the ancestral gene for one 
branch and the recently cloned Drosophila CP2 (Gemini) as the ancestral gene for the 
other. Functionally, Grainyhead, the best-studied protein in its subfamily, is mainly a 
regulator of developmental control genes in D.melanogaster, such as Ultrabithorax, dopa 
decarboxylase, tailless and decapentaplegic (Ting et al., 2003). Fruit flies carrying
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grainyhead mutations display an embryonic lethal phenotype. Like grainyhead, the human 
Grhl3 gene produces several distinct isoforms with differing functional properties through 
alternative splicing.
Tail Bud Region PNP Category Subsequent Spinal Development
I I
Normal 
Normal
Tail Flexion Defects
Tail Flexion Defects 
and 
Spina Bifida
Figure 1.9 Diagrams of tail bud regions of curly tail embry os. The diagram illustrates 
the five PNP categories and subsequent spinal development. Modified from Copp, 1985
The tissue distributions of these isoforms differ and all display highly restricted expression 
patterns. These findings indicate that Grhl3, like its family members, may play important 
roles in mammalian development. By database analysis, Ting et al. (2003) mapped the 
mouse Grhl3 gene to chromosome 4 and, by in situ hybridization, they detected Grhl3 
expression at mouse embryonic day (E) 8.5 in the non neural ectoderm immediately 
adjacent to the neural plate, which was undergoing folding to form the neural tube. At later
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time points, more widespread expression was observed in the surface ectoderm, as well as 
in other tissues lined by squamous epithelium, including the oral cavity, urogenital sinus, 
and anal canal. Expression progressively increased until E l5.5.
The curly tail gene has recently been claimed to be Grhl-3. Ting et al., (2003) found that 
targeted Grhl3 null mouse embryos displayed neural tube defects, including 
thoracolumbosacral spina bifida and curled tail, as well as spinal skeletal abnormalities such 
as kyphosis, splayed spinal processes, and lack of vertebral arch formation. Spina bifida 
was caused by a primary failure o f neural tube closure. They noted that the phenotype of the 
Grhl3-null mice is similar to that of curly tail mice (ct/ct). The authors found that the mouse 
Ghrl3 locus maps to the same 13-Mb contiguous sequence on chromosome 4 as the ct locus 
but failed to find a coding region mutation in ct mice. Ghrl3 mRNA expression in curly tail 
mice is decreased to about 30% of normal. However, there were some phenotypic 
differences; most notably, inositol treatment had no effect on the severity and incidence of 
spina bifida in Grhl3-null embryos. Ting et al. (2003) concluded that Grhl3 and ct may 
regulate one another, be allelic, or be involved in the same pathway, and suggested that 
Grhl3 is a good candidate for the gene underlying the curly tail phenotype.
Mace and colleagues found that grainyhead activates wound repair genes in cells 
surrounding injuries in the outer layer of fly embryos (Mace et al., 2005). They created 
wounds in flies and analyzed that grainyhead initiates repair. They also found that in flies 
lacking grainyhead, wounds failed to heal. Moreover, mice lacking grainyhead proved to 
have more permeable skin than normal mice and had deficient wound repair (Ting et al., 
2005). Such a conserved genetic mechanism for wound repair is considered an important 
finding, given that little is known about how wound repair is halted when injuries are
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healed. Nor is it understood how cancer cells evade this stop program. The discovery that 
grainyhead-like factors are required for the response to injury opens up new avenues of 
research in the field of wound healing as well as cancer research and development, since 
many cancer cells and developmental processes activate genes normally involved in 
wound healing in order to kick start processes such as cell division and cell migration
1.7.3 The curly tail defect at the morphological level
In 1954, Griineberg suggested, from morphological observations, that spinal neural tube 
malformations in curly tail embryos were the result o f delayed closure of the posterior 
neuropore (PNP). Further evidence was provided by Copp (1985) who followed the in 
vitro development of individual curly tail embryos that exhibited varying extents of delay 
in PNP closure. He classified the axial length of the PNP, at the stage of 25-29 somites, 
into five categories (Fig. 1.9). In categories 1 and 2, the PNP is restricted to the expanded 
distal region of the tail bud. In category 3, the PNP extends beyond the distal region of the 
tail bud, but does not reach the level of the hindlimb bud rudiment. In category 4, the PNP 
extends into the region of the hindlimb bud but does not encroach upon the rows of 
somites. In category 5, the PNP overlaps, in its cranial extent, with the somite rows. It was 
found that when the PNP was restricted to the expanded distal region of the tail bud the 
majority of curly tail embryos (63 %) were unaffected and developed a straight tail in vitro 
while the rest of the embryos had tail flexion defects. When the PNP extends beyond the 
distal expansion, but does not reach the level of the hindlimb bud rudiment, significantly 
more embryos (71 %) developed tail flexion defects with a few (8  %) having spina bifida 
as well. On the other hand when the PNP extends into the region o f the hindlimb bud or 
when the PNP overlaps, in its cranial extent, with the somite rows, only 8 % of the 
embryos were normal, and the proportion of embryos that developed spina bifida
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increased to 34 % (Copp, 1985). This understanding of different development of embryos 
according to the length of unclosed neural folds at the PNP allows comparison between 
prospective normal and affected curly tail embryos at a stage that precedes the 
development of fully formed spinal NTDs (Copp, 1985).
During the course of other experiments with curly tail mice, it was noticed that embryos 
which have a large PNP often exhibit excessive ventral curvature of the caudal region 
(Copp et al., 1988a). To determine whether there is a true relationship between the size of 
the PNP and the angle of curvature, these two parameters were measured in individual 
embryos. The angle of ventral curvature of the caudal region was found to vary 
significantly with neuropore size, such that the curvature is greatest in embryos with a 
large PNP and least in embryos with a small neuropore (Brook et al., 1991a). This was an 
interesting observation in view of previous suggestions that curvature of the body axis can 
affect the rate of neurulation in the cranial region of the mouse embryo (Jacobson and 
Tam, 1982); (van Straaten et al., 1992). Moreover, splitting of the caudal region to prevent 
development of curvature was effective in reducing PNP length in curly tail embryos, 
strongly supporting the idea that ventral curvature is the cause of delayed PNP closure 
(Brook et al., 1991a), (van Straaten and Copp, 2001)
1.7.4 The curly tail defect at the cellular level
Regional variations in the rate of cell proliferation have been suggested to be an important 
factor determining the success or failure of normal neurulation in higher vertebrates 
(Kauffman, 1968); Wilson, 1982). In studies of mouse mutants with neural tube defects, a 
prolonged neuroepithelial cell cycle was found in regions of open cranial neural tube of 
homozygous splotch mutant mouse embryos (Wilson, 1974); (Wilson and Center, 1974). 
The increased ventral curvature in curly tail embryos appears to result from a growth
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imbalance in the caudal tissues of the embryos. When the different cell types in the PNP 
region of normal and affected curly tail embryos were compared, a reduced proliferation 
rate, equivalent to a 25% increase in cell cycle time, was found in gut endoderm and 
notochord. Other cell types, including neuroepithelium, surface ectoderm and mesoderm, 
showed no difference between normal and abnormal embryos (Copp et al., 1988c).
E9.5 CT
E15ST E15CT E15, EX+SB
Figure 1.10 Neural tube malformations in curly tail embryos. (ST) straight tail; 
(CT) curly tail; (EX) excencephaly; (SB) spina bifida. Arrow poins to the open 
PNP. (E) embryonic day.
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This imbalance of growth between the dorsally situated neuroepithelium and the ventrally 
situated notochord and gut endoderm, in the PNP region, has been shown to be responsible 
for the development of spinal NTDs in affected curly tail embryos. Evidence comes from 
experiments in which NTDs were prevented by re-establishing a balance of proliferation 
between the slowly growing notochord/gut endoderm and the unaffected neuroepithelium. 
This was achieved by retarding the growth of the embryo in two ways (Copp et al., 
1988c): In utero, by depriving pregnant females of food for 48 hours and, in vitro, by 
elevating the culture temperature from the optimal 38 °C to 40 °C for 15-23 hours, prior to 
PNP closure. Both treatments resulted in normalization of PNP closure and prevented the 
development of spinal NTDs. 3H-thymidine labelling of in vitro growth retarded embryos 
showed that while the proliferation rate of all tissues was reduced, the more rapidly 
growing neuroepithelium suffered a greater reduction in proliferation rate than other cell 
types. Thus, the absolute magnitude of the cell proliferation imbalance was diminished by 
in vitro growth retardation of the embryo.
1.7.5 Molecular abnormalities in curly tail embryos
Extracellular matrix molecules, particularly glycosaminoglycans, have been suggested to 
play a role in neurulation because they show specific patterns of deposition that correlate 
spatially and temporally with neurulation (Solursh and Morriss, 1977); (Morriss and 
Solursh, 1978); (Morris-Wiman and Brinkley, 1990). Comparisons of glycoconjugates 
were made prior to the completion of neurulation, between normally developing curly tail 
embryos and those developing spinal NTDs. Newly synthesized hyaluronan, which 
accumulates in large quantities in the posterior neuropore of normal embryos, was found 
to be significantly reduced in amount in the developing basement membranes beneath the 
medial aspect of the neuroepithelium and around the notochord in the PNP region of
affected curly tail embryos (Copp and Bemfield, 1988b). Other embryonic regions and 
other glycoconjugates showed no differences between normal and affected curly tail 
embryos, and their accumulation pattern was similar to non-mutant embryos (Copp and 
Bemfield, 1988a).
Affected curly tail embryos also exhibit abnormal binding of the iron-binding growth 
factor, transferrin, which is taken up and localised in the hindgut of neurulation stage 
mouse embryos (Copp et al., 1992). Reduced binding was observed in the hindgut of 
affected curly tail embryos compared with their unaffected littermates, although the level 
and sites of expression of the transferrin receptor are not altered (Hoyle et al., 1996).
Several studies have demonstrated an interaction between retinoic acid and the frequency 
of NTDs in curly tail embryos (Chen et al., 1994) and this has been correlated at the 
molecular level with altered expression of nuclear retinoic acid receptors (Greene and 
Copp, 1997a).
1.7.6 Curly tail, a mouse model of folate-insensitive NTDs
Although some cases of human NTDs can be prevented by folic acid, there is increasing 
evidence that many cases do not respond. For instance, there was no reduction in NTD 
frequency in the U.K. during the first ten years after folic acid supplementation was 
introduced (Abramsky et al., 1999). In 1994 Seller provided preliminary evidence that 
exogenous myo-inositol reduces NTD frequency in curly tail mice. Greene and Copp 
(1997) repeated and extended this study using the curly tail mouse as a model of folate- 
resistant NTDs. They found that intraperitoneal injection of pregnant female mice with 
myo-inositol at various times during the critical phase of neural tube closure significantly
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decreased the frequency of spina bifida in developing embryos. A single injection on 
embryonic day 9.5 reduced NTDs frequency by 70% in ct embryos.
Figure 1.11 Diagram representing what was known prior to this thesis about the 
possible inositol mechanism in normalising PNP closure in curly tail embryos.
Greene and Copp (1997) demonstrated further that inositol prevents spinal NTDs in vitro 
and showed that inositol increases the flux through the inositol/lipid cycle, stimulates 
protein kinase C activity, and up-regulates the expression of retinoic acid receptor beta. 
They concluded that their findings in the curly tail mutant reveal a molecular pathway of 
NTD prevention and suggest possible efficacy of combined treatment with folate and
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inositol in overcoming the majority of human NTDs (Greene and Copp, 1997a). This 
hypothesis is currently being tested in a clinical trial.
1.8 INOSITOL
Inositols are cyclic carbohydrates with a basic 6 -carbon ring structure. There are actually 
sevaral isomers of inositol, of which myo-inositol is the most abundant in the central 
nervous system of mammals (Baker et al., 1990). Myo-inositol is distinct in that it has a 
single axial hydroxyl group at the number 2 carbon. Inositol metabolism is extremely 
complex with multiple isomers (over a hundred) of inositol phosphates and inositol 
phospholipids present in the cell (Bansal and Majerus, 1990). Several preparations of 
phosphoglycan molecules that appear to mediate insulin action as second messengers 
contain D-chiro-inositol, an epimer of myo-inositol that was unknown in mammals until 
recently (Asplin et al., 1993). D-chiro-inositol has an axial hydroxyl group at the number 2 
carbon in an inverted position to myo-inositol (Fig. 1.12). It has been shown (Insmed 
Incorporated, unpublished data) that diabetic subjects excrete 5-40 times as much D-chiro- 
inositol in the urine as normal subjects and that the rate of excretion depends critically on 
the degree of diabetic control. Plasma D-chiro-inositol levels are influenced by insulin 
treatment and are a strong predictor of hypertriglyceridemia, the most common lipid 
abnormality in diabetic patients (Lamer, 2001). D-chiro-inositol can be obtained from the 
diet in the form of pinitol, a methyl inositol found in legumes. The effects of D-chiro- 
inositol on diabetic subjects are being studied (Insmed Incorporated, unpublished data). 
The exact structure of the D-chiro-inositol-containing molecules thought to be responsible 
for these effects at the biochemical level has not been reported (Lamer, 2001).
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Figure 1.12 Diagram illustrating myo-inositol and D-chiro-inositol (structural 
differences are enhanced in red colour).
1.8.1 Mechanisms of inositol signalling
The inositol/lipid cycle plays a central role in inositol metabolism and is involved in 
signal transduction leading to the regulation of many cellular functions (Berridge, 1995). 
Cellular uptake of inositol occurs via a sodium-coupled transporter, which is a member of 
the sugar transporter superfamily (Nikawa et al., 1991). Inositol is utilised in synthesis of 
the membrane lipid, phosphatidylinositol (PI), in which it constitutes the polar head 
group. Subsequent phosphorylation steps lead to generation of phosphatidylinositol 
diphosphate (PIP2) which is the major substrate for receptor activated phospholipase C 
(Figure 1.13). The major two pathways for activation of isoforms of PLC involve G- 
protein linked receptors which activate PLCp via GTP-binding proteins and receptor 
tyrosine kinases which activate PLCy (Berridge, 1993). Hydrolysis of PIP2 generates 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) which are major downstream 
effectors of the cycle. DAG is physiological activator of protein kinase C (PKC), an 
important family of regulatory enzymes (Hinchliffe and Irvine, 1997). The potential 
function of PKC in prevention of NTDs is one focus of this study and is, therefore,
reviewed in more detail in Section 1.9. Binding of IP3 to its receptor leads to mobilisation 
of calcium from intracellular stores which may regulate cellular processes such as 
fertilisation, growth control, regulation of actin assembly and neuronal signalling (Martin 
et al., 1994). The end product of each pathway is inositol, which is recycled back as a 
component of the original PI precursor. In addition, this parent compound, 
phosphatidylinositol, can modulate the activity of numerous membrane enzymes.
1.8.2 Phosphatidylinositol 3-kinase
Aside from the inositol/lipid cycle, phosphoinositides have an additional role in 
signal transduction involving the enzyme, phosphatidylinositol 3-kinase (PI 3- 
Kinase) which is recruited and concomitantly activated following stimulation of 
various receptor tyrosine kinases (Divecha and Irvine, 1995). Following auto­
phosphorylation and dimerisation, the activated receptors for ligands such as 
platelet-derived growth factor a  and p, colony stimulating factor-1, c-kit and 
hepatocyte growth factor, are able to interact directly with PI 3-Kinase (Rodgers 
and Theibert, 2002). An alternative mechanism is also utilised in which the 
activated receptor interacts with PI 3-Kinase via an adapter molecule such as insulin 
receptor substrate- 1 and erb/B3 in the case of the insulin and epidermal growth 
factor receptors respectively (Banker, 2003).
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Figure 1.13 The inositol phosphate signalling pathway. When the G-protein coupled 
receptor B is activated, it activates a ‘G protein’ which in turn stimulates phospholipase C 
(PLC). PLC cleaves phosphoinositol diphosphate (PIP2) into inositol 1,4,5 triphosphate 
(IP3) and diacylglycerol (DAG). DAG is a physiological activator of PKC. The second 
messenger, IP3 releases Ca2+ from the endoplasmic reticulum into the cytoplasm which 
triggers further biochemical reactions. Diagram from Martin, 2001.
The active PI3-Kinase enzyme, a heterodimer of regulatory (85 kDa) and catalytic (110 
kDa) subunits, phosphorylates the D-3 position of PI, PIP and PIP2, the later probably 
being the major substrate in vivo (Chou et al., 1998). Functions for the lipid products of PI 
3-Kinase have been proposed in activation of Ca2^ ‘atypical PKC (PKC Q, vesicular 
trafficking, organisation of actin and planar cell polarity (reviewed by (Cantley, 2002). 
The downstream function appears to be mediated through Rac, a member of the Rho class 
GTP-binding proteins, which is activated by exchange of bound GDP for GTP (Parker, 
1995).
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1.9 PROTEIN KINASE C
1.9.1 Members of the PKC family of enzymes
The PKC (protein kinase C) family comprises a multigene family of related 
serine/threonine kinases that play key roles in growth regulation and programmed cell 
death. My particular interest has been in the PKC-activated signalling mechanisms during 
neurulation using the curly tail mouse mutant as a model.
Traditional models of PKC activation have focused on the role of physiological second 
messengers (such as calcium and diacylglycerol (DAG)) or tumour-promoting phorbol 
esters (such as PMA) to anchor PKCs in their active conformations on membranes 
(Berridge, 1987). However, most cells co-express multiple PKC isoforms that have 
distinct (and occasionally functionally opposing) cellular responses. PKC isoform 
specificity has been attributed to distinctive compartmentalization patterns for individual 
PKC isoforms (Abeliovich et al., 1993a;Bareggi et al., 1995). The prevailing model holds 
that protein-protein interactions between a particular PKC isoform and its unique 
membrane-associated anchoring protein (itself localized to a specific membrane sub- 
domain) serve to recruit the PKC isoform to a distinct sub-cellular compartment, in close 
proximity with its unique target substrates (Dekker and Parker, 1994;Nakhost et al., 
2002).
1.9.2 PKC structure and regulation
PKC isoforms are single polypeptide chains with N-terminal regulatory domains that 
contain an autoinhibitory pseudosubstrate domain, two membrane-targeting modules 
(termed Cl and C2) and a highly conserved C-terminal catalytic domain (that contains the
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C3 and C4 motifs required for ATP/substrate binding and catalytic activity) (Figure 1.14) 
(Parker and Murray-Rust, 2004). PKC isoforms are broadly subdivided into three 
subfamilies based upon their structurally distinct N-terminal regulatory domains. The 
conventional PKCs are a , pi, pH and y (cPKCs), all o f which contain two membrane- 
targeting modules, designated Cl and C2 (Parker and Murray-Rust, 2004). The Cl 
domain consists of tandem ~5 0-residue DAG/PMA-binding sequences termed CIA and 
C1B; each adopts a globular conformation and co-ordinates Zn2+ at a metal ion-binding 
site formed by three cysteines and one histidine. X-ray crystallographic studies identify 
Cl domains as hydrophobic switches (Parker and Parkinson, 2001). Each C l domain 
consists of two p-sheets and a short C-terminal a-helix. PMA (or endogenously generated 
DAG) binds to a hydrophilic cleft situated in an otherwise hydrophobic surface at the tip 
of the Cl domain (between two ‘unzipped’ P-strands) (Mochly-Rosen and Kauvar, 2000). 
By capping this polar groove, PMA (or DAG) forms a contiguous hydrophobic surface 
that promotes PKC binding to membranes (Balogh et al., 1995). The second cPKC 
membrane targeting motif is the C2 domain, a motif that is found in many proteins that 
participate in membrane trafficking and signal transduction. C2 domains characteristically 
consist of eight P-strands connected by loops of variable lengths. C2 domains of cPKC 
isoforms bind anionic phospholipids in a calcium-dependent manner due to the presence 
of several invariant calcium-binding residues in three loops at one end of the structure 
(Asaoka et al., 1992).
Novel PKCs (nPKCs: 8 , s, q and 0) also have twin Cl domains and a C2 domain. 
However, C2 domain-like sequences of nPKCs lack calcium-co-ordinating acidic residue 
side chains. Hence nPKCs are maximally activated by DAG/PMA, without requiring
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calcium (Parker and Murray-Rust, 2004); (Dekker and Parker, 1994); (Mochly-Rosen and 
Kauvar, 2000)).
cPKC
Species Regulatory domain
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Figure 1.14 Protein Kinase C Isoforms. Scheme depicting the sequence homology 
between PKC isoforms and their subfamilies. (Diagram adapted from (Disatnik et al., 
2 0 0 2 ). c: classical; n: novel; a: atypical.
Atypical PKCs (aPKCs: £ and i/X) are the third PKC isoform subfamily. aPKCs lack a 
calcium-sensitive C2 domain and contain only a single cysteine-rich zinc finger structure 
that does not bind DAG or PMA. As a result, aPKC isoforms are not allosterically 
regulated by calcium or DAG/PMA (Parker and Murray-Rust, 2004). Rather, aPKCs are 
activated by a distinct set of phospholipid cofactors, as well as by stimulus-induced
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phosphorylation events (a topic that is beyond the scope of this thesis (see (Hirai and 
Chida, 2003); (Standaert et al., 1997).
Current models of PKC activation are based largely on studies of cPKC isoforms which, 
in the absence of calcium or DAG, interact only weakly/transiently with membranes. 
Agonists that promote phosphoinositide hydrolysis and Ins( 1,4,5)7*3 generation lead to the 
mobilization of intracellular calcium, which binds to the C2 domain and increases its 
affinity for membranes (Blobe et al., 1996). This initial association of cPKC with 
membranes facilitates the interaction of the Cl domain with DAG (the other product of 
phosphoinositide hydrolysis) (Fig. 1.14) (Parker and Murray-Rust, 2004). C1/C2 domain 
engagement with membranes promotes a conformational change that expels the 
autoinhibitory pseudosubstrate domain from the substrate-binding pocket and facilitates 
the PKC-mediated phosphorylation of membrane substrates (Parker and Murray-Rust, 
2004). With the exception of the C2 domain-mediated effects of calcium, nPKC isoform 
activation for the most part follows a similar mechanism. For both cPKC and nPKC 
isoforms, translocation to membranes generally is considered an indication of activation 
(Mochly-Rosen and Kauvar, 2000).
1.9.3 Importance of PKC interaction with scaffolding proteins
Most cells co-express multiple PKC isoforms that display only limited substrate 
specificity in vitro and yet elicit distinct cellular responses in intact cells. PKC isoform 
specificity in vivo has been attributed to isoform-specific interactions with various 
anchoring proteins that localize individual PKC isoforms to specific membrane 
microdomains (in close proximity with their allosteric activators and/or substrates) 
(Mochly-Rosen and Kauvar, 2000). To date, a relatively large number of PKC-binding 
partners have been identified, including STICKs (substrates that interact with C-kinase),
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various cytoskeletal proteins (such as actin or tubulin), true scaffolding proteins such as 
caveolin isoforms and AKAPs (A-kinase anchoring proteins), and RACKs (receptors for 
activated C-kinase) (Jaken and Parker, 2000). The RACK family of membrane-associated 
PKC-anchoring proteins has figured particularly prominently in the recent literature, since 
peptides designed to block or promote PKC isoform-selective interactions with their 
cognate RACKs are currently being evaluated for various cardiovascular indications in 
humans (Buensuceso et al., 2001). RACK proteins consist of a seven-WD40-motif repeat 
structure. The current model holds that cells express a unique RACK, with a distinct 
subcellular localization, for each PKC iso form (Stebbins and Mochly-Rosen, 2001). By 
selectively/saturably binding only the activated conformation of a PKC, each RACK 
protein recruits its cognate PKC isoform (in an active conformation) to a specific 
membrane compartment (Mackay and Mochly-Rosen, 2001) (Fig. 1.15). To date, proteins 
with characteristics of RACKs for PKCp (RACK1), PKCe (RACK2 or b-COP) and 
PKC8  (p32/gClqBP) have been identified (Chen et al., 2001). However, it is important to 
note that RACK proteins can also fulfil functions unrelated to PKC. For example, 
RACK1 is reported to act as a scaffold to organize signalling complexes containing SFKs, 
heterotrimeric G-protein Py subunits, STAT1 (signal transducer and activator of 
transcription 1) and the receptor protein tyrosine phosphatase PTPm (Chen et al., 2001). 
RACK2 (or P-COP, a coated-vesicle protein that participates in intracellular transport and 
vesicular release) was identified as a binding partner for certain RGS (regulators of G- 
protein signalling) proteins (Mackay and Mochly-Rosen, 2001).
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Figure 1.15 Signal transduction PKC cascades: the interaction of calcium-dependent PKCs with 
selective activators diacylglycerol (DAG), phosphatidylserine (PS) and calcium (Ca2+) reduces the 
affinity of the pseudosubtrate domain for the catalytic site, thus opening the folded conformation and 
allowing the activation of the enzyme. The activated PKC can be directed to specific cellular 
compartments via anchoring proteins such as RACKs. (Diagram adapted from Amadio, 2006).
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1.9.4 How PKC peptide inhibitors work
As described above, following activation, each activated isoform is localized to a unique 
subcellular site due to its binding to the corresponding RACK (Mochly-Rosen and Kauvar, 
2000). The activated isoform is thus anchored next to a subset of substrates and away from 
others. Therefore, isoform-selective functions are determined by their cellular localization. 
Based on that idea, Professor Mochly Rosen (Aley et al., 2000) identified the interaction 
site for each RACK on the corresponding PKC isoform and identified isoform-selective 
inhibitory peptides for all the PKC isoforms. The translocation inhibitors are 6-8  amino 
acids long and they selectively inhibit translocation and function of their corresponding 
isoforms (Fig. 1.16) (Mochly-Rosen and Kauvar, 2000)
‘ep tide inhibitor
RACK
Activated
No physiological responses
Physiological
responses
Figure 1.16 Translocation inhibitors. On the left, PKC (lilac) binding to its RACK 
(Orange) results in anchoring of the activated isoform near its substrate (blue). 
Phosphorylation (P) of that substrate leads to the physiological responses of that isoform. 
On the right, a peptide corresponding to the RACK-binding site on PKC (green) inhibits 
the translocation and function of its corresponding isoform. The translocation inhibitor,
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derived from the RACK-binding site on the PKC, binds to the RACK and blocks the 
binding of the activated isoform to that RACK. Hence, the physiological response 
mediated by that PKC isoform is not observed. (Diagram adapted from (Mochly-Rosen 
and Kauvar, 2000)
1.9.5 Function of PKC
Roles for PKC have been proposed in regulation of a variety of cellular processes 
including function of membrane proteins, cell cycle control and transcription of various 
genes (reviewed by (Nishizuka, 1986); Mochly Rosen 2004). At the molecular level, the 
effect of PKC is mediated through phosphorylation of protein substrates on serine or 
threonine residues.
The functions of PKC at the cell membrane include down regulation of target receptors, 
such as the epidermal growth factor (EGF) receptor and modulation o f ion channel targets, 
such as the Na+/H+ exchanger (Sardet et al., 1990). PKC activity also affects long-term 
responses such as cell proliferation and gene expression. For example, induction of 
expression of the transcription factor, c-fos, by insulin or insulin related growth factor- 1 
occurs via PKC-dependent pathway (Heidenreich et al., 1993). Phosphorylation by PKC 
also regulates the activity of the activator protein (AP) transcription factors, AP-1 (through 
phosphorylation of c-fos) and AP-2 (Nishizuka, 1992). Activation of c-Raf kinase 
following phosphorylation by PKC may also be involved in regulation of AP-1 (Hug and 
Sarre, 1993).
The major PKC substrate MARCKS may be of particular interest in relation to neural tube 
closure as the null mutant mouse displays exencephaly (Stumpo et al., 1995a). Moreover, 
knockout of the MARCKS family protein, MRP also causes NTD (Chen et al., 1996).
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1.10 EXPERIMENTAL APPROACH
This thesis provides a study of both the development and prevention of NTDs in the 
mouse embryo. The events of posterior neural tube closure are studied using the whole 
embryo culture system, which allows a detailed analysis of neurulation as a dynamic, 
ongoing process.
In Chapter 3, the previously demonstrated prevention of spina bifida in the curly tail 
mutant by inositol (Greene & Copp) is investigated further by analysis of two different 
isomers of inositol, with comparison of their relative efficacy. Both myo- and D-chiro- 
inositol, were found to prevent spinal NTDs but with greater potency observed for D- 
c/hro-inositol. The possibility that inositol therapy might cause fetal malformations was 
carefully analyzed, as a “pre-clinical” evaluation, prior to using inositol as an adjunct 
therapy to folic acid for prevention of NTDs in a human clinical trial.
The aim of Chapter 4 was to investigate the possible involvement of specific isoforms of 
PKC in the mechanism of the curly tail defect and/or in the biochemical and molecular 
basis o f the inositol protective effect. In this chapter I examined neurulation-stage embryos 
for PKC expression and applied chemical and peptide PKC inhibitors to curly tail embryos 
developing in culture. This study revealed an absolute dependence on the activity of 
PKC/31 and y for prevention of NTDs by inositol, and partial dependence on PKC£ 
whereas other PKCs were found dispensable for the protective effect of inositol. 
Interestingly, inhibition of PKCs does not appear detrimental to normal development 
during neurulation.
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The curly tail cell proliferation defect was investigated in Chapter 5 in order to determine 
whether the protective effect of inositol may work via stimulating cell proliferation in 
curly tail embryos. Defective proliferation of hindgut cells is a key component of the 
pathogenic sequence leading to NTDs in curly tail. Hindgut cell proliferation was found to 
be stimulated specifically by inositol, as judged by PCNA and phospho-histone H3 
immunohistochemistry, an effect that required activation of PKCpI. This final chapter, 
reveals the cellular basis by which specific PKC isoforms function during the prevention 
of mouse spinal NTDs by inositol.
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CHAPTER 2 
MATERIAL AND METHODS
All the reagents used in this thesis were obtained from Sigma unless otherwise specified. 
The components of individual solutions are described in the text except for certain general 
solutions, which are listed in section 2 .8 .
2.1 MICE
2.1.1 Generation of experimental litters
Experimental litters were generated by timed matings in which females were paired with 
males overnight and checked for copulation plugs the following morning. The day of 
finding a plug was designated embryonic day (E) 0.5.
2.1.2 Curly tail mice
The curly tail mutation is maintained in our laboratory as a closed, random-bred stock of 
homozygous (ct/ct) individuals (Van Straaten and Copp, 2001). The background of the 
stock, although not inbred, appears homogeneous with respect to genes that influence the 
incidence of NTDs. The background is probably a mixture of the GFF and CBA/Gr 
inbred strains that comprised the original breeding pair (Griineberg, 1954). The mice are 
fed with R&M Diet (Quest Nutrition) and tap water. They are maintained in a ventilated 
room at 22°C on a light/dark cycle with the dark period from 1 a.m. to 9 a.m. About two- 
thirds of the curly tail mice are affected with spinal NTDs (10-15 % spina bifida, 40-50 % 
curly tails), whereas the rest are unaffected and have no morphological abnormality. To 
obtain experimental litters, affected males (tail flexion defect) were mated with females 
that were either unaffected (straight tail) or had tail flexion defects. Both affected and 
unaffected females were used as a source of experimental embryos, since the incidence of 
NTDs has been shown to be the same in both types of litter (Copp et al., 1982). In order 
to allow accurate estimation of gestational age, for certain experiments timed matings
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were performed by pairing two females with one male, at approximately 8:30 a.m. and 
checking for copulation plugs 3-4 hours later.
2.1.3 CD1 mice
The CD1 stock was used as a non-mutant control in all experiments. It is maintained as a 
random bred colony with males obtained from Charles River U.K. Ltd. (Margate, U.K.).
2.2 EMBRYO CULTURE
2.2.1 Embryo dissection
Pregnant mice were killed by cervical dislocation at the appropriate day o f gestation, 9 
days 5 hours for curly tail mice. Conceptuses were explanted using watchmaker’s forceps 
into pre-warmed (37°C) Dulbecco’s Modified Eagles Medium (Gibco) containing 10% 
fetal calf serum (Advance Protein Products). Using fine watchmaker’s forceps, embryos 
were dissected free from the decidua, trophoblast and Reichert’s membrane leaving the 
yolk sac and ectoplacental cone intact (Fig. 2.1). Embryos were then either:
1) Cultured intact (Section 2.2.2)
2) Dissected immediately from the yolk sac and amnion and fixed in 4% PFA. The yolk 
sac in same studies was rinsed in PBS and frozen for PCR genotyping (Section 2.7.1).
3) Dissected and the caudal region dissociated to prepare primary cell cultures (Section 
2 .6.2)
2.2.2 Embryo culture
Groups of three embryos were cultured in 30 ml disposable plastic tubes (Nunc, 
Universal) containing 3 ml immediately-centrifuged heat-inactivated rat serum (the 
culture method was modified from (Cockroft, 1990). In general there was a delay of 2
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hours between killing the female mouse and putting the embryos into culture. Cultures 
started at 9 days 6  hours {curly tail) or 9 days 14 hours (CD1) of gestation, were gassed 
for 1 minute with 20% 0 2, 5% C 02, 75% N2 (all gases from Cryoservice Ltd.) and 
incubated at 38°C in a roller bottle incubator (Cockroft, 1990). After approximately 17 
hours, the cultures were again gassed for 1 minute with 40% 0 2, 5% C 02, 55% N2 and 
incubated for a further 7 hours.
2.2.3 Preparation of rat serum
Rat blood was collected from the abdominal aorta of rats anaesthetized with diethyl ether. 
The blood was collected in a 20 ml plastic syringe and immediately centrifuged for 5 
minutes at 3,500 rpm to pellet the red cells. The fibrin clot that formed in the upper 
plasma layer was squeezed to release the serum. The blood was re-centrifuged for 5 
minutes at 3,500 rpm for 5 minutes and then the clear supernatant serum was drawn off 
with a Pasteur pipette. The serum was centrifuged again for 5 minutes at 3,500 rpm to 
pellet any remaining red cells and then the supernatant was drawn off and divided into 5 
ml aliquots. The serum was heat inactivated in a water bath at 56 °C for 30 minutes and 
then stored at -20 °C.
2.2.4 Analysis of embryo cultures
At the end of the culture period, embryos were first assessed for viability: any embryos 
that did not exhibit a vigorous yolk sac blood circulation (grade 1 or 2 ) and heart beat 
were eliminated from subsequent analysis (see Table 2.1). Extraembryonic membranes 
were then removed and embryos were scored for: (i) posterior neuropore length (the 
distance between the rostral end of the posterior neuropore and the tip of the tail bud), (ii)
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crown-rump length (Figure 2.2A.2) and (iii) somite number. Length measurements were 
made using an eyepiece graticule on a Zeiss SV6 stereomicroscope (Table 2.2).
Yolk sac circulation category Description
Very good + ++(1) Blood circulation vigorous and affecting whole yolk 
sac
Good ++(2 ) Blood circulation slow and /or in only part of the 
yolk sac
Bad/no circulation + (3) No blood circulation visible
Table 2.1 Assessment of yolk sac circulation
Yolk sac circulation Mouse Embryo Yolk sac
Ectoplacental cone
Figure 2.1 Yolk sac circulation. Yolk sac circulation was here used as a measurement of 
development. On the left panel the yolk sac vessels were injected with black ink with the 
sole purpose to enhance the view of the yolk sac circulation on the photograph.
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Feature assessed Expected appearance after culture 
(normal development)
Potential abnormalities
Yolk sac circulation Category 1 or 2 (see Table 2.2.1) No yolk sac circulation
Crown rump length Normal when compared to 
littermates with all other 
developmental criteria normal
Significantly reduced size 
when compared to normal 
litter mates
Somites Clearly defined somite boundaries 
Correct expected somite number = 
Time of culture/2 + original somite 
number
Irregular or unaligned 
somites
Fewer somites than expected 
for time in culture
Neural tube Closed head region and caudal 
neural tube or small PNP at E l0.5 
(approx. 30 somites)
Regions of open neural tube 
Wavy or distorted neural 
tube
Heart Looped heart and beating No heart beat
Axial rotation Embryo fully turned by E9.5 
(approx. 2 0  somites)
Turning incomplete
Table 2.2. Assessment of development after embryo culture
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Somites
Crown Rump
Heart
Length
Figure 2.2.Assessment of development after embryo culture. Physiological parameters 
such as the developing circulatory system (Heart), crown rump length and somite 
numbers were used as a measurement of development after embryo culture.
2.3 IN  VITRO TREATMENT OF EMBRYOS
2.3.1 Administration of inositol
Thirty minutes after the start of culture, myo-inositol (Sigma, UK) or D-c/n'ro-inositol 
(InsMed, Virginia, USA) was added to the medium (62.5 pi of inositol stock per ml rat 
serum) to achieve a final concentration of 5, 10, 20 or 50 pg/ml inositol in the cultures. 
Control cultures received an equal volume of phosphate buffered saline (PBS). In order to 
avoid variations in outcome as a result of differences in developmental stage among the 
cultured embryos, cultures were initiated using only embryos with approximately 17-19 
somites (assessed by dissection and somite counting of specimen embryos from each 
litter). Following 24 hours culture, embryos that fell outside the 29-31 somite range (one
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somite is added every two hours in mouse development) were discarded from analysis. 
Embryos within individual litters were allocated randomly to treatment groups in order to 
minimise the effect of litter-to-litter variations on developmental outcome.
2.3.2 In vitro treatment of embryos with chemical PKC inhibitors
Embryo cultures were supplemented with 1% (v/v) additions of phosphate buffered saline 
(PBS) or wyo-inositol, to a final concentration of 50 pg/ml. Each culture also received 
chemical or peptide PKC inhibitors as 1% (v/v) additions, as follows. 
Bisindolylmaleimide (Bis) I and V, Go6976, HBDDE and LY294002 (all from 
Calbiochem) were each diluted in a minimal volume of dimethyl sulfoxide (DMSO) and 
further diluted in PBS to give 1 mM stock solutions, which were added to embryo 
cultures to a final concentration of 10 pM. DMSO diluted in PBS was added to control 
cultures.
Inhibitor Concentration used* PKC isoform inhibited
Bis I 10 pM a, pi, pll, y, s
Bis V 10 pM Inactive form of BisI
Go 6976 10 pM a, pi, pil, y
HBDDE 50 pM a, y
LY294002 1.4 pM PI3K
Table 2.3 Concentration information for chemical PKC inhibitors
* Concentrations chosen to reflect I C 5 0  values for each PKC isoform
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2.3.3 In vitro treatment of embryos with peptide PKC inhibitors
Peptide PKC inhibitors coupled to carrier peptide were provided by Professor Daria 
Mochly-Rosen (Stanford University), and 100 juM solutions in PBS were added to 
embryo cultures to a final concentration of 1 pM.
Peptide inhibitor 
code number
Region against which 
peptide was designed
Isoform inhibited
ppl09 (C2-4) a
PP 97 (V5-3) PI
pp 96 ( V5-3) pn
pp 110 (C2-4) Y
pp 101 (5V 1-1/carrier) 5
pp 106 epsilon agonist 8
PP 98 Pseudosubstrate inhibitor 
of zeta
?
pp 94 (carrier-carrier) Control peptide
Table 2.4 Peptide translocation-inhibitors of PKC isoforms coupled to an 
Antennapedia carrier peptide, as used in this study
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2.4 A D M IN IS T R A T IO N  O F  IN O S IT O L  I N  UTERO
2.4.1 Methods for in utero administration
Inositol was administered to embryos in utero by two methods. Osmotic mini-pumps 
(capacity 100 pi, delivery rate 1 pl/hour, for 72 hr; Model 1003D, Alzet) were filled with 
solutions of 30, 75 or 150 mg/ml inositol (which delivered inositol at 29, 72 and 144 pg/g 
body weight/day respectively, for an average 25 g mouse). Control mice received mini­
pumps containing PBS. Mini-pumps were incubated in sterile PBS at 37°C for 4 hours 
and then implanted subcutaneously on the back of pregnant mice at E8.5 (Fig. 2.3). 
General anaesthesia was induced by an intra-peritoneal injection of 0.01 ml/g body 
weight of a solution comprising 10% Hypnovel® (Midazolam 5 mg/ml) and 25% 
Hypnorm® (fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/ml) in sterile distilled water. 
In a separate experiment, pregnant mice were gavaged with 0.5 ml inositol solution in 
PBS (400 pg inositol/g body weight) at 12 hourly intervals from E8.5 to E l0.5 (six doses 
in total). Hence, the dose of inositol delivered orally was 800 pg/g body weight/day.
Figure 2.3 Osmotic mini pumps were subcutaneously implanted in the upper body of 
ct mice
87
2.4.2 Analysis of fetuses following inositol treatment in utero
Pregnant females were killed at E l8.5, the uterus was opened and the total number of 
implantations, classified as viable fetuses or resorptions, was recorded. Fetuses were 
dissected from the uterus and inspected immediately for the presence of open lumbo­
sacral spina bifida and tail flexion defects, which are the primary manifestations of the 
curly tail genetic defect (Van Straaten and Copp, 2001). A randomly selected sample of 
fetuses was fixed in Bourn’s fluid and subjected to detailed internal pathological analysis 
(performed by Dr Sheila Tesh) by free-hand serial sectioning, using the method of Wilson 
(1965). A further sample of fetuses was fixed in 95% ethanol and processed for skeletal 
examination (performed by Dr John Tesh), by the method of Whittaker and Dix (1979). 
Fetuses and skeletal preparations were photographed using a Zeiss SV11 
stereomicroscope.
2.5 IMMUNOfflSTOCHEMISTRY
2.5.1 Preparation of routine histological sections
2.5.1.1 Dehydration and embedding
Embryos were fixed in 4% paraformadehyde (PFA) in PBS at 5 °C overnight. Before 
embedding in paraffin wax, the tissue was dehydrated by passage through a series of 
ethanol solutions of increasing concentration: 30%, 50%, 70% and 100%. Twenty-minute 
changes at each step were employed. Since alcohol is not miscible with molten paraffin, 
the alcohol in the tissue was removed by a 15 minute exposure to a mixture of equal parts 
of absolute ethanol and Histoclear (National Diagnostics) followed by two 15 minute 
changes in pure Histoclear. The tissue was transferred using a pipette to a glass- 
embedding dish containing molten paraffin wax (melting point 56 °C) in an embedding 
oven. After 30 minutes, the paraffin wax was poured out, and was replaced by fresh wax.
After another 30 minutes, when the tissue was thoroughly infiltrated with paraffin wax, 
the tissue was embedded as follows. While observing with a dissecting microscope, the 
dish containing the embryo was allowed to cool until the bottom layer of wax started to 
solidify. The tissue was properly orientated, in order to yield transverse sections when cut 
parallel to the bottom surface of the dish, using two pairs of heated blunt forceps. The 
paraffin wax was left at room temperature for several hours and then the dish was stored 
at -20 °C overnight. This enabled the paraffin block to be removed from the dish, after 
which it was then stored at 4 °C until required for sectioning.
2.5.1.2 Sectioning
The paraffin block was roughly trimmed using a razor blade and the base o f the block was 
slightly melted and attached to a wooden block, which was clamped to the microtome 
chuck. Ribbons of sections were cut at a thickness of 6  pm using a Leitz microtome. The 
ribbons were cut into short lengths and transferred to TESPA-coated slides (TESPA, 3- 
aminopropyl-triethoxy-silane glass slides, Sigma). Water, at 40 °C, was pipetted onto the 
surface of the slides, the sections were placed on top of the water and then the slides were 
placed on a slide dryer at 37°C in order to allow the sections to float and spread. Excess 
water was then removed from the slides, which were left to dry overnight. Slides were 
stored at 4°C until used for staining.
2.5.2 Immunodetection of PKC isoforms
Sections were re-fixed in 4% paraformaldehyde in PBS for 5 minutes at room 
temperature and subsequently washed twice in PBS, 1% BSA, 0.25% Triton X-100 for 15 
minutes. Antibodies were diluted prior to application as determined by prior titration 
studies. A range of dilutions for each antibody was tested initially, based on information
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provided in data sheets from commercial suppliers, or from previous usage by other 
groups. The dilution providing optimal signal with minimal background was selected for 
all subsequent experiments. Typically 100 pi of primary antibody was prepared for each 
section. Antiserum was diluted in the same solution utilised for non-specific protein 
blocking (10% fetal calf serum in PBS containing 1% TWEEN 20 (PBS-T)). Primary 
antibodies were diluted as shown in Table 2.5, and applied immediately following 
blocking, without washing. The blocking solution was carefully poured from the slide 
onto a folded tissue; and replaced with antibody solution. In the case of negative control 
tissue sections, the blocking solution was not replaced. Primary antibodies were applied 
overnight at 4 °C. Next day, any excess antibody was rinsed from the sections by 
immersion in a Coplin jar containing PBS-T for 10 minutes with gently shaking. This was 
repeated 3 times to ensure all unbound antibody had been washed off, to minimise 
background staining. The selection of secondary antibody varied with the species from 
which the primary was obtained, and with the desired choice of detection method. The 
secondary antibodies were raised in goat and directed against either rabbit or mouse 
immunoglobulin, and conjugated to FITC. Secondary antibodies were diluted (1:40) in 
PBS, 10% FCS, 0.25% Triton X-100, and incubated for 1 hour at room temperature in a 
humid chamber. The humid chamber was covered with aluminium foil to prevent the 
fluorescence from becoming ‘bleached’ by exposure to light. Unbound secondary 
antibody was then rinsed from the sections by three 10 minute washes in PBS-T. Slides 
were dried and mounted in Citifluor (anti-photobleaching mounting medium for 
immunofluorescence, Citifluor Ltd.). Controls for immunohistochemistry were: 1) 
Omission of primary antibody (to test non-specific staining of secondary antibody); 2) 
Substitution of primary antibody by non-specific IgG; 3) Pre-absorption of primary 
antibody with the specific peptide against which antibody was raised. Peptide sources are
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shown in Table 2.5. In addition, when fluorescence immunodetection was used, Hoechst 
nuclear dye was also added to the secondary antibody mixture. This resulted in all nuclei 
staining blue in colour under fluorescent illumination.
2.5.3 Immunochemical Reagents
PKC isotype hyphen-specific affinity purified rabbit IgG primary antibodies were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA) (See Table 2.3 for details). 
The secondary antibody was a FITC-conjugated goat anti-rabbit IgG (Jackson Immuno 
Research).
2.5.4 PCNA
The Proliferating Cellular Nuclear Antigen (PCNA) was detected using a mouse 
monoclonal IgG2a antibody derived by fusion of spleen cells from a BALB/c mouse 
immunised with recombinant PCNA with Sp2/0-Ag 14 myeloma cells (Santa Cruz 
Biotechnology). It reacts against the PCNA p36 protein expressed at high levels in 
proliferating cells of human, murine, insect and yeast origin.
2.5.5 H3
Anti-phospho-Histone H3 (Upstate Biotechnology, Buckingham, UK) specifically 
recognises the phosphorylated 17 kDa histone H3 that is found only in mitotic cells. The 
antibody was raised in the rabbit, using amino acids 7-20 of the human H3 as 
immunogen.
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2.5.6 Hoechst Dye
Staining of cell nuclei was performed using Hoechst 33258 at 1.2 mg/ml dilution in 
water. This stock was further diluted 1 in 500 prior to use.
Antigen detected *Primary antibody 
code
Concentration used
PKC a Sc208 1:200
PKC pi Sc209 1:100
PKC p il Sc210 1:100
PKC y Sc211 1:200
PK Cs Sc214 1:200
PCNA PC10 1:100
Phospho Histone 
H3
(Upstate Biotech, 
Buckingham, UK)
1:100
Hoechst 33258 1:1000
Table 2.5 Immunochemical reagents
*Unless stated, all primary antibodies were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA)
2.6 MOUSE CELL CULTURE
2.6.1 Generation of curly tail primary cell lines
Embryos at the 27 somite stage were removed from the uterus and placed in PBS in a 
plastic dish. The posterior neuropore region was excised from around the level of somite
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20 and cut into small pieces, minced, and transferred into a 15 ml centrifuge tube 
containing 10 ml dissociation buffer (GIBCO™ Cell Dissociation Buffer, enzyme free, 
Hanks'-based) (roughly enough for 15 tails) and incubated for 20 minutes at room 
temperature with gentle shaking. The large tissue clumps were dissociated by repeated 
pipetting using a 10 ml serological pipette and by passage through a Nitex filter. The 
supernatant was transferred into a fresh centrifuge tube and spun for 5 minutes at 1,000 
rpm at room temperature. The supernatant was discarded and the cells were resuspended 
in 5 ml growth medium. Cells were counted using a haemocytometer and the final 
volume was adjusted to 2x 106 cells/ml. The cells were seeded directly on plastic dishes 
and cultured at 37°C in 5% CO2 for 5 passages.
2.6.2 Culture methods
Cells were cultured on glass cover slips coated for 30 minutes with poly-L-lysine and 30 
minutes with fibronectin (to allow attachment of cells to the glass substrate). The cover 
slips were transferred to a 24-well culture dish, seeded with approximately lx l04 cells 
and cultured for 5 hours in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
10% v/v heat inactivated fetal bovine serum and 1% v/v penicillin-streptomycin solution 
(1 0 ,0 0 0  units penicillin and 10  mg streptomycin per ml).
2.6.2.1 Culture splitting
All solutions were pre-warmed to 37°C. The cells were briefly washed with PBS (without 
CaCb and MgCb) and then detached by adding a few drops of trypsin-EDTA solution 
(0.05% porcine trypsin and 0.02% EDTA.4Na) and incubating at room temperature as 
necessary. Adding 2 ml of growth medium inactivated the trypsin. The cells were 
centrifuged for 5 minutes at 1,000 rpm, at room temperature, and the supernatant was
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discarded. The cells were then resuspended in the desired amount of fresh growth 
medium and seeded in plastic dishes.
2.6.2.2 Immortalised cells used in control cultures
3T3 mouse cell line used was obtained from the Dunn School Cell Bank (Department of 
Pathology, University of Oxford). They were grown in DMEM in a humidified 37°C 
incubator, with 5% CO2.
2.6.3 Treatment of cells with TPA and PKC peptide inhibitors
In all experiments, cells were serum starved by culture in DMEM containing 1% fetal calf 
serum for 18 hours. Some samples were then treated with 100 mM TPA for 10 minutes 
and then for 20 minutes with 100 mM PKC isoform-specific peptide-bound inhibitors.
2.6.4 Immunocytochemical analysis
Cells grown on cover slips were stained with anti-PKC antibodies (Table 2.2.5). All 
solutions were applied in 100  pi volumes, which were sufficient to entirely coat the 
coverslip. Coverslips were placed on top of small pedestals (lids from screw-capped 
eppendorf tubes). This allowed the coverslips to be manipulated easily. Cells were fixed 
in 4% PFA solution for 8 minutes. After fixation, coverslips were lifted using forceps and 
excess solution was removed by touching the side of the coverslip on some folded tissue 
paper. The coverslip was then washed by dipping successively in three 30 ml tubes 
containing PBS. Each dip lasted around 4 seconds. The primary antibody (diluted 1:200 
in 10% fetal calf serum in PBS) was then applied and left for 1 hour at room temperature. 
Following this, the primary antibody was blotted off, and the coverslip was washed three 
times in PBS as before. The secondary antibody (diluted 1:40 in 10% fetal calf serum in
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PBS) was then applied and left for 1 hour at room temperature. The coverslip was then 
washed a further 3 times in PBS, followed by a brief wash in distilled water. Finally, 
Citifluor was used to mount the coverslips on clean glass slides. Translocation of specific 
PKC isoforms was assessed using PKC isoform-specific antibodies (Santa Cruz 
Biotechnology) in immunofluorescence studies and the percentage o f cells showing 
translocation was determined by counting labeled cells, in a blinded fashion. Each 
isoform experiment was performed in triplicate. The slides were visualised using a Zeiss 
fluorescence microscope fitted with a digital camera, and images were recorded using 
Northern Eclipse computer software and scanned directly into OpenLab.
2.6.5 Labelling indices
The labelling indices (total number of labelled cells divided by the total cell number, 
multiplied by hundred) were obtained from alternate transverse sections through the 
rostral end of the PNP stained for PCNA or histone H3. Experiments were carried out in 
triplicate by an observer blinded for treatment type.
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CHAPTER 3 
PREVENTION OF FOLATE-RESISTANT NTDs
3.1 INTRODUCTION
Folic acid supplementation during early pregnancy can prevent a proportion of NTDs, as 
indicated by several clinical trials and other observational studies (Abramsky et al., 
1999);(Wald et al., 2001); (Antony and Hansen, 2000). Nevertheless, NTDs may occur 
even following maternal folic acid supplementation. For example, in the randomized 
controlled trial conducted by the Medical Research Council Vitamin Research group, UK 
(Wald et al., 1991), the recurrence rate of NTDs was reduced by approximately 72%. 
Thus, NTDs still occurred despite maternal supplementation with 4 mg folic acid per day. 
Interestingly, the recurrence rate in folic acid-treated pregnancies in this MRC trial (1 %) 
was ten times higher than the usual occurrence rate in the population (0.1  %, or 1 per 
1000). Furthermore, the recent introduction of folic acid fortification of bread flour in the 
USA has resulted in only a 26% decline in the prevalence of NTDs (Honein et al., 2001). 
While these findings may indicate the need for increased levels of folic acid 
supplementation, they are also consistent with a proportion of NTDs exhibiting resistance 
to prevention by exogenous folic acid.
Mouse genetic models of NTDs provide further evidence for the existence of folate- 
resistant NTDs types Wald, 2001;(Carmichael et al., 2003). Mutant strains including 
Cartl, crooked tail and splotch exhibit NTD that can be prevented by folic acid 
administered during early pregnancy (Zhao et al., 1996), whereas folic acid is ineffective 
in preventing NTDs in the mutant strains curly tail, Axial defects and ephrin-A5 
(Glanville and Cook, 1992;Tran et al., 2002). Of these ‘folate-resistant’ strains, curly tail 
provides a particularly useful model for human NTDs both in terms o f its etiology and 
pathogenesis (van Straaten and Copp, 2001).
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3.1.1 Inositol as a preventive therapy for folie acid-resistant NTDs in mice
Previous work has shown that a proportion of the folate-resistant NTDs in curly tail mice 
can be prevented by treating pregnant females, or embryos in vitro, with myo-inositol 
(Greene and Copp, 1997a). This work was prompted by the earlier finding that deficiency 
of myoinositol in the culture medium of rat and mouse embryos causes a high incidence 
of cranial NTDs (Akashi et al., 1991). Moreover, NTDs that develop in rat embryos 
cultured under hyperglycemic or diabetic conditions are associated with depletion of 
inositol (Kubow et al., 1993) and can be ameliorated by supplementation with myo­
inositol (Baker et al., 1990). These findings raised the possibility that inositol may offer a 
potential alternative therapeutic option for prevention of folate-resistant NTD. Although 
the effect of inositol on human NTD recurrence, in cases of suspected folate-resistance, 
has not yet been rigorously evaluated, a recent case study has highlighted a possible 
beneficial effect. Myo-inositol therapy was associated with a normal third pregnancy 
outcome, in a family with two previous consecutive NTD pregnancies despite full folic 
acid supplementation (Cavalli and Copp, 2002).
The purpose of this chapter is to evaluate in detail the potential of inositol as a primary 
therapeutic agent in preventing mouse NTDs using the curly tail mouse as a model. The 
aims were to test different routes of administration and to investigate any possible 
harmful effects of inositol on the developing embryo. In addition, I compared the efficacy 
of two enantiomers of inositol, myo-inositol and chiro-inositol.
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3.2 RESULTS
Embryos were exposed to inositol either by direct treatment in whole embryo culture, or 
by dosing pregnant females via subcutaneous and oral routes.
3.2.1 D-c/uro-inositol has greater potency than myo-inositol in normalising neural 
tube closure
Curly tail embryos were cultured in the presence of inositol for 24 hours from E9.5, the 
period during which the neural tube is closing in the low spinal region of the mouse 
embryo. In normal embryos, primary neurulation is completed by closure of the posterior 
neuropore at E l0.5 (at the 29-30 somite stage) (Copp et al., 1999), whereas in curly tail 
embryos neuropore closure is delayed, or fails to be completed, leading to the 
development of tail flexion defects and spina bifida, respectively(Copp et al., 1988c). 
Posterior neuropore length at E l0-10.5 (Fig. 3.1) is positively correlated with the 
likelihood that an embryo will progress to develop a spinal NTD (Copp et al., 1988b).
Both myo- and D-c/zzVo-inositol showed a dose-dependent normalisation of posterior 
neuropore length in embryo culture, as judged by the statistically significant reduction in 
neuropore length observed in embryos treated with higher inositol doses (Table 3.1). 
Strikingly, however, D-c/zzro-inositol reduced neuropore length significantly at both 20 
and 50 pg/ml whereas a comparable effect was seen only with 50 pg/ml myo-inositol. In 
fact, embryos exposed to 20 pg/ml myo-inositol (and 5-10 pg/ml D-c/nro-inositol) 
exhibited neuropore lengths that were not significantly different from PBS-treated 
controls (Table 3.1). Therefore, it appears that D-c/u>o-inositol has increased potency 
compared with myo-inositol in normalizing neurulation, an effect that is detectable in 
vitro, outside the maternal environment.
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Figure 3.1 PNP closure in curly tail mouse embryo. A. Curly tail embryo after 24 hours 
culture from E8.5 to E9.5. Box indicates the posterior neuropore region. B, C. Higher 
magnification views of the caudal end of cultured curly tail embryos showing posterior 
neuropores of varying length. The region of open neural folds occupies the dorsal part of 
the caudal region, between the arrows in (B) and (C). Embryos with a large neuropore (C) 
progress to develop spina bifida and/or a tail flexion defect, whereas embryos with a 
small neuropore (B) complete neural tube closure normally. Scale bars: A = 0.5 mm; B,C 
= 0 .2  mm.
3.2.2 Neither myo- nor D-chiro-inositol affects the rate of embryonic growth in 
embryo culture
In the experimental design, embryos in the different treatment groups were matched for 
somite number, both before and following the culture period (see section 2.3.1). The aim 
was to avoid differences in developmental outcome (PNP length) that might arise from 
comparing embryos of different stages. As expected, therefore, mean somite number 
following culture was closely similar in all the treatment groups (Table 3.1). There was
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no significant difference in crown-rump length between embryos treated with either myo- 
or D-c/hro-inositol and PBS-treated controls (Table 3.1), suggesting that the effect of 
inositol is specific to the closing posterior neuropore, and not mediated via embryonic 
growth acceleration or retardation. In particular, the greater potency of D-c/nVo-inositol 
does not appear to result from a differential effect on embryonic growth.
TREATMENT
Cone.
(pg/ml) No. embryos Somite number 1 Crown-rump length 
(mm)
PNP length 1 
(mm)
PBS 0 16 30.3 ±0.15 3.56 ± 0 .10 0.59 ±0.13
myo 20 16 30.5 ±0.12 3.50 ±0.12 0.62 ± 0.06
50 16 30.5 ±0.14 3.57 ± 0 .07 0.06 ± 0.03*
D-chiro 5 15 30.6 ±0.13 3.50 ± 0 .10 0.62 ±0.11
10 15 30.5 ±0.13 3.39 ± 0 .10 0.55 ±0.11
20 18 30.6 ± 0 .16 3.55 ± 0 .10 0.09 ±0.11*
50 15 30.3 ± 0 .16 3.49 ± 0.08 0.07 ± 0.03*
Table 3.1. Comparison of growth and developmental parameters in curly tail 
embryos cultured in the presence of myo- and D-c/uro-inositol
1 Values presented are: mean ± SEM. Statistical analysis: somite number and crown-rump 
length do not differ significantly between treatment groups (Analysis of variance on 
ranks: p  = 0.72 and 0.54 respectively), whereas posterior neuropore (PNP) length varies 
significantly between treatment groups (p < 0 .0 0 0 1 ).
Ordinal regression analysis shows that PNP length is significantly reduced (marked with 
asterisk) in embryos treated with wyo-inositol (50 pg/ml) and D-c/uro-inositol (20 and 50 
pg/ml) compared with those exposed to PBS alone (p < 0.05), whereas PNP length in 
other inositol-treated groups does not differ significantly from the PBS control group.
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3.2.3 D-c/t/ro-inositol reduces the frequency of spinal neural tube defects to a greater 
extent that myo-inositol following in utero administration
I next evaluated the possibility of using subcutaneous and oral routes of inositol 
administration to prevent NTDs in the fetuses of pregnant curly tail females. In order to 
administer inositol at a constant rate over a period of 72 hours of pregnancy, to 
encompass the stages of neural tube closure, osmotic mini-pumps were surgically 
implanted. These delivered inositol by subcutaneous infusion at a rate of 1 pl/hour. Using 
this approach a dose-dependent effect of both myo- and D-c/uro-inositol was observed.
At a dose of 29 pg/g body weight/day, neither myo- nor D-c/nro-inositol produced a 
significant reduction in the frequency of fetuses developing spina bifida nor was the 
distribution of fetuses between the three phenotype categories (spina bifida, tail defect 
and normal) altered significantly (Table 3.2.). In contrast, dosing levels of 72 and 144 
pg/g body weight/day both produced a significant reduction in the frequency of spina 
bifida compared with PBS-treated pregnancies and caused a significant shift in the 
distribution of fetuses towards the mild end of the phenotype spectrum (Table 3.2.). D- 
c/nro-inositol appeared most effective at both 72 and 144 pg/g body weight/day, causing 
a 73-83% decrease in spina bifida frequency relative to PBS controls. Myo-inositol 
produced a consistent 54-56% reduction in spina bifida frequency, but this did not reach 
statistical significance (see below).
Statistical comparisons between the PBS, D-chiro- and myo-inositol treatment groups, 
separately at each dose level ( 3 x 2  chi-square tests), reveals significant variation in 
frequency of spina bifida at 72 and 144 pg/g body weight/day (p = 0.014 and 0.006 
respectively) but not at 29 pg/g body weight/day (p = 0.494 respectively). Pairwise
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testing reveals a significantly lower frequency of spina bifida among fetuses treated with 
D-c/hro-inositol compared with PBS at 72,144 pg/g body weight/day ip = 0.006, and 
0.013 respectively) but not at 29 pg/g body weight/day ip = 0.291). Frequency of spina 
bifida among fetuses treated with myo-inositol is consistently intermediate between the 
values for D-c/hro-inositol and PBS, and does not differ from either treatment group at 
any dose level ip > 0.05). Hence, D-c/nro-inositol exerts a significantly more potent 
preventive effect against spina bifida than myo-inositol when delivered sub-cutaneously.
As an alternative route of treatment, inositol was administered to pregnant females by 
gavage, using a twice-daily dosing regime, from E8.5 to E l0.5 that delivered 800 pg/g 
body weight/day (equivalent to the intraperitoneal dose used in the previous study 
(Greene and Copp, 1997a). As with sub-cutaneous administration, there was a marked 
reduction in the frequency of spina bifida among the offspring of mice treated with either 
myo- or D-c/nro-inositol. There was also observed a significant shift in the distribution of 
fetuses between the three phenotype categories (Table 3.2). D-c/hro-inositol was most 
effective, causing a statistically significant 8 6 % reduction in the frequency of spina bifida 
ip = 0.032), while the 53% reduction observed for myo-inositol was not statistically 
significant ip = 0.059).
I investigated whether clustering of fetuses of particular phenotypes within litters may 
have affected the outcome of the comparison between myo-inositol, D-c/zzVo-inositol and 
PBS. An ordinal multilevel regression model (which took into account the potential non­
independence of fetuses within litters) was fitted to the data. This confirmed that fetuses 
treated subcutaneously with D-c/u>o-inositol are significantly more likely to be normal 
than those treated with PBS ip < 0.0005). The comparison between myo-inositol and PBS
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also reached statistical significance in this analysis (p < 0.002). In the oral dosing study, 
fetuses were more likely to be normal when treated with D-c/nVo-inositol than PBS {p = 
0.0097), whereas the values for /wyo-inositol and PBS did not differ significantly (p = 
0.13).
Importantly, the multilevel analysis indicated that the difference between treatment 
groups is unaffected when possible litter effects are taken into account. Hence, it appears 
that the reduction in NTD frequency following treatment with myo- and D-c/n'ro-inositol 
is unlikely to arise from litter-to-litter variations.
3.2.4 No evidence of an adverse effect of inositol on pregnancy success or fetal 
outcome
One possible explanation for a decrease in spina bifida frequency following maternal 
inositol administration could be an increase in loss of affected fetuses during pregnancy. 
Therefore, resorption rate and litter size were examined in pregnancies receiving either 
subcutaneous mini-pumps or twice-daily gavage. No significant differences were found 
between pregnancies treated with inositol and those receiving PBS alone (Table 3.3). This 
strongly suggests that there is no adverse effect of inositol dosing on the overall success 
of mouse pregnancy. A noticeable reduction was found, however, in the litter size of mice 
subjected to oral inositol administration, where litters contained fewer fetuses than those 
receiving inositol subcutaneously (Table 3.3). As litter size did not vary between 
treatments this difference is thought to reflect the increased maternal stress caused by 
daily gavage (without anaesthesia) compared to a single surgical operation, under general 
anaesthesia, to insert a subcutaneous miniosmotic pump. To identify any adverse effects 
of inositol treatment on fetal outcome, an extensive pathological analysis of treated
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Table 3.2 Frequency of neural tube and tail defects among curly tail fetuses treated 
in utero with myo- and D-c/«>0 -inositol
1 Inositol dose is expressed as: pg inositol/g body weight/day.
2 Phenotype frequencies are expressed as number of fetuses with % of total for treatment 
group.
3 Statistical analysis: distribution of embryos among the three phenotype categories varies 
significantly with treatment group at 72, 144 and 800 pg inositol/g body weight/day (Chi- 
square tests,/? = 0.0005, 0.0051 and 0.026 respectively) but not at 29 pg inositol/g body 
weight/day (p = 0.34).
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Table 3.2
9  *3Phenotype of fetuses ’
Route of 
administration
Treatment Inositol 
dose 1
Spina bifida + 
curly tail
Curly tail Normal
PBS - 6  (24.0) 14 (56.0) 5 (20.0)
myo 29 6  (20.7) 12(41.4) 11 (37.9)
D-chiro 29 3(11.5) 17(65.4) 6(23.1)
PBS - 14(13.5) 63 (60.6) 27 (25.9)
Sub­ myo 72 4 (6.0) 37 (55.2) 26 (38.8)
cutaneous D-chiro 72 2 (2.3) 39 (45.4) 45 (52.3)
PBS - 19(18.6) 49 (48.0) 34(33.3)
myo 144 8 (8.5) 52 (55.3) 34 (36.2)
D-chiro 144 5 (5.0) 46 (46.5) 48 (48.5)
PBS - 8(18.2) 21 (47.7) 15(34.1)
Oral myo 800 3 (8 .6 ) 15 (42.9) 17(48.6)
D-chiro 800 1 (2 .6 ) 12 (30.8) 26 (66.7)
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fetuses was performed, using both free-hand serial sectioning and skeletal preparation 
(carried out by our collaborator, Ms Sheila Tesh). This analysis confirmed the occurrence 
of spina bifida and tail defects in a proportion of fetuses (Figure 3.3), as also scored by 
external fetal inspection.
Additionally, exencephaly, a failure of cranial neural tube closure, was observed in a 
small proportion of fetuses (Tables 3.4 and 3.5). Exencephaly is a recognised defect in 
curly tail homozygotes (Casey et al., 1997). In the present study, no overall increase or 
decrease in this defect in inositol-treated fetuses was observed compared with PBS 
controls, although the low frequency of affected fetuses may have obscured any treatment 
effect.
Internal and skeletal examination of control and inositol treated fetuses revealed almost 
no major structural defects, apart from NTDs (Tables 3.4 and 3.5). For instance, no major 
malformations of the heart, lungs, kidney, gut or limbs were identified. Among the 
morphological changes observed in the analysis, most were minor (e.g. small additional 
liver lobe) and the great majority occurred as frequently in PBS controls as in fetuses 
treated with myo- or D-c/uro-inositol (Tables 3.4 and 3.5). D-c/hro-inositol (144 pg/g 
body weight/day) was associated with a somewhat elevated frequency of enlargement of 
the renal pelvis/ureter (Table 3.4), and occurrence of anomalous cervical vertebrae and 
rudimentary ribs on the 7th cervical vertebra (Table 3.5). However these associations were 
not statistically significant.
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Figure 3.2 Skeletal preparations of E18.5 curly tail fetuses.. The tail flexion defect (A) 
comprises 360° curl of the tail, compared with the normal fetus which exhibits a straight 
tail (B).Compared with a normal fetus in (B), the fetus with spina bifida (C) exhibits 
vertebral pedicles widely spaced apart and absent neural arches in the low lumbar/sacral 
region (long arrow in C). The tail (short arrow in C) is enclosed in a skin sac and appears 
reduced in length owing to deformation and fusion of caudal vertebrae. Scale bars = 2 
mm.
Interestingly, anomalous cervical vertebrae appear to be especially associated with 
exencephaly: both defects were found in a fetus treated with myo-inositol (144 pg/g body 
weight/day) and in a second fetus treated with D-c/z/ro-inositol (144 pg/kg body 
weight/day), which also exhibited thoracic rib anomalies. A further two fetuses from the 
same D-c/z/ro-inositol treated litter had cervical vertebral anomalies and a third had 
thoracic vertebral and rib anomalies, while a single fetus from a different litter had 
cervical vertebral anomalies. It seems likely that these cervical anomalies may form part 
of the spectrum of vertebral column defects present in the curly tail mouse, often in 
association with exencephaly.
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Route of  
administration
Treatment Inositol 
dose 1
No.
litters
No.
viable
fetuses
No. uterine 
resorptions2
Mean litter size 
± SEM 3
PBS - 4 25 3 (10.7) 6.25 ±  1.03
myo 29 4 29 2 (6.5) 7.25 ±  1.80
D-CHIRO 29 3 26 1 (3.7) 8.67 ±  1.76
Sub-cutaneous
PBS - 12 104 10(8.8) 8.67 ± 0 .50
myo 72 8 67 7(9.5) 8.38 ± 0 .78
D-CHIRO 72 12 86 8 (8.5) 7.17 ± 0 .89
PBS - 12 102 9(8.1) 8.50 ± 0 .79
myo 144 12 94 9 (8.7) 7.83 ±  0.44
D-CHIRO 144 14 99 6(5.7) 7.07 ±  0.75
PBS - 7 44 5 (10.2) 6.29 ± 0 .36
Oral myo 800 6 35 3 (7.9) 5.83 ±0.48
D-CHIRO 800 6 39 3(7.1) 6.50 ±  1.09
Table 3.3 Survival of embryos and fetuses among curly tail litters treated in utero 
with myo- and D-cA/ra-inositol
1 Inositol dose is expressed as: pg inositol/g body weight/day.
2 Values in parentheses indicate resorptions as a % of total number of implantations (i.e. 
viable fetuses + resorptions). Logistic regression analysis: the proportion of resorptions 
does not differ significantly between wyo-inositol and PBS litters (p = 0.87), between D- 
c/nro-inositol and PBS litters (p = 0.33), or between inositol dose levels (p = 0.88).
3 Litter size (viable fetuses per litter) does not vary significantly with treatment group or 
inositol dose level (two-way analysis of variance: treatments, p = 0.987; inositol dose 
level,/? = 0.054).
Litters treated with oral inositol contain an average of 1.6 (95% confidence intervals: 0.4, 
2 .8 ) fewer animals than litters treated with sub-cutaneous inositol.
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Table 3.4 Internal pathological analysis, by freehand serial sectioning, of curly tail 
fetuses treated in utero with myo- and D-chiro-inositol
1 A single fetus may have more than one morphological finding.
9 • • • •Values are number of fetuses with defect (% of total for treatment group is indicated in 
parentheses).
3 Proportion of fetuses with renal pelvis/ureter defect does not differ significantly between 
fetuses treated with D-c/z/ro-inositol (144 pg/g body weight/day) and PBS controls 
(Fisher's exact test; p  = 0.231).
4 Calculation of % based on number o f male fetuses.
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Table 3.4
myo D-chiro
Inositol dose 
(p.g/g body weight/day) 72 144 72 144 72 144
No. fetuses examined 1 27 17 11 21 24 19
No. males : females 13 : 14 6 : 11 5 : 6 9 : 12 15 : 9 7 : 12
Head:
Exencephaly + open e y e 2 1 (3.7) 2(11.8) - 2 (9.5) - 1 (5.3)
Hydrocephaly 1 (3-7) - 1 (4.8) - 1 (5.3)
Haemorrhage in/around brain “ 2(11.8) - 2 (9.5) - 1 (5.3)
Microphthalmia “ 1 (5.9) - - - -
Macrophthalmia 1 (3-7) “ - - - "
Blood in nasopharynx - 2(11.8) - - 1 (5.3)
Thorax and abdomen:
Bleeding in thorax/abdomen 6 (22.2) 4 (23.6) 2(18.2) - 2 (8 .4 ) 1 (5.3)
Thyroid lobe reduction 1 (3-7) - 1 (4.8) - -
Carotid artery displaced laterally - - - - 1 (5.3)
Intrahepatic bleeding | 1 (5-9) 1 (9.1) 1 (4.8) -
Small additional liver lobe 9 (33.3) 4 (23.5)
i
6 (54.5) 4 (19 .0 ) 6 (25.0) 4(21 .1)
Fissure in liver lobe 2(11.8)
i
1 (9.1) - - 1 (5.3)
Umbilical hernia 1 (3.7) _ - - -
Kidney elongated - - 1 (4.2) -
Renal papilla absent bilaterally 1 (5.9) - - - -
Renal pelvis/ureter enlarged 3 1 (3-7) - - 1 (4.2) 3 (15.8)
Testis displaced cranially4 1 (7.7) - “ - 1 (6.7) -
Anal opening reduced in size 2 (7 .4) ■ - -
Subcutaneous oedema 1 (3.7) - - -
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Table 3.5 Skeletal analysis of curly tail fetuses treated in utero with myo- and D- 
chiro-inositol
1 A single fetus may have more than one morphological finding.
. Values are number of fetuses with defect (% of total for treatment group).
Three fetuses were from the same litter, one of which exhibited exencephaly. The 
proportion of fetuses with anomalous cervical vertebrae does not differ significantly 
between fetuses treated with D-c/uVo-inositol (144 pg/g body weight/day) and PBS 
controls (Fisher exact test; p  = 0.11).
4 Proportion of fetuses with rudimentary ribs on 7th cervical vertebra does not differ 
significantly between fetuses treated with D-c/u>o-inositol (144 pg/g body weight/day) 
and PBS controls (Fisher exact test; p  = 0.14).
5 Both affected fetuses are from the same litter, one also exhibited with exencephaly and 
cervical vertebral anomalies.
A dash (-) indicates that no fetuses exhibited that finding.
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Table 3.5
PBS
control
myo D-chiro
Inositol dose 
(pg/g body weight/day) 72 144 72 144 72 144
No. fetuses examined 1 29 18 16 18 22 21
Exencephaly - - - 2(11.1) - 2 (9 .5 )
Bony plaque in frontonasal suture 1 (3.4) - 1 (6.3) - - 1 (4.8)
Anomalous cervical vertebra(e) - - - - 1 (5 .6 )5 4 (1 9 .0 )3
Rudimentary ribs on 7th 
cervical vertebra 4 4(13 .8) 2(11.1) 1 (6.3) 3 (16.7) 1 (4.5) 7(33.3)
Anomalous thoracic vertebrae and/or ribs - - - - - 2 (2 .5 )5
Rudimentary 14th ribs - 1 (5.6) - 1 (5.6) - 1 (4.8)
Stemal fusions 1 (3.4) - - - - 2(9 .5)
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3.3 DISCUSSION
This chapter describes studies to evaluate the ability of exogenous inositol to prevent 
spina bifida in a mouse genetic model of folate-resistant NTDs. Maternal inositol 
administration significantly reduced the frequency of spina bifida in curly tail mice and 
normalized closure of the PNP in whole cultured embryos. A striking finding was the 
increased potency of D-chiro- compared with myo-inositol. At identical dosage levels, 
subcutaneously administered D-c/»>o-inositol caused a consistently greater reduction in 
frequency of spina bifida than myo-inositol. Moreover, in vitro, D-c/u>o-inositol was 
effective in normalizing neural tube closure at a concentration at which myo-inositol had 
no effect.
3.3.1 Possible reasons for the greater potency of D-chiro-inositol in preventing NTDs
Previous work suggested that the protective effect of myo-inositol is mediated via the 
phosphoinositide cycle (Greene and Copp, 1997a). Briefly, this cycle involves hydrolysis 
of phosphatidylinositol diphosphate by receptor-activated phospholipase C, to generate 
the second messengers inositol triphosphate and diacylglycerol (DAG) (Majerus, 1992). 
Among the downstream events of this signalling pathway, activation of protein kinase C 
(PKC) by DAG appears to be critical for normalisation of neuropore closure in curly tail 
embryos. For instance, activation of PKC by phorbol esters mimics the effect of inositol 
supplementation, whereas PKC inhibitors abrogate the protective effect (Greene and 
Copp, 1997a).
Although the role of PKC in mediating the effect of D-c/z/ro-inositol has not yet been 
investigated, one possibility is that both inositol enantiomers act through the same PKC- 
dependent pathway. In this case, the greater potency of D-c/nro-inositol may result from
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its differential incorporation and metabolism within the phosphoinositide cycle. Such 
increased potency of D-chiro- compared to myo-inositol has been demonstrated in other 
systems. Thus, insulin stimulation of rat fibroblasts
expressing the human insulin receptor leads to a significant increase in the incorporation 
of D-c/uro-inositol into phospholipids whereas the effect on myo-inositol incorporation is 
only marginal (Pak et al., 1993). Moreover, D-c/»>o-inositol induces a much larger 
reduction in plasma glucose level in rats rendered diabetic by streptozotocin 
administration compared with exogenous myo-inositol (Ortmeyer et al., 1993). These 
findings suggest an inherently greater potency or bioactivity of D-c/u>o-inositol than 
myo-inositol, perhaps as a result of incorporation into different phosphatidylinositol 
species (Pak and Lamer, 1992). I suggest that the greater potency of D-c/zz'ro-inositol in 
preventing NTD in curly tail mice, may reflect a relatively greater production of second 
messengers and/or downstream stimulation of PKC by D-c/uro-inositol. It is striking, 
however, that these differences of in vivo potency are maintained in the face of the 
demonstrated interconversion of the two inositol isomers. Pak et al. (1992) showed that 
[ H]myo-inositol is converted to [ H]D-c/u>o-inositol in rat tissues. Perhaps the rate of 
interconversion is too low to obscure the inherently greater potency of D-c/uVo-inositol in 
short-term effects on embryonic development.
3.3.2 Relevance of the findings for clinical application of inositol therapy
In order for these experimental findings to be translated into a clinical application, 
inositol supplementation must be demonstrated to be both effective in preventing NTDs 
and safe for use during human pregnancy. In terms of efficacy, this study has 
demonstrated a protective effect of inositol in a mouse NTD model, using subcutaneous
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and oral routes of administration, and these findings are supported by previous work in 
which myo-inositol was injected intraperitoneally (Greene and Copp, 1997a). Oral dosing 
is most likely to be useful in humans, and further support for the effectiveness of oral 
supplementation with myo-inositol comes from the finding of a reduction in the incidence 
of diabetes-induced abnormalities in rats by oral administration of myo-inositol 
(Khandelwal et al., 1998). The efficacy of inositol in preventing human NTDs has not yet 
been tested in a clinical trial. However, in a recent case study, inositol supplementation 
was associated with a normal pregnancy outcome in a woman who had experienced two 
consecutive NTD pregnancies while taking 4 mg folic acid throughout the peri- 
conceptional period (Cavalli and Copp, 2002). The empirical recurrence risk of NTD 
following two previous affected fetuses is approximately 1 in 9 (Seller, 1981) so, clearly, 
the association of inositol therapy with normal pregnancy outcome in this case may have 
been a chance association. A larger study of pregnancies at risk of ‘folate-resistant’ 
NTDs is needed to test the idea that inositol may be effective in humans, as in mice.
With regard to the safety of inositol therapy during pregnancy, the pathological survey of 
fetuses from inositol-treated mice revealed no major defects, apart from NTDs, and no 
increase in the frequency of embryonic or fetal loss in utero. These findings are 
indicative of the relative safety of inositol usage during pregnancy, although direct 
information from use in human pregnancy is also urgently needed. In the case of the 
mother who took inositol in a third pregnancy, following two apparently ‘folate-resistant’ 
NTD pregnancies, a dose of 0.5 g inositol per day was used, with no apparent side effects 
for mother or baby (Cavalli and Copp, 2002). In particular, there was no evidence of 
abnormal uterine contractions, such as have been suggested as a possible adverse effect of 
inositol therapy (Limpach et al., 2000). The reproductive toxicology of D-c/nVo-inositol
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has been the subject of several studies in both rats and rabbits at doses up to 2000 
mg/kg/day. In these studies, there were no adverse effects on mating, fertility or 
embryo/fetal development (Dr G. Allan, Insmed Inc., personal communication). Other 
lines of evidence also suggest that inositol supplements may be used clinically without 
adverse side effects. For instance, myo-inositol has been previously tested in adults for 
prevention of depression, panic disorder and obsessive compulsive disorder (Belmaker et 
al., 1996;Atack, 1996)} and in children for treatment of autism (Levine et al., 1997). No 
significant side effects were reported in these studies which employed relatively high 
inositol doses: up to 18 g per day in adults and 200 mg/kg in children. D-c/zz>o-inositol 
has recently been demonstrated to increase the action of insulin in patients with 
polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum 
androgen concentrations, blood pressure and plasma triglyceride concentrations (Nestler 
et al., 1999).
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CHAPTER 4
PKC INVOLVEMENT IN NEURAL TUBE CLOSURE
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4.1 Introduction
In Chapter 3, it was shown that NTDs in the curly tail mouse can be prevented by 
administration of not only myo-inositol but also D-c/uVo-inositol. This effect of inositol 
was previously shown to be mediated through the activity of the inositol/lipid cycle 
({Greene, 1997 13402 /id}). Of particular relevance to the present studies, DAG which is 
produced during inositol phospholipid signalling binds to and activates PKC, and this 
process appears essential for the action of inositol in preventing NTDs (Greene and Copp, 
1997a).
The purpose of the studies in the present chapter was to further investigate the role of 
PKC in mediating the protective effect of inositol. I first performed an 
immunohistochemical analysis to verify the relationship between PKC isoform 
distribution and posterior neuropore closure in the curly tail mouse. Second, the 
requirement for the various isoforms of PKC was investigated using chemical and peptide 
inhibitors of PKC in embryo culture. The specificity of the peptide inhibitors was also 
verified using primary cell cultures from curly tail mouse embryos.
Embryonic development requires that a wide variety of information be relayed via 
intracellular signalling pathways. A number of these signals are transduced into a cell 
through cell surface receptors, which by binding to their ligands, initiate one or more 
signal transduction cascades and alter the state of phosphorylation of several cellular 
components through the action of both kinases and phosphatases.
One of these signal transducers is protein kinase C (PKC), which functions during 
embryo development. The serine/threonine protein kinase C plays a major role in
119
transmembrane signal transduction (Mochly-Rosen and Kauvar, 2000). It is activated by 
diacylglycerol originated from membrane phospholipids upon cell stimulation by various 
ligands, i.e. hormones or growth factors (Dom et al., 1999). The existence of a wide range 
of PKC isoenzymes in mammalian tissues has been shown following the first 
identification of PKC by Nishizuka (Nishizuka, 1988). PKC heterogeneity poses the 
question as to why so many isoenzymes exist, and suggests that each of them could have 
a specific relevance in the regulation of various cellular functions (Braun and Mochly- 
Rosen, 2003). Moreover, a major distinguishing feature of PKC isoforms is their distinct 
and selective organ and tissue distribution. Several different techniques have been used to 
examine the expression of PKC isoforms in post-natal and adult tissues (Nishizuka, 
1988); (Wetsel et al., 1992); (Bareggi et al., 1995); (Hunter, 1995) Most of the PKC 
isoenzymes (a, pi, pH, 8, s and £) have been found to be ubiquitously distributed, e. g. in 
brain, lung, spleen, thymus and skin, whereas PKC y  has been found in the central 
nervous system (Wu et al., 2000); (Harris and Juriloff, 2007c). PKC isoforms appear to be 
expressed at low levels during the late stages of gestation and early in the postnatal period 
and to increase during the first 2 to 3 weeks after birth. However, expression data for 
PKC during embryonic development were not available prior to day 15 of gestation, 
preceding the work described in this thesis.
4.1.1 Possible requirement for PKC isoforms in mediating the preventive effect of 
inositol
Greene and Copp (1997) found that brief treatment with TP A, a PKC activator that 
mimics DAG, caused a reduction in PNP length of curly tail embryos following culture. 
This effect of TPA was comparable to that observed following inositol supplementation. 
The protective effect of TPA suggested that PKC activation is crucial in preventing spinal
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NTDs in curly tail embryos and, since only the conventional and novel PKC isoforms are 
DAG and TPA-responsive, this focussed attention on these classes of PKC isoforms as 
likely mediators of the inositol effect. Use of the PKC inhibitor Bisindolylmaleimide I 
(BisI; GF 109203x) provided support for this idea as addition of Bis I prior to, and during, 
inositol treatment reversed the protective effect of TPA on closure of PNP (Greene and 
Copp, 1997a). This inhibitor study indicated that the mechanism of action of inositol 
involves activation of PKC, and suggested, furthermore, that the critical PKC isoforms 
might include PKC a , P, y and 8. These isoforms are reportedly to be selectively inhibited 
by Bis I at 10 pM, the concentration used by Greene and Copp (1997). To extend this 
analysis, the present study used a series of additional PKC inhibitors, both chemical and 
peptide, in order to identify the specific PKC isoforms required for the inositol effect.
4.1.2 PKC chemical inhibitors
The aminoalkyl bisindolylmaleimide I (Bis I; GF109203x; Go6850) is a staurosporine 
analogue with selective inhibitory activity against PKC (IC50 = 1 0  nM). Importantly, 
studies of diverse effects of Bis I in intact cells provide evidence for selective recognition 
of cellular PKC by the inhibitor and therefore suggest the usefulness of Bis I as a probe of 
PKC function in cell culture. Bis I is known to inhibit cPKCs (a, pi, pil and y) and PKC s 
((Parker and Parkinson, 2001)). Another staurosporine analogue used in this study is the 
indole carbazole, Godecke 6976 (Go6976) [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13- 
methyl-5-oxo-5H-indolo(2,3-a)pyrrolo (3,4-c)-carbazole] which inhibits PKC a , pi and 
pH. It has been found that this PKC inhibitor also inhibits DNA synthesis suggesting a 
pro-proliferative role for the Go6976-inhibited PKC isoforms (Iankov, 2002). Go6976 
inhibition of DNA synthesis could be rescued by subsequent incubation with vehicle 
suggesting that the action of the inhibitor is not irreversibly toxic (Beltman et al., 1996).
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Pre-incubation of cells with Go6976 leads to enhancement of IL-6-induced p44/p42 
MAPK activity (Martiny-Baron et al., 1993). These findings suggest that in addition to a 
role in proliferation, PKC is also required for negative regulation of the MAPK pathway. 
Another selective PKC inhibitor used was 2,2’,3,3’,4,4,-hexahydroxy-l,r-biphenyl-6,6’- 
dimethanol dimethyl ether, (HBDDE) which inhibits PKC a  and y but not PKC pil, 8 or 8 
(Mathur and Vallano, 2000). In order to identify a possible involvement of the atypical 
PKC isoform £, LY294002 was used at a concentration of 2 pM. At this concentration, 
this inhibitor also blocks the phosphatidylinositol-3-kinase pathway (Vlahos et al., 1994), 
something to be taken into account when analysing these results. Bisindolylmaleimide V 
(Bis V; an inactive analogue of GF109203X) was used as a negative control compound, 
as it does not inhibit PKC (Asakai et al., 2002).
4.1.3 PKC peptide inhibitors
Chemical inhibitors may be specific for sub-classes of PKC isoforms, at certain 
concentrations, but do not allow the role of single PKC isoforms to be evaluated. For 
example, the cell-permeable, inhibitor HBDDE is reported to be a selective inhibitor of 
PKC a  and y with IC50 values of 43 and 50 mM, respectively, using an in vitro assay. 
However, data examining the potency and selectivity of HBDDE in intact cells are 
lacking. Moreover, the concentrations of chemical inhibitors found to block certain 
groups of PKC isoforms in cultured cell lines, or in cell-free systems, may not apply to 
biological systems, especially complex multicellular organisms such as mouse embryos. 
Hence, it is dangerous to assume that use of a chemical inhibitor at a particular 
concentration in embryo culture will block the same group of PKC isoforms as in cell 
culture. For this reason, the experiments with chemical inhibitors were extended by the 
use of peptide PKC inhibitors, which offer isoform-specificity of PKC inhibition.
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4.1.3.1 Molecular basis of PKC isoform inhibition by the peptides
Receptor for Activated C-Kinase (RACK) is responsible for the binding of active forms 
of PKCs. There are different RACKs for different isoforms of PKC (Section 1.3.4), which 
thus mediate differential subcellular targetting of the isoforms. Inactive forms of PKC 
occlude the RACK binding site with a pseudo-RACK peptide sequence (Dorn et al., 
1999). Peptides that mimic the PKC binding site on RACK proteins are able to inhibit the 
translocation and thus the activity of PKC. This property results from the fact that 
anchoring is necessary for the function of individual PKC isoforms, such that inhibition 
of anchoring inhibits their kinase activity. The peptide sequences bind in a competitive 
manner to the PKC iso form RACK binding site, blocking its translocation (Dorn et al., 
1999). See Chapter 1.
4.1.3.2 Use of antennapedia pepetide to carry peptides into the cell
To facilitate transfer of peptides into the cell, they were coupled to a sequence from the 
homeodomain protein antennapedia. Homeoproteins are a class of transcription factors 
that bind DNA through a structure of 60 amino acids length, called the homeodomain. 
The idea that transcription factors could traverse from cell to cell results from the 
observed internalisation of the homeodomain of the Drosophila protein antennapedia 
(Joliot, 1991). The antennapedia third helix (amino acids 43-58) is necessary for 
translocation (Derossi et al., 1994); (Theodore et al., 1995). Therefore, to ensure 
penetration into the cell, peptides are bound to the antennapedia third a  helix peptide, 
which will deliver a ‘cargo’ into the cell. Internalisation occurs at both 4°C and 37°C, 
implying that it does not involve classical receptor-mediated endocytosis. Derossi, 1994 
has proposed a model in which the positively charged peptide interacts with negatively 
charged phospholipids on the outer layer of the plasma membrane. Due to the interactions
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between tryptophan residues in the peptide and the lipids, the planar form of the outer 
phospholipid monolayer is distorted, encouraging the formation of inverted micelles, 
which will contain the peptide (Derossi et al., 1994).
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4.2 Results
4.2.1 Specificity of PKC antibodies
The specificity of anti-PKC antibodies was first tested using sections of adult mouse 
cerebellum (Figure 4.1) as a positive control in which staining patterns have been 
previously reported. As expected, anti-PKC a, y and s stain only Purkinje cells, whereas 
anti-PKC 61 and 611 stain only granule cells (Figure 4.1 and Table 4.1). These results 
correlate with those previously described for the rat cerebellum (Bareggi et al., 1995).
4.2.2 PKC isoform expression during mouse embryogenesis
In order to identify the isoforms that might play a role in prevention o f NTDs, it was 
imperative to determine which PKC isoforms are expressed in mouse embryos 
undergoing spinal neurulation (E9.5 to E10.5). A member of our laboratory performed 
western blot analysis, which detected expression of all PKC isoforms in whole E 9.5 and 
E 10.5 embryos. However, this approach was insufficiently sensitive to detect PKC 
isofoim expression in specific embryonic regions, such as the posterior neuropore (PNP), 
the site of spinal neurulation. I thus performed immunohistochemical staining on 
histological sections throughout the PNP region. Expression of PKCs was detected in the 
closing neural tube, hindgut, notochord and presomitic mesoderm, at both E9.5 and E l0.5 
in curly tail embryos (Figure 4.2). A control was run with each experiment to test for non­
specific staining of the primary antibody (Figure 4.1). In this control, affinity purified 
rabbit IgG from pre-immune serum (Sigma) was used instead of isozyme specific primary 
antibody. Additional controls received only primary antibody or secondary antibody. In 
all cases, the negative controls gave a complete lack of staining.
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Figure 4.1 Distribution of Protein Kinase C isoforms in cerebellum
Immunohistochemistry was used to detect isoforms of protein kinase C within the adult 
cerebellum. Sagittal sections were immunostained for PKC a  (A-B), PKC (3 (C-D), PKC 
y (E-F). Cells in the purkinje cell layer (pcL) are immunoreactive to the antisera to PKC a  
(A-B) and y, whereas cells in the granular layer (gL) are negative. In contrast, granule 
cells are immunoreactive to the antiserum to PKC p, whereas purkinje cells are 
negative (C-D). A control section that was not incubated in any primary antiserum is also 
shown (G). B, D and F are high magnifications of A, C and E respectively. For A, C, E 
and G, scale bar = 20 pm; from B, D and F, scale bar = 250 pm.
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Figure 4.1
Figure 4.2 Expression of PKC isoforms during mouse spinal neurulation
Immunohistochemistry reveals ubiquitous expression of PKC isoforms during mouse 
spinal neurulation. Transverse sections through the posterior neuropore region of curly 
tail mouse embryos at E9.5 (A, C, E, G, I) and E l0.5 (B, D, F, H, J) were stained with 
antibodies specific for PKC a , 131, 1311, and y. All PKCs exhibit ubiquitous expression in 
the neural plate (Np), notochord (N), hindgut (H) and presomitic mesoderm (M) of the 
posterior neuropore region. Scale bar represents 20 pm.
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4.2.3 Evaluation of possible effects of chemical inhibitors on growth and 
development of cultured embryos
In order to investigate the potential role of different PKC isoforms during closure of the 
PNP, a series of inhibitors was applied to curly tail embryos in culture. It was important 
to first identify the most appropriate concentration to use for each inhibitor, so as not to 
cause generalised toxicity or growth retardation. Growth retardation is known to reduce 
the delay of closure of the PNP in curly tail embryos (Copp et al., 1988c)) and it was 
important to determine whether PKC inhibitors alone had any effect on growth, prior to 
using them to investigate the protective effect of inositol. Inhibitors were first tested in a 
non-mutant strain, CD1, and then in curly tail embryos.
In cellular models of phosphorylation, PKC activity is inhibited with IC50 values (half 
maximal inhibitory concentration) of 0.2 to 10 pM. For example, in an assay of vimentin 
phosphorylation in Swiss 3T3 cells maximal inhibition of PKC was obtained at a 
concentration of 2.5-5 pM Bis I, with no inhibition of cAMP-dependent PKA even at the 
highest concentration. Based on cell culture data, each inhibitor was used at two 
concentrations, as shown in Tables 4.2 and 4.3 in cultures of CD1 and curly tail embryos 
respectively. For each inhibitor, the lower concentration was typical of that used in cell 
culture. A higher concentration was also tested, in case it was necessary to overcome any 
decreased uptake of the inhibitor due to the intact yolk sac surrounding the embryo, as 
compared with cultured cells which are likely to be more accessible to cell-permeable 
inhibitors. At the end of the culture period, the crown rump length was measured as an 
indicator of growth and the number of somites was counted as a measure of 
developmental progression. In addition, any malformations or abnormalities were noted 
as these could indicate teratogenic effects of the inhibitors. The yolk sac circulation was 
recorded as a measure of overall health of the embryo.
4.2.3.1 Chemical inhibitors of PKC do not affect growth or developmental 
progression of embryos in vitro
In CD1 embryos (Table 4.1), there was no difference in mean somite number or mean CR 
length between PBS/DMSO controls and either low or high concentrations of BisI, or the 
inactive BisV. Yolk sac circulation was also unaffected and no teratogenic effects, such 
as irregular somites, under-developed branchial arches, enlarged pericardium or failure of 
embryonic turning were observed. In contrast, cultures of curly tail embryos gave a 
somewhat different result (Table 4.2). In cultures exposed to the lower concentration of 
each PKC inhibitor, all treatment groups were comparable in terms of developmental 
progression and growth, with no significantly difference from PBS/DMSO controls. 
However, at the higher PKC inhibitor concentrations, curly tail embryos showed 
retardation of developmental progression, as judged by a significant lower somite number 
at the higher concentration compared to the lower concentration for each inhibitor (p < 
0.05). Despite this effect, yolk sac circulation was normal in all embryos and 
malformations were not observed. Moreover, while crown-rump length varied 
significantly between treatment groups overall (ANOVA; p< 0.05), pair-wise 
comparisons failed to detect significant differences between high or low concentrations of 
each inhibitor (after correction for multiple comparisons; Holm-Sidak method). Hence, 
this preliminary culture analysis reveals a greater susceptibility of mutant curly tail 
embryos than wild type CD1 embryos to PKC inhibitor, and indicated the need to use the 
lower inhibitor concentrations in subsequent curly tail culture studies.
4.2.4 Investigating the effect of chemical PKC inhibitors on PNP closure
PNP length was measured after culture as an indicator of risk of developing spina bifida.
In CD1 embryos cultured in the presence of BisI for 24 hours to the 30-32 somite stage,
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all the embryos had completed closure of the PNP suggesting that the inhibitors did not 
have a major deleterious effect.
Treatment Cone. No.
embryos
Mean somite 
no. ± SEM 1
Mean CR length 
(mm) ± SEM2
Yolk sac 
circulation
PBS/DMSO 10 31.0 ±0.09 3.02 ± 0.03 3
Inositol 50 (ig/ml 10 31.6 ±0.20 3.19 ± 0.11 3
BisI 10 fiM 10 30.3 ±0.11 3.37 ± 0.09 2.9
B isI 30 fiM 10 31.2 ±0.32 2.97 ±0.12 3
BisV3 10 (iM 10 31.6 ±0.10 2.90 ±0.21 2.8
BisV 30 pM 10 30.3 ± 0.08 3.42 ±0.13 2.9
Table 4.1 CD1 embryos cultured for 24 hours from E9.5 to E10.5 in the presence of 
the PKC chemical inhibitor BisI
PKC inhibitors were diluted in DMSO and further diluted in PBS. A DMSO-PBS 
solution was used as a control. Inhibitors do not adversely affect developmental 
progression or growth in CD1 embryos after 24 hr in vitro culture. 
lNo significant difference in somite number by analysis of variance between treatments,
P> 0.05
2 * •No significant difference in crown rump (CR) length by analysis of variance between 
treatments, P> 0.05
3BisV is an inactive variant of BisI
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Table 4.2 Curly tail embryos cultured for 24 hours from E 9.5 to E 10.5 in the 
presence of PKC chemical inhibitors
]One way ANOVA shows significant difference in somite number. Pairwise multiple 
comparisons by the Holm-Sidak method show that for each inhibitor the higher dose 
tested caused a significant reduction in somite number compared to the PBS/DMSO 
control and to the lower dose of the same inhibitor, (p< 0.001). There was no significant 
difference in somite number between PBS/DMSO control and lower dose of any 
inhibitor.
One way ANOVA (p<0.017) shows significant variation overall in crown rump length. 
However, pairwise multiple comparisons by the Holm-Sidak method show that for each 
inhibitor there is no difference between high and low concentration of each inhibitor, nor 
between high inhibitor dose and PBS/DMSO control.
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Table 4.2
Treatment Cone. No.
embryos
Mean somite 
no. ± SEM 1
Mean CR length 
(mm) ± SEM2
Yolk sac 
circulation
PBS/DMSO _ 10 30.09 ± 0.06 3.04 ± 0.07 2.9
BisI 10 pM 10 30.3 ±0.15 3.56 ±0.10 3
30 pM 10 23.2 ± 0.70 2.50 ±0.50 3
BisV 10 pM 10 30.6 ±0.13 3.50 ±0.10 3
30 pM 10 25.5 ±0.55 1.80 ± 0.64 2.8
Go6976 10 pM 10 30.5 ±0.13 3.39 ±0.10 2.9
30 pM 10 22.3 ± 0.82 2.00 ±0.21 2.7
HBDDE 50 mM 10 30.6 ±0.16 3.55 ±0.10 3
150 mM 10 25.8 ± 0.54 2.70 ± 0.80 2.8
LY294002 1.4 pM 10 30.3 ±0.16 3.49 ± 0.08 2.8
42 pM 10 24.6 ± 0.67 2.60 ± 0.76 3
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Curly tail embryos were exposed to each inhibitor alone to determine whether there was 
an effect on PNP closure. Embryos were also treated with inhibitor and inositol to 
determine whether suppressing PKC activity reduced the effect of inositol. The mean 
PNP length of embryos exposed to PBS alone was 0.6 mm (Figure 4.3A), reflecting the in 
vivo situation in which curly tail embryos exhibit delayed closure of the PNP, leading to 
development of NTDs or tail flexion defects in 60% of embryos (Van Straaten and Copp, 
2001). When added alone, none of the inhibitors significantly altered PNP length in 
cultured curly tail embryos after twenty four hours (p> 0.05; yellow bars, Figure 4.3). 
Treatment of curly tail embryos with 50 pg/ml of wyo-inositol (first red bar, Figure 4.3) 
resulted in a significant decrease in PNP length after culture, to a mean value of 0.08 mm, 
which is characteristic of normally developing embryos. Thus, as demonstrated in 
Chapter 3, inositol normalises PNP closure in vitro as well as in vivo.
PNP length in the presence of inositol plus inhibitor was 60-90% of that in the presence 
of inhibitor alone (blue bars, Figure 4.3). Embryos cultured in the presence of inositol and 
Bis I, exhibit a PNP length that is significantly larger than the PNP length of embryos 
cultured in the presence of inositol alone, suggesting that the protective effect has been 
blocked. Similarly when embryos were cultured in the presence of Go6976 and inositol or 
in HBDDE and inositol, the PNP length of embryos after cultured was significantly larger 
than the embryos cultured in the presence of inositol alone. In the case of LY294002 the 
effect of inositol was partially blocked suggesting a role for PKC £ and/or PI3-kinase. In 
contrast, the inactive analogue BisV did not prevent the reduction in PNP length caused 
by co-administration of inositol (second red bar in Figure 4.3). Therefore, the use of 
chemical inhibitors highlights the potential importance of PKCa, p, y, s and C,( i.e. those 
isoforms acted upon by the chemical inhibitor) in mediating the effect of inositol although
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the chemical inhibitors do not give sufficient specificity to narrow down the effect to 
individual isoforms.
-- No inositol -  -- Plus inositol -- -- % Control --
Figure 4.3 Normalization of spinal neural tube closure by inositol in curly tail 
embryos is abrogated by inhibition of specific PKC isoforms.
Chemical inhibitors of PKC were applied to curly tail mouse embryos cultured from E9.5 
for 24 h, and the posterior neuropore (PNP) length was measured as an indicator of 
predisposition to spinal NTD. Yellow bars: PNP length of embryos exposed to PKC 
inhibitors in the absence of inositol; red bars: PNP length of embryos exposed to PKC 
inhibitors in the presence of inositol; blue bars: PNP length in the presence of PKC 
inhibitor plus inositol as a % of the value in the presence of PKC inhibitor alone (right 
axis). Inositol significantly reduces PNP length in the absence of inhibitor (PBS;
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PO.OOl) and in the presence of inactive BisV (P<0.002), whereas the inositol effect is 
abrogated in the presence of chemical inhibitors BisI, Go6976, HBDDE and LY294002 
(P>0.05).4.2.5 Use of peptide inhibitors to identify the specific PKC isoforms required 
for protection of PNP closure by inositol.
The use of chemical inhibitors of PKC provided an indication of which PKC isoforms 
may be required for prevention of NTDs by inositol but did not permit individual 
isoforms to be implicated. For this reason I decided to make use of peptide inhibitors 
which prevent translocation, and therefore activation, of specific PKC isoforms (Ron and 
Mochly-Rosen, 1995), (Johnson et al., 1996). Curly tail embryos were cultured in the 
presence of the different isoform-specific peptide PKC inhibitors for 24 hours, from E9.5 
to E10.5.
A series of isoform-specific peptides were used in addition to a general cPKC peptide 
inhibitor and a control inactive peptide. No differences in growth or development 
progression, as indicated by crown-rump length and number of somites, were detected 
between treatment groups (Table 4.4). Moreover, no teratogenic effects were observed. 
These data suggest that any effect on PNP closure results from specific inhibition of PKC 
as opposed to generalised toxicity of inhibitors. As shown in Chapter 3, embryos cultured 
in the presence of inositol show a significant reduction in PNP length compared with PBS 
treated controls and this effect of inositol was maintained in the presence of specific 
inhibitors for PKCa, pn, 8, and s, as well as the inactive peptide used as a negative 
control (Figure 4.4). In contrast, when inositol was added in the presence of inhibitors 
specific for PKCpI, y or ^ the therapeutic effect of inositol was largely abolished (red bars 
in Figure 4.6). Mean PNP lengths were 74%, 81% and 56% respectively of the values
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observed in the absence of inositol (blue bars in Figure 4.4). These findings correlate well 
with the results of the chemical inhibitor study, and indicate the need for pi and y among 
the conventional PKCs, and additionally PKCC, among the atypical PKCs, in order for 
inositol to mediate its enhancing effect on PNP closure in curly tail embryos.
4.2.6 Evaluation of peptide inhibitors of PKC in cultured cells
At the outset of this experiment the efficacy of isoform-specific PKC inhibitory peptides 
had not been verified in embryonic mouse cells. In order to check the effect of the peptide 
inhibitors on PKC activity, I generated primary fibroblastic cell lines from curly tail 
embryos and used antibody staining to localise PKC isoforms following addition of the 
DAG analogue TP A to activate PKC.
After culture of primary fibroblasts in medium containing 1% fetal calf serum, 
immunohistochemistry showed that PKC a , pi, pH, y and s were all localised in a diffuse 
pattern throughout the cytoplasm (Figure 4.4). A parallel set of cultures was treated with 
TP A, and in each case PKC was seen to have translocated the nucleus (Figure 4.4). 
Another set of cultures was treated with TPA and one of the isoform-specific peptide 
inhibitors. Staining for the corresponding PKC isoform showed that the presence of 
inhibitor prevented translocation of that isoform to the nucleus (Figure 4.4).
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Table 4.3 Development of curly tail embryos following culture from E 9.5 to E l0.5 in 
the presence of inositol and/or PKC pepetide inhibitors
!No significant difference in somite number by analysis of variance between treatments, 
P> 0.05
No significant difference in crown rump (CR) length by analysis of variance between 
treatments, P> 0.05
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Table 4.3
Number o f embryos Mean somite number 
±  SEM1
Mean CR 
length (mm) ±  SEM2
Yolk sac circulation
+ PBS + Inositol + PBS + Inositol + PBS + Inositol + PBS +Inositol
No
inhibitor 10
10
31.7 ± 0.05 30.5 ± 
0.10
3.5 ±0.21 4.45 ± 0.01
2.8 3
cPKC 10 10 30.4 ±0.11 31.2 ±0.8 3.6 ± 0.09 3.60 ± 0.33 2.7 2.7
Control-
peptide
10 10
31.2 ±0.49 30.8 ± 
0.19
3.5 ± 0.72 3.8 ±0.22
2.8 3
PKC a 10 10 31.7 ±0.05 30.2 ± 
0.12
3.8 ± 0.09 3.93 ±0.10 3 2.8
PKC (31 10 10 30.5 ± 0.02 31.6 ± 
0.81
3.9 ± 0.73 3.44 ± 0.32 2.9 3
PKC PII 10 10 30.3 ±0.10 30.2 ± 
0.15
3.5 ± 0.09 3.52 ±0.19 3 2.8
PKC y 10 10 30.8 ±0.21 31.5 ± 
0.73
3.9 ± 0.74 3.6 ±0.41 3 3
PKC 8 10 10 31.7 ±0.30 31.1 ± 
0.10
3.7 ± 0.68 3.8 ±0.65 3 2.7
PKC 5 10 10 30.5 ± 0.08 30.8 ± 
0.66
3.7 ±0.55 3.45 ± 0.34 2.8 2.9
p k c <; 10 10 31.1 ±0.05 31.6 ± 
0.25
3.5 ±0.43 4.3 ± 0.09 2.9 3
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Figure 4.4 Inhibition of specific PKC isoforms in cultured curly tail embryos -effect 
on PNP length
Peptide inhibitors of PKC were applied to curly tail mouse embryos cultured from E9.5 
for 24 h, and the posterior neuropore (PNP) length was measured as an indicator of 
predisposition to spinal NTDs. Yellow bars: PNP length of embryos exposed to PKC 
inhibitors in the absence of inositol; red bars: PNP length of embryos exposed to PKC 
inhibitors in the presence of inositol; blue bars: PNP length in the presence of PKC 
inhibitor plus inositol as a % of the value in the presence of PKC inhibitor alone (right 
axis). Normalization of spinal neural tube closure by inositol in curly tail embryos is 
abrogated by inhibition of specific PKC isoforms. Inositol significantly reduces PNP 
length in the absence of inhibitor (PBS; PO.OOl) and in the presence of inactive peptide 
(Pept) or peptide inhibitors to PKC a, BH, 8 (P<0.005) and s (P<0.05), whereas the 
inositol effect is abrogated by inhibitors to PKCBI, y and £ (P>0.05). There is no effect on 
PNP length of either chemical or peptide inhibitors in the absence of inositol (analysis of 
variance, .P>0.05).
141
H
~ i
0
0
30
13
O
oc
■ Dc/>
NJ
- 
No 
inositol -- 
-- 
Plus 
inositol -- 
- 
% 
C
ontrol -
Posterior neuropore length (mm + SEM)
% PNP length of control (no inositol)
Figure 4.5 Inhibition of PKC isoform translocation
Iso form-specific antibodies were used to detect PKC isoforms (as in Figure 4.1 and 4.2) 
in curly tail primary embryonic cell cultures. Cells cultured for 18 h in growth medium 
containing 1% FCS were either fixed with no additional treatment (‘serum starved’; A, D, 
G, J, M), exposed to 100 pM TPA for 10 min prior to fixation (+TPA; B, E, H, K, N), or 
exposed to 1 mM isoform-specific PKC inhibitor for 20 min and to TPA for 10 min prior 
to fixation (TPA+Inhib; C, F, I, L, O). PKCs are uniformly located in the cytoplasm of 
serum starved cells whereas a 10 min treatment with TPA induces translocation to the 
nucleus in all cases. Pre-treatment with isoform-specific PKC inhibitors prevents TPA- 
induced translocation and all PKC isoforms exhibit cytoplasmic staining. Inset in (O) 
shows same field stained with DAPI to demonstrate nuclei. Scale bar represents 20 pm.
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Figure 4.5
4.2.7 Specificity of inhibitors for PKC pi and (311
Due to the close relationship between PKC 131 and its alternatively spliced variant PKC 
BII, I decided to test whether abrogation of the inositol effect by the PKC BI inhibitor 
might have resulted from antagonism of both PKC BI and BII activation. Therefore, cells 
were exposed to TPA in culture and the effect on both pi and pH inhibitors were 
determined by immunohistochemistry. PKC BI translocated to the nucleus following TPA 
stimulation, and this translocation to the nucleus was blocked by the BI inhibitor, but not 
by the BII inhibitor (Figure 4.5 A-C). Conversely, translocation of PKC BII was blocked 
by the BII inhibitor but not the BI inhibitor (Figure 4.5 D-F). This finding confirms that 
the peptide inhibitors of PKC BI and BII are isoform-specific and suggests separate roles 
for these splice variants in the protective effect of inositol in curly tail PNP closure. This 
finding strongly suggests that the requirement for specific PKC isoforms is unlikely to 
reflect differential activity of the peptide inhibitors, but may reflect a difference in 
participation of PKC isoforms in the action of inositol in preventing mouse NTDs. Figure 
4.5 also shows that inositol induces translocation of PKC a  to the nucleus, demonstrating 
that apart from the essential isoforms (pi and y) other isoforms may be activated 
following inositol treatment. However, their activity is not essential for the prevention of 
NTDs.
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Figure 4.6 Inhibitors of PKCBI and BII exhibit isoform-specificity
Inositol stimulates PKC translocation, whereas peptide inhibitors to PKCBI and BII 
exhibit isoform-specificity in blocking translocation. PKC isoforms were localized by 
immunocytochemistry on primary cell cultures established from curly tail mouse 
embryos. Serum starved cells exhibit PKCBI and BII immunoreactivity in the cytoplasm. 
TPA-induced translocation to the nucleus of PKCBI can be blocked by the BI inhibitor (C) 
but not by the BII inhibitor (B). Conversely, translocation to the nucleus of PKCBII can be 
blocked by the inhibitor to BII (E) but not by the inhibitor to BI (F). Addition of 50 pg/ml 
wyo-inositol to serum starved cells 6 h prior to fixation induces translocation of PKC a  to 
the nucleus (H) whereas PKC a  is cytoplasmic in untreated cells (G). This effect of 
inositol is not unique to curly tail cells as similar results were obtained in 3T3 cells. Scale 
bar represents 20 pm.
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Figure 4.6
serum +TPA +TPA
starved + pil inhib. + pi inhib.
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4.3 Discussion
4.3.1 Distribution of PKC isoforms
This Chapter demonstrates that several different iso forms of PKC are present in curly tail 
embryos, during the process of neurulation. The PKC isoforms a , pi, pil and y were 
detected by immunohistochemistry and all other known isoforms have been detected by 
western blot (Cogram et al., 2004a). Together these results show that the neurulation 
stage mouse embryo contains representatives from all three categories of PKCs, the 
conventional, atypical and novel forms. These three categories of PKC isoforms have 
different requirements for activation of the kinase and are enriched in different sub- 
cellular localizations in a developmental stage specific fashion (Dorn et al., 1999). This 
presents the possibility that different isoforms of PKC are differentially activated and 
involved in different events during embryonic development. The detection of all PKC 
iso forms fromE9.5 to E 17.5 is in agreement with previous analysis of PKCs in El 5-17 
fetuses (Dorn et al., 1999). However, my results contrast with a study of E l0.5 embryos 
that detected PKC a , and y, but not £ and BII ((Dorn et al., 1999)). This difference may 
reflect the previously reported low abundance of cPKCs on western blot (Dorn et al., 
1999), whereas in the present study all isoforms were clearly detectable in the PNP region 
by immunohistochemistry.
The published observations that individual isoforms are found in different sub cellular 
compartments suggest that they are regulated differently (Courage, 1995); (Dorn et al., 
1999). For instance, cPKCs are confined to the cytoplasm, suggesting minimal activation 
during undisturbed development. This finding is consistent with a role for the cPKCs y 
and BI, in mediating the preventive effect of inositol, since activation of these isoforms 
may be limited in the absence of inositol, providing capacity for activation after treatment.
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The results presented in this chapter demonstrate that activation of PKC by inositol 
treatment of curly tail embryos in vitro has a protective effect on closure of the PNP 
which like inositol supplementation would in vivo lead to reduction in spinal NTDs. This 
suggests a possible mechanism for the prevention of spinal NTDs by inositol 
supplementation in which there is increase in flux through the inositol/lipid cycle leading 
to activation of PKC.
Abrogation of the protective effect of inositol by Bis I, a broad spectrum chemical 
inhibitor of PKCs strongly suggests that the activity of one or more of the classical PKC 
isoforms is indispensable for normalisation of neural tube closure. Moreover, the 
chemical inhibitors Go 6976 and HBDDE also inhibited the inositol effect arguing for the 
requirenment for specific PKC isoforms. The high degree of specificity of the inhibitor 
Bis I for PKC (Toullec et al., 1991) shows that the effect of inositol (or TP A) on closure 
of PNP is due to activation of PKC rather than activation of another enzyme. The 
inhibitor studies also suggest that the mechanism of action of inositol (or TP A) involves 
activation of PKC rather than secondary negative feedback caused by depletion of PKC 
as in conditions of sustained treatment (Heidenreich et al., 1993). In the later case, the 
inhibitor would be expected to mimic the effect of TPA since both inhibition and 
depletion resulting from chronic TPA treatment reduces cellular PKC activity. 
Subsequent exposure of embryos to inhibitors of individual isoforms indicates a 
requirement for PKC pi, y and possibly ^ in prevention of spinal NTDs by inositol.
In this study use was made of the fact that phorbol esters such as 12-O-tetradecanoyl- 
phorbol-13-acetate (TPA) can substitute for DAG in activation of PKC, by binding to the 
same region of the Ci structural motif (Section 1.5.5). Unlike DAG which is rapidly 
metabolised, TPA is metabolically stable and can thus cause sustained activation of PKC
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(Castagna et al., 1982). PKC activation is probably responsible for the tumor promoting 
activity of phorbol esters which disturb both proliferation and differentiation events. 
Prolonged activation of PKC by TPA causes alterations in enzyme activity, in addition to 
those elicited by transient generation of DAG. Extended exposure to TPA initiates 
degradation of activated membrane-associated PKC by proteolytic cleavage which leads 
to depletion of cellular PKC (Nishizuka, 1988). TPA thus has a dual action on PKC, with 
transient positive activation followed by negative regulation owing to degradation of the 
enzyme. This complex regulation must be considered when interpreting the effects of 
TPA treatment on mouse embryos.
4.3.2 Differential requirement for PKC pi and pH
The two most closely related isoforms, PKC pi and pH, are distinct but highly 
homologous with 96% identity at the amino acid level. They are identical for the first 621 
amino acids and differ only in their carboxy-terminal 50-52 amino acids, in which they 
are 45% homologous {Chapter 1, Figure 1.3). The PKCp gene, and its products pi and 
PH have well defined structural differences between the two isoforms which presumably 
account for the isoform specific functions. For example, PKC pn has been found as an 
actin-binding protein that translocates to the actin cytoskeleton in cells, while antibodies 
to PKC pn, but not to PKC pi, co-immunoprecipitate actin, (Blobe et al., 1996)). Thus, 
pn can be distinguished from pi through its interaction with F-actin, perhaps suggesting 
that the protective effect of inositol in curly tail embryos is not due to an effect of PKC on 
actin function.
Another important difference between the two isoforms comes from a difference in 
carboxy terminal phosphorylation, which has been indicated in regulating their function 
and sub-cellular localization. Biochemical and immunolocalization studies of
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phosphorylation site mutant proteins reveal that negative charge at this position is require 
for cytosolic localization of PKC and phorbol ester dependent translocation (Mochly- 
Rosen and Kauvar, 2000). PKC pi is phosphorylated at T642 whereas PKC pil is 
phosphorylated at T646, which may contribute to difference in function and localization 
of the two isoforms (Banan et al., 2004).
Interestingly it has been shown previously that pi and pH play a very important role in 
cell proliferation but at distinct check points during the cell cycle. PKC pi appears to play 
a role in control of Gl-S progression while pH is implicated in the G2/M transition. The 
differential role of PKC p isoforms in cell cycle regulation is notable as the underlying 
defect in curly tail embryos involves a cell proliferation defect (see Chapter 6)
4.3.3 Requirement for conventional and atypical PKCs
It was previously reported that treatment of curly tail embryos with phorbol ester, which 
acts as a DAG analogue, can mimic the effect of inositol (Greene and Copp, 1997a). This 
action was proposed to be mediated through activation of conventional or novel PKC 
isoforms as atypical isoforms are not DAG-responsive. Recent evidence suggests that in 
some cell types phorbol ester treatment also leads to activation of PI3-kinase and PKC^ 
(Kim et al., 2001). The data in the present study do indeed suggest some requirement for 
atypical PKCs, as also indicated by the ability of LY294002 and the PKC^ inhibitor to 
abrogate the effect of inositol in this study.
It is possible that the PKC £ isoform could augment the effect of PKC pi and PKC y on 
neural tube closure, either through activation of PDK-1 or phosphorylation of additional 
substrates.
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The phosphoinositide cycle involving diacylglycerol and PKC<J is activated downstream 
of PI3-kinase (Standaert et al., 1997); (Kim et al., 2001). PKC^ may phosphorylate 
substrates that are directly involved in normalisation of neural tube closure or 
alternatively could play an indirect role through phosphorylation and regulation of other 
PKC isoforms {(Ziegler et al., 1999)}. Two obvious possibilities could explain the 
reduction in inositol efficacy following inhibition of PI3-kinase. First, the effect could be 
simply due to reduced activation of PKC^ as described for the specific PKC^ inhibitor. 
Second, activity of all groups of PKCs, like other members of the AGC kinase family, 
depends on phosphorylation of the T-loop in the kinase domain {(Parekh et al., 2000)}. 
This phosphorylation is catalysed by 3-phosphoinositide-dependent protein kinase-1 
(PDK1) {(Chou et al., 1998), (Dutil et al., 1998)}, in a reaction that, as the name 
suggests, requires activity of PI3-kinase. PDK1 provides a functional link between 
activity of PI3-kinase and regulation of PKC signalling that could explain how inhibition 
of PI3-kinase reduces the magnitude of the PKC-dependent response to inositol in curly 
tail embryos.
4.3.4 Requirement for PKC isoforms during neural tube closure
The results in this chapter show that PKC isoforms are required for prevention of curly 
tail NTDs by inositol. However, in the absence of inositol, inhibition of PKC either by 
chemical or peptide inhibitors did not worsen the delay in PNP closure in cultured 
embryos. Nor did it have any adverse effect on neural tube closure in wild type embryos. 
Thus, it appears that inositol stimulates a novel action of PKC as opposed to an 
underlying function of PKC in normal neural tube closure. This hypothesis is supported 
by the lack of an NTD phenotype in null mutant mice for any of the PKC isoforms that 
are essential for prevention of NTDs. PKC y null mice exhibit mild defects in learning 
tasks associated with function of the hippocampus (Abeliovich et al., 1993b), while PKC
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P null mice display low alcohol tolerance but no apparent developmental disturbance 
(Harris et al., 1995). However, as compound mutant mice for these PKC isoforms have 
not been generated it remains possible that inhibition of both PKC p and y in the same 
embryo might have detrimental effects on neurulation.
4.3.5 Which proteins are downstream of PKC activation?
The link between PKC activity and correction of PNP closure in curly tail embryos 
presumably involves phosphorylation of one or more target proteins. There are a number of 
potentially important PKC substrates that are proteins with direct cellular activity or 
transcription factors that regulate expression of further downstream proteins. Roles for PKC 
have been proposed in regulation of a variety of cellular processes including function of 
membrane proteins, cell cycle control and transcription of various genes (reviewed by 
(Nishizuka, 1986); (Hug and Sarre, 1993).
The major PKC substrate myristoylated alanine-rich C kinase (MARCKS) may be of 
particular interest in relation to neural tube closure as the null mutant mouse displays 
excencephaly (Blackshear et al., 1996b); (Chen et al., 1996). Moreover, knockout of a 
MARCKS family protein, known as MARCKS-related protein (MacMARCKS or F52) also 
causes NTDs, inducing both spina bifida and excencephaly (Arbuzova et al., 2002). In 
future work the identification of substrates for specific PKC isoforms might contribute 
towards understanding the function of PKC in prevention of NTDs by inositol.
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CHAPTER 5 
INOSITOL AND CELL PROLIFERATION
5.1 INTRODUCTION
5.1.1 Analysis of proliferation in the posterior neuropore region of developing curly 
tail embryos
As described in Chapter 1, NTDs in ctlct embryos are associated with delay and failure of 
posterior neuropore (PNP) closure between the 24- and 32-somite stages (Copp, 1985; 
van Straaten et al. 1992). Copp et al. (1988) analysed cell proliferation in the developing 
caudal region of ct/ct embryos and observed decreased cell proliferation in the hindgut 
endoderm and notochord of embryos with severely enlarged PNP compared to those with 
normal or near-normal phenotypes. In contrast, neuroepithelial cell proliferation was the 
same in both groups. Recently, Ting et al (2003) also demonstrated reduced proliferation 
around the hindgut in embryos lacking Grhl3 expression, a strong candidate for the ct 
gene. It is proposed that the resulting proliferation imbalance between dorsal and ventral 
tissues causes increased ventral curvature of the caudal region as the normal 
neuroepithelium is tethered via extracellular matrix to the underlying defective notochord 
and gut endoderm. Indeed, enhanced axial curvature was observed in affected ct/ct 
embryos in association with delayed PNP closure and spina bifida development (Brook et 
al., 1991b).
Further support for the general role of axial curvature in regulating neurulation comes 
from experiments in which the angle of axial curvature of the chick embryo was 
experimentally altered by culturing the embryo on curved (either concave or convex) 
substrates in vitro (van Straaten et al., 1992). Either increasing or decreasing the curvature 
led to delay in PNP closure and there was a direct correlation between the extent of delay 
and the degree of curvature. Thus, it seems possible to conclude that excessive curvature, 
both convex and concave, can oppose neurulation movements in vertebrate embryos. Any 
factor that alters the angle of curvature can be expected, therefore, to affect the rate of 
progression of neural fold closure.
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It has been proposed that the NTDs in curly tail result from reduced expression of Grhl3 
(Auden et al., 2006). Thus, if  reduced proliferation is indeed responsible for the failure of 
PNP closure in curly tail embryos it would also be predicted to be present in Grhl3 
mutant embryos. Indeed, when in vivo bromodeoxyuridine (BrdU) incorporation was used 
to examine cellular proliferation in the caudal regions of Grhl3+/+ and Grhl3'A embryos, 
Ting et al (2003) found that Grhl3'A embryos at the 21-25-somite stage exhibited a 
consistent reduction in the number of proliferating cells in the ventral, but not the dorsal, 
half of this region, compared to wild-type controls. This reduction in BrdU incorporation 
was particularly evident around the hindgut endoderm, comparable to the findings in the 
ct/ct mice.
Two additional studies have detected abnormalities that may be related to proliferation 
defects in a subset of diet embryos prior to the phenotypic divergence of embryos with 
normal and enlarged posterior neuropores (21-25-somite stages). Peeters et al. (Peeters et 
al., 1998) reported a greater proportion of S-phase nuclei in dorsal compared to ventral 
tissues of the caudal region, and Gofflot et al. (Gofflot et al., 1998) reported reduced 
expression of Wnt5a, a cell proliferation-related gene (Christian et al., 1991), in ventral 
mesoderm.
5.1.2 Protein Kinase C: a possible role in regulation of cell proliferation
A key outstanding question regarding the mechanism of action of inositol relates to 
whether the underlying proliferation defect is corrected, or whether inositol enhances 
closure through an alternative mechanism. Activation of PKC by TPA treatment of curly 
tail embryos in vitro has a protective effect on closure of the PNP which, like inositol 
supplementation, would lead to a reduction in frequency of spinal NTDs (Greene and 
Copp, 1997b). This suggests a possible mechanism for the prevention of spinal NTDs by 
inositol supplementation in which there is increased flux through the inositol/lipid cycle
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leading to production of diacylglycerol (DAG) and activation of PKC. Moreover, the 
influence of PKC inhibitors in reversing the protective effect of inositol on closure of the 
PNP in curly tail embryos provides support for this idea (Chapter 4).
In several studies, PKC activity has been associated with regulation of cellular 
proliferation, suggesting that there could be a direct effect of inositol and PKC on the 
underlying cell proliferation defect in curly tail embryos. Effects of different isoforms on 
cell growth have been investigated by stable over-expression of individual PKC isoforms 
or through the use of PKC agonists that differentially activate specific members of the 
PKC family. Emerging evidence increasingly points to roles for PKCa, 8 and i in 
negative growth regulation and/or differentiation (Nakashima, 2002), and for PKC p, y, 
and s in positive control of cell growth (Yamamoto et al., 1998). Interestingly, different 
isoforms may have opposing effects in the same cell type. For example, over-expression 
of PKC pi in the R6 rat embryo fibroblast cell line resulted in enhanced growth (Suzuma 
et al., 2002), while over-expression of PKC a  led to a marked inhibition of cell growth 
(Nakashima, 2002). It should also be emphasized that the actions of individual isoforms 
appear to be highly dependent on cellular background, and may differ between biological 
systems. For example, while over-expression of PKC /3I in fibroblasts resulted in 
enhanced growth (Kuo et al., 1990), increased levels of this isoform in colon 
adenocarcinoma cells produced growth arrest and reduced tumorigenicity in nude mice 
(Yamamoto et al., 1998). Taken together, these findings suggest that the varying growth 
regulatory effects of PKC agonists in different systems may be the result of differential 
activation of individual members of the PKC family.
A full understanding of the function of PKC iso forms in control of the cell cycle under 
normal and pathological conditions requires clarification of the specific actions of these
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molecules on cell cycle progression and on individual components of the cell cycle 
machinery. This is an emerging field and our current understanding of the molecular 
pathways is limited. However, accumulating evidence points to a role for member(s) of 
the PKC family in control of cell cycle progression at two sites: the G1 to S and the 
G 2toM  transitions (Kampfer et al., 2001);(Thompson and Fields, 1996);(Yamamoto et 
al., 1998).
The aim of this chapter was to determine whether the protective effect of inositol on PNP 
closure in ct/ct embryos was mediated through correction of the proliferation defect in the 
hindgut endoderm.
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5.2 RESULTS
Curly tail embryos were cultured in the presence of inositol, or PBS as a vehicle control, 
for 24 hours from E9.5, the period during which the neural tube is closing in the low 
spinal region of the mouse embryo. After culture, the extra-embryonic membranes were 
dissected away and each embryo was observed directly under a dissecting microscope. 
Crown-rump length and PNP length were measured and number of somites was noted. 
Any embryo which fell outside the 27-29 somite range was excluded. After the 
measurements were made, the embryo was cut into two parts at the level between somites 
13 and 14. The rostral half was discarded and transverse histological sections of the 
posterior half were used to examine the neuroepithelium, notochord and hindgut 
endoderm by immunostaining to allow labelling indices to be determined in order to 
quantitate regional cell proliferation.
The population of dividing cells in the curly tail PNP was investigated in two ways: by 
immunostaining (i) for proliferating cell nuclear antigen (PCNA) and (ii) for phospho- 
histone H3. PCNA is expressed by proliferating cells and has a longer half-life than 
phospho-histone H3. Expression of PCNA is maintained through G1 and S phases of the 
cell cycle, labelling those cells about to enter or within the DNA synthetic phase. In 
contrast, phospho-histone H3 is detected only in cells that are currently in M-phase of the 
cell cycle.
5.2.1 PCNA analysis
PCNA-positive and total nuclei (visualised by DAPI staining) were counted within neural 
tube, notochord and gut endoderm at X 60 magnification (Fig. 5.1). The fraction of 
proliferating cells, as revealed by the proportion of cells in Gl/S-phase, was calculated as 
the number of PCNA positive cells within a specific domain divided by the total number
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of cells within the same domain. PNP length was determined by counting the number of 
serial sections between the first section with a clearly differentiated neural plate and the 
first section to show contact of the neural folds in the dorsal midline.
Figure 5.1 PCNA immunostaining in curly tail embryos after 24 hours culture from 
E8.5 to E9.5. A, B: immunohistochemistry for PCNA on transverse sections of caudal 
embryonic regions. Intensively green stained nuclei are those in S to G 1 phase of the cell 
cycle. Section A is through the caudal part of the PNP, whereas section B is nearer the 
point of neural fold fusion C, D: DAPI staining, which labels all nuclei. Scale bar: 250 
pm
Cell proliferation, is most rapid in neuroepithelium, less intense in hindgut endoderm and 
slowest in notochord (Fig. 5.2), as described previously (Copp et al., 1988c). No 
difference in PCNA labelling index, between inositol-treated and PBS-treated embryos 
was detected in the neuroepithelium or notochord. However, there was a significant 
increase in PCNA labelling index in the hindgut of inositol-treated embryos.
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Figure 5.2 Inositol stimulates hindgut cell proliferation during NTD 
prevention. Cell proliferation was measured by PCNA labelling in tissues of the 
PNP region of cultured curly tail embryos a measure of cells in S-phase. Inositol 
significantly increased PCNA labelling index in the hindgut (,P<0.005), whereas 
inositol has no significant effect on PCNA labelling in either neuroepithelium or 
notochord. Labelling index values are mean ± SEM of at least 10 embryos per 
treatment.
5.2.2 Phospho-histone 3 analysis
As an independent measure of cell proliferation marker, I also used phospho-histone H3 
immunostaining in order to assess the proportion of cells in M-phase in the 
neuroepithelium, notochord and hindgut endoderm. Only a few cells were found to be 
labelled on each section (Fig. 5.3), in contrast to PCNA staining, reflecting the smaller 
proportion of cells in M-phase compared to Gl/S phase.
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Figure 5.3 Phospho-histone H3-labelling in the PNP region of curly tail embryos 
after 24 hours culture from E8.5 to E9.5. Transverse section through the PNP, stained 
for phospho-histone H3 and photographed using epifluorescence plus Nomaski optics. 
Mitotic (H3-positive) nuclei appear as bright dots on the section. Note mitoses in 
neuroepithelium (NE) and hindgut (HG) but not in notochord (NC). Scale bar: 150 pm.
Inositol treatment caused a significant increase in the phospho-histone H3 labelling index 
in the hindgut (Fig. 5.4), suggesting a stimulatory effect on cell proliferation, as found by 
PCNA staining. In contrast, there was no significant effect of inositol treatment on 
phospho-histone H3-labelling in the neuroepithelium or notochord (Fig. 5.4). The 
increase in labeling of both a Gl/S-phase and an M-phase marker strongly suggests that 
proliferation rate is indeed increased following inositol treatment, in association with 
prevention of PNP closure delay, and that this stimulation of cell proliferation specifically 
affects the hindgut epithelium.
A parallel set of cultures was performed to determine whether inhibition of a PKC 
isoform, PKC pi, that is required for prevention of NTDs (Chapter 4), is also essential for 
the effect of inositol on proliferation. As a control, another set of embryos were cultured 
in the presence of inositol plus the PKC £ inhibitor, that was found to be dispensable for
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the inositol preventive effect (Chapter 4). Co-administration of the peptide inhibitor of 
PKC pi blocked the stimulatory effect of inositol on hindgut proliferation (Fig. 5.4), 
whereas the PKCs inhibitor had no effect. In the presence of inositol, neither inhibitor 
significantly altered proliferation in neuroepithelium or notochord. Hence, inositol 
overcomes the genetically-determined defect of cell proliferation in curly tail embryos, an
effect that specifically requires activation of PKC 131.
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Figure 5.4 Cell proliferation was measured in tissues of the PNP region of cultured 
curly tail embryos using phospho-histone H3 as a measure of the proportion of cells 
in metaphase. Inositol significantly stimulates histone H3 labelling (P<0.02) in hindgut 
endoderm (hindgut 4th bar versus 1st bar), whereas inositol has no significant effect on 
histone H3 labelling in either neuroepithelium or notochord. In hindgut endoderm, 
inhibition of PKC 61 significantly reduces histone H3 labelling compared with inositol 
alone (P<0.05), whereas inhibition of PKCs has no significant effect (P>0.05). Blocking 
PKC 61 or s has no significant effect on histone H3 labelling in neuroepithelium or 
notochord (P>0.05). No notochordal cells were positive for histone H3 in the presence of 
inositol and the PKC 61 inhibitor. Labelling indices are mean ± SEM of at least 10 
embryos per treatment.
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5.3 DISCUSSION
In this chapter, I have demonstrated that inositol stimulates cell proliferation in the 
hindgut of curly tail embryos, reversing the imbalance of cell proliferation that is known 
to lead, via enhanced ventral curvature of the caudal region, to delay or failure of PNP 
closure (Copp et al., 1988c). Since the prevention of NTDs by inositol in curly tail mice 
requires specific PKC isoforms, it was predicted that these PKC isoforms would also be 
required for stimulation of the cell cycle in the embryonic hindgut. Indeed, I found that 
PKC BI, which is required for correction of PNP closure, is also required for this 
stimulation of cell proliferation. S-phase entry/progression has been suggested to be 
defective in hindgut cells of curly tail embryos (Copp et al., 1988c), raising the possibility 
that activation of PKC BI may reverse this defect, leading to ‘rescue’ of the mutant 
phenotype. Interestingly, inositol treatment of cells for 6 h resulted in nuclear 
translocation of PKC BI as also observed for short-term exposure to TPA (see Chapter 4). 
This nuclear localization suggests that a role of PKC BI in cell cycle regulation is 
plausible. However, PKC a  also exhibits nuclear translocation in inositol-treated cells 
(both curly tail and non-mutant), but does not play an essential role in the prevention of 
NTDs, demonstrating that nuclear translocation per se is not sufficient to achieve the cell 
cycle regulation necessary for normalization of PNP closure.
PKC activation has previously been shown to regulate cell cycle progression in a wide 
variety of cell types (e.g., vascular endothelial cells (Kinsella et al., 1992), vascular 
smooth muscle cells (Suzuma et al., 2002), melanoma cells (Szalay et al., 2001), 
fibroblasts (Nakashima, 2002), keratinocytes (Suzuma et al., 2002), myeloid leukemia 
cells (Miyamoto et al., 2002), breast carcinoma cells (Kuo et al., 1990), and intestinal 
epithelial cells (Kuo et al., 1990). In particular, PKC BI, the isoform required in 
prevention of curly tail defects, has been previously associated with increased cell cycle
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entry. Its over-expression leads to increased proliferation of aortic endothelial cells, in 
contrast to PKC pn  which has an inhibitory effect (Yamamoto et al., 1998). Similarly, 
proliferation of vascular smooth muscle cells is stimulated by PKC BI, through increased 
S-phase entry, but inhibited by PKC BII, through extension of S-phase (Yamamoto et al., 
1998).
Furthermore, Aaltone et al (2006) in the study cell proliferation within transitional cell 
carcinoma, reported an increased PKC substrate phosphorylation which correlated with 
increased expression and nuclear localization of PKC pi in tumor samples and in cultures 
with increased PKC pi immunosignal. Moreover, they found that, in normal epithelium, a 
significant number of cells were negative for PKC pi nuclear localization, whereas in 
cancerous tissue, particularly in highly proliferative areas, nearly all nuclei were positive 
for immunosignal. Interestingly, in transitional cell carcinoma cultures, nuclear PKC pi 
appeared as a 65-kDa fragment, whereas in the cytoplasm, it was present as a full-size 79- 
kDa form, as demonstrated by La Porta et al. (La Porta, 1997) in a Western blotting study. 
There are earlier reports locating PKC-pI in the nucleus (Svensson et al., 2000); 
Raghunath et al. 2003), and it has been demonstrated that PKC-pI is transported to the 
nucleus and fragmented (Bastiaens and Jovin 1996). Others have shown a 65-kDa 
fragment for PKC pi in the membrane fraction of cells (al-Mazidi HA, 1998) and in 
whole-cell lysates (Pfaff et al. 1999; Redling et al. 2004). It is thus possible that PKC pi is 
fragmented during activation and that localization of the 65-kDa fragment in membranes 
(possibly nuclear membrane) is necessary for activation. Taken together, these reports 
confirm the likely involvement of PKC pi in cell cycle regulation, as also indicated by the 
findings presented in this thesis. In future work, it would be interesting to determine 
whether increased PKC substrate phosphorylation is correlated with PKC pi activity 
during inositol-mediated prevention, and whether there is a requirement for PKC pi
cleavage, in order to allow nuclear tranlocation and nuclear activity of PKC pi in curly 
tail embryos.
The possibility must also be considered that changes in PKC expression, as seen in this 
thesis, reflect changed activity of other cell signalling pathways affecting cell cycle 
progression. As an example, oncogenic Ras has been shown to up-regulate PKC a , c-myc 
oncogene induces increased PKC P expression, and wild-type p53 has been shown to 
suppress PKC y expression (Barr et al. 1991; Delage et al. 1993; Zhan et al. 2005). 
Further studies would be needed to fully evaluate the role of such regulatory interactions 
during mouse neurulation.
The next step in studying the role of inositol in hindgut cell cycle regulation, would be to 
determine the effects of inositol treatment on phosphorylation of known PKC targets 
involved in proliferation, including the nuclear lamins and MARcKS (Aderem, 1992b). 
Specific isoforms of PKC regulate the transcriptional control of cyclin D1 (CCND1) 
expression, which plays a critical role in the progression of mammalian cells through the 
G1 phase of the cell cycle (Kampfer et al., 2001). G1 to S transition is a critical step 
because abnormalities in this step can enhance cell proliferation, genome instability, and 
tumor progression. However, the possibility that PKC pi, y and £ may stimulate cyclin D1 
promoter activity in curly tail embryos remains to be investigated. Further studies might 
include the assessment of knockout mice lacking function of putative PKC targets, to 
determine whether double mutant combinations with curly tail would render the NTDs 
resistant to inositol-mediated prevention.
An interesting question that remains to be answered is why inositol stimulates PKC pl- 
dependent cell proliferation only in the hindgut endoderm and not in the neuroepithelium, 
which is an even more mitotically-active tissue than the hindgut. PKC pi, like all the PKC
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isoforms studied, is expressed in all tissues of the caudal embryonic region (Chapter 4). 
Hence, selective PKC expression cannot explain the specific effect of inositol. It is 
possible that the sub-normal hindgut proliferation in curly tail embryos might reflect 
“available” capacity for a PKC pi-dependent response. Whereas non-mutant embryos 
have “maximal” hindgut proliferation and cannot be further stimulated. The same 
argument could apply to the neuroepithelium in curly tail embryos in which proliferation 
appears normal. This idea would predict that inositol would not stimulate enhanced 
proliferation in the hindgut of wild type embryos, a suggestion that could be addressed in 
future work.
Sections of curly tail mouse embryos at the stage just prior to PNP closure were recently 
analyzed by in situ hybridization for Grhl3, a compelling candidate for the ct gene. 
Specific expression in the hindgut endoderm was observed (Greene, unpublished data), 
raising the possibility that Grhl3 expression may be required for an embryonic tissue to 
show a proliferative response to inositol. Grhl3'/' embryos do not respond to inositol 
treatment (Ting et al, 2003) in support of this idea. Currently, there is no information, 
however, on a possible molecular regulatory link between inositol/PKC pi, Grhl3, and the 
cell cycle machinery.
Last, Ting et al (2003) showed that Grhl3'A embryos exhibit NTDs and growth 
retardation, particularly around the hindgut endoderm, results which are comparable to 
this chapter’s finding in the ct/ct mice.
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CHAPTER 6 
GENERAL DISCUSSION
6. GENERAL DISCUSSION
Although some cases of human NTDs can be prevented by folic acid, there is increasing 
evidence that many cases do not respond. For instance, there was no major reduction in 
NTD frequency in the U.K. during the ten years after folic acid supplementation was 
introduced (Locksmith, 1998). The objective of this thesis was to investigate inositol as a 
possible treatment for folate-resistant NTDs, in order to prevent a larger proportion of 
human NTDs than is currently possible.
The specific aims of this theses were:
1. To use the curly tail mouse as a model of folate-resistant NTDs, in order to find 
the optimal dose and treatment method for maximal reduction of NTD frequency.
2. Determine the critical PKC isoformes that mediate the preventive effect of inositol 
in preventing folate-resistant NTDs, and determine the tissue-localisation of these 
PKC isoformes
3. Correlate inositol treatment/PKC activation with rates of cell proliferation in the 
caudal region of curly tail embryos, as their NTDs are being prevented.
The overall findings of this thesis are that exogenous inositol is able to prevent NTDs by 
stimulating specific PKC isoforms, and whose actively impinges upon the hindgut cell 
cycle in curly tail embryos to regulate spinal neurulation.
6.1 INOSITOL AND FOLATE-UNRESPONSIVE NTDS IN THE 
CURLY TAIL MUTANT.
Primary prevention of NTDs in humans became a reality when clinical trials 
demonstrated that folate-containing multivitamins (Smithells, 1998) and specifically folic 
acid (Wald, 1995) can reduce recurrence risk (a second NTD pregnancy in a family) and
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perhaps reduce first occurrence of NTDs (Czeizel, 1995). Folate supplementation is 
underway by health advice in the UK, and by 'food fortification' in the USA (Simthells, 
1998). Several major issues remain. First, little is known of the molecular basis of folate 
action in preventing NTDs. A genetic polymorphism in the methylene tetrahydrofolate 
reductase (MTHFR) gene is weakly related to NTD risk (Barber et al., 1999), but variants 
of other folate-related genes are not NTD-related. While several mouse models of NTD 
are folate-preventable (Barber, 1999), none result from mutation in folate-related genes. 
A second critical point is that a significant proportion of NTDs: around 30% in the MRC 
folate trial (Kirke, 1992), appear unresponsive to folic acid supplementation. The poor 
response to folate supplementation, with barely any decline in NTD frequency in the UK 
(Locksmith and Duff, 1998), and only a 19% decline in the USA (Kirke et al., 1992); 
(Honein et al., 2001), suggests adjunct therapies are needed to prevent folate-resistant 
NTDs.
While the mechanism of folic acid preventive action has not been studied in this thesis, 
new information has been gathered on the normalisation of neurulation, by inositol, in the 
folate-unresponsive NTDs of the curly tail mutant (Cogram et al., 2002; 2004). The thesis 
has shown that: (1) inositol is active in preventing these NTDs, with a greater potency of 
the D-chiro- than wyo-inositol isoform; (2) inositol can prevent NTDs either via maternal 
administration or by a direct effect on the cultured embryo; (3) inositol stimulates PKC, 
an effect that is required for NTD prevention; (4) PKC isoforms /31 and y  are required to 
mediate the inositol effect, whereas a, /3II and all novel PKCs are dispensable; (5) inositol 
reverses the cell proliferation defect that was described previously in the hindgut of curly 
tail embryos (Copp et al., 1998); (6) the inositol effect is non-toxic during pregnancy, and 
not associated with an increase in other birth defects. In addition, (7) a case report of 
inositol usage in humans has been associated with a normal third pregnancy following
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two consecutive NTDs while on folate therapy (Cavalli and Copp, 2002). It can be 
concluded, therefore, that inositol may offer a potential novel method for preventing 
human NTDs. As a result of these findings a pilot clinical trial is now in progress (Copp, 
Greene and others, unpublished). Hence this research, which began in a mouse genetic 
model, is being “translated” into clinical application.
6.2 GRHL3, CT AND INOSITOL PREVENTION
The effect of folate and inositol administration on pregnant Grhl3+I~ females mated with 
Grhl3+/~ males was studied by Ting et al (2003). Folate did not rescue spina bifida in 
Grhl3~embryos and, contrary to expectation neither did inositol (Ting et al., 2003). 
Hence, although the Grhl3 gene seems very likely to be altered in curly tail mice, the 
Grhl3 knockout appears inositol-resistant. Possible mechanisms for this difference in 
inositol responsiveness of ct/ct and Grhl3~A mice could be related to the fact that ct is a 
hypomorphic allele of Grhl3, and therefore more easily normalised than the null Grhl3 
allele, or that the residual Grhl3 function in ct/ct embryos enables inositol to exert its 
effect on hindgut cell proliferation, whereas complete loss of Grhl3 renders the hindgut 
corresponsive to inositol (Chapter 5)
Interestingly, clones of grh mutant cells in the adult Drosophila epidermis have defects in 
pigmentation, cell polarity, and epidermal hair differentiation (Lee and Adler, 2004). Loss 
of Grhl3 results in embryos with defective epidermal wound repair (Ting et al., 2005) 
suggesting that Grhl3 may have other roles in epithelial fusion events. Furthermore, over­
expression of grh in Drosophila embryos causes a failure in dorsal closure (Attardi, 
1993), a widely studied epithelial fusion event that has many similarities to wound repair 
(Wood et al., 2002). Recent cellular and molecular studies have substantially increased 
our understanding of the elegant cascade of signalling events necessary for the wound
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healing process (Frank, 2002). For example, several important biochemical mediators of 
cell migration and growth have been identified that are involved in tissue reformation 
(Frank, 2002).
Inositol receptor-mediated signal transduction can occur by various pathways to affect 
downstream targets which are ultimately involved in wound healing, planar cell polarity 
and cell proliferation. Activation of PKC stimulates the mitogen-activated protein kinase 
(MAPK) cascade leading to MAPK activation, and modulation of transcription factor 
activity. This can lead to changes in cell behaviour such as proliferation, as is seen in a 
variety of growth factor-mediated events of receptor tyrosine kinase stimulation (Liaw, 
1995) Hence, stimulation of cell proliferation in curly tail embryos by inositol could act 
via this pathway. A prediction would be that intermediates in the MAPK pathway (e.g. 
ERK) would show increased phosphorylation after inositol stimulation. It is currently 
unknown how Grhl3 might interact with such signalling pathways.
6.3 CHIRO- VS MFO-INOSITOL IN PREVENTING CURLY TAIL 
NTDs
The data presented in Chapter 3 confirm previous observations supporting a role for 
inositol in neurulation, since administering inositol to ct/ct embryos reduces the incidence 
of spina bifida. In a prior study, relatively high doses of myoinositol were required to 
give a protective effect (Greene and Copp, 1997a). However, here it has been shown that 
an alternative isomer, D-c/zzroinositol, provides a similar protective effect at lower 
concentrations, indicating that it is more effective than myoinositol at lowering the 
incidence of spinal neural tube defects. This observation has been shown in four 
independent experiments, involving three different routes of administration to the 
developing embryo. At present the reason for enhanced efficacy of D-c/zzVoinostitol is
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not known. It is important to take into account the fact that myoinositol converts to D- 
c/hroinositol in vivo, and since the D-chiro-form seems to be more effective, it would be 
very interesting to investigate the biosynthesis of D-chiro-inositol from myo-inositol in 
curly tail mice.
If it is to be used clinically, it is imperative that inositol is a safe treatment during 
pregnancy. It has been suggested that inositol treatment could stimulate uterine 
contractions during pregnancy (Colodny and Hoffman, 2000). The idea behind this 
suggestion is that oxytocin (a uterine stimulator) acts via activation of phospholipase C. 
However, although oxytocin is activated via the inositol phospholipid signalling pathway 
and can stimulate uterine contractions, there is no evidence to suggest that inositol 
supplementation has this effect. In the case report of a woman who took inositol in a third 
pregnancy, following two NTD pregnancies, there were no abnormal uterine contractions 
reported (Cavalli and Copp, 2002). Moreover, according to the data presented here 
(Chapter 3) there was no significant difference in pregnancy loss between the treated and 
the placebo groups of curly tail mice, suggesting that inositol is an effective and safe 
treatment, at least during mouse pregnancy.
6.4 INOSITOL ACTION IN NTDs IS MEDIATED VIA PKC
Using specific PKC inhibitors, both chemical and peptide in whole embryo culture, I 
showed in Chapter 4 that the preventive effect of inositol is mediated via specific PKC 
iso forms. All PKC isoforms were detected, during mouse development from E9.5 to 
E l7.5, in agreement with previous analysis of PKCs in E l5-17 fetuses (Blackshear et al., 
1996a). These findings contrast with a study of E l0.5 embryos that detected PKCa, but 
not BI, BII, and C, (Wilda et al., 2001). This difference may reflect the low abundance of
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cPKCs on western blot, at early stages (E9.5-11.5) in particular (Cogram et al., 2004b), 
although all isoforms were clearly detectable in the PNP region by 
immunohistochemistry. Another member of the laboratory, Andrew Hynes, carried out 
the western blot analysis and found that each isoform exhibited a distinct distribution 
between sub-cellular fractions, which likely reflects the degree of activation. For instance, 
cPKCs were confined to the cytoplasmic fraction, suggesting minimal activation during 
undisturbed development, whereas aPKCs were present in membrane-associated and 
insoluble fractions throughout development, suggesting constitutive activation (Cogram et 
al., 2004b). This finding is consistent with a role for the cPKCs, BI and y, in mediating the 
preventive effect of inositol, since activation of these isoforms may be limiting in the 
absence of inositol, providing capacity for activation after treatment.
6.5 MOLECULAR BASIS OF THE REQUIREMENT FOR PKC AND 
PI3-KINASE
The normalizing effect of inositol on PNP closure was partially blocked by both the 
chemical inhibitor LY294002 and the peptide inhibitor specific for PKC <J. LY294002 has 
activity against both PKC C, and also the PI 3-kinase pathway, suggesting a possible role 
for the latter in the mechanism of inositol action. To test this idea, I performed 
preliminary experiments using the PI 3-kinase inhibitor wortmannin in whole embryo 
culture. Even at the low concentration of 0.1 pM, wortmannin proved extremely toxic to 
neurulation stage embryos, with all treated embryos dying during the culture period. 
Clearly, PI 3-kinase activity is essential for mouse embryonic development at this stage. 
The fact that LY294002 did not exhibit similar toxicity may indicate a more selective 
action, and the finding that specific inhibition of PKC C, produced no general toxicity but 
a similar partial blockade of inositol-mediated prevention supports the idea that PKC
and not the entire PI 3-kinase pathway was mainly affected in these studies.
6.6 IS PKC IMPLICATED IN THE MECHANISM OF NEURAL 
TUBE CLOSURE?
Several lines of evidence suggest that spinal neurulation per se does not depend on 
inositol and PKC activation and that defective closure in curly tail embryos is unlikely to 
result from an intrinsic deficiency in inositol or specific PKC isoforms. First, exposure of 
curly tail embryos to PKC inhibitors, in the absence of inositol, did not affect PNP 
closure. Second, uptake and incorporation of 3H-inositol occurs similarly in cultured curly 
tail and non-mutant embryos, while inositol deficiency in vitro does not increase the 
penetrance of spinal NTDs in curly tail embryos (Copp et al., 1998) although the 
frequency of cranial NTDs is increased (Cockroft et al., 1992). Finally, mice with 
targeted inactivation of the genes encoding PKC, 13, y and ^ do not exhibit neurulation 
defects (Erin, 2007).
6.7 CELLULAR ACTION OF INOSITOL
I propose that prevention of NTDs in curly tail mice by exogenous inositol operates via
stimulation of the cell cycle in the embryonic hindgut, an effect that requires activation of
specific PKC isoforms. I have shown in Chapter 5 that cell proliferation, as judged by the
percentage of cells positive for the S-phase marker PCNA, and the mitotic marker
phospho-H3, is significantly increased in the hindgut endoderm of inositol-treated
embryos, whereas proliferation in other tissues is not significantly affected. Hence, I have
demonstrated that insoitol therapy, via PKC stimulation, corrects the cell behavioral
defect that leads to spina bifida in the curly tail mouse (Copp et al., 1988c). Inositol is
also reported to prevent NTDs in animal models of diabetes, whereas inositol deficiency
causes cranial NTD, even in non-mutant mice (King, 2006). It remains to be determined
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whether the protective action of inositol also involves stimulation of cell proliferation in 
these cases.
6.8 POSSIBLE INVOLVEMENT OF INS-DAG AND PKC IN CELL 
PROLIFERATION.
It is well known that many growth regulatory signals are directly or indirectly coupled to 
protein kinases intrinsic to, or associated with, the receptors for a variety of growth 
factors (Banan et al., 2004). These protein kinases have been subdivided into two major 
groups according to their ability to phosphorylate either serine or threonine residues of 
substrate proteins. Binding of growth factors to their surface receptors often leads to the 
activation of specific phospholipases (either by receptor-activated tyrosine 
phosphorylation or receptor coupling to GTP-binding proteins), which results in the 
elevation of intracellular calcium and diacylglycerol (DAG). It would be interesting in 
our system to measure levels of intracellular DAG in mutant curly tail and non-mutant 
mice. The purpose would be to understand the role of PKC subtypes in the regulation of 
cell proliferation in the hindgut endoderm of curly tail embryos, and to identify possible 
mechanisms by which inositol-DAG and PKC may contribute to the proliferation defect 
in curly tail mouse mutants.
The role of PKC in normal growth regulation is based on the idea that this enzyme family 
is the principal transducer for DAG that is generated upon activation of a phospholipase- 
linked cell surface receptor (Nishizuka, 1992). Intracellular levels of DAG have been 
considered a marker for the activation condition of PKC, since DAG initiates a broad 
range of cellular responses by activating PKC isoforms and other proteins (Nishizuka, 
1992). One consequence of this regulation may be to modulate cell proliferation. Indeed, 
(Besson et al., 2004) demonstrated that PKC activity was an important factor regulating
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cell proliferation and that a sustained increased in the cellular DAG and, PKC activity 
was required for cell cycle progression. Consequently, there is a possibility that normal 
hindgut cells have higher DAG levels and, therefore, a higher rate of proliferation 
compared with curly tail hindgut cells.
DAG binds to and activates PKC subtypes, together with acid phospholipids and Ca2+ 
(Nishizuka, 1992); (Dekker and Parker, 1994). Activation of PKC goes together with the 
tight association of the enzyme with membranes, a process referred to as ‘translocation of 
PKC’ (Anderson et. al. 1985; Wolf et al. 1985). Ca2+-chelators promote the cytosolic 
localization of the cPKCs, whereas elevated Ca2+ levels encourage association of PKC
2_j_
with membranes. It is interesting to speculate that varying levels of Ca may affect PKC 
translocation in curly tail cells and thus, affect cell proliferation.
6.9 PKC DOWNSTREAM TARGETS
In this thesis I have identified the PKC isoforms that mediate the preventive effect of 
inositol. The logical next step would be to identify proteins that may be phosphorylated 
by PKC during inositol action, for instance by comparing treated and untreated embryos. 
Below, I consider some possible PKC substrates, which are putative candidates to form 
part of the inositol-PKC preventive effect of inositol in curly tail embryos.
6.9.1 MAPK
Because of the possible link between Grhl3 and MAPK, this would be the first candidate 
I would analyze. MAPK pathways are evolutionarily conserved kinase modules that link 
extracellular signals to the machinery that controls fundamental cellular processes such as 
growth, proliferation, differentiation, migration and apoptosis. There are two isoforms of 
MAPK, the p44 MAPK (Erk-1) and the p42MAPK (Erk-2), which are expressed in most
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cell types. The substrates of MAPK include nuclear transcription factors and non-nuclear 
substrates such as the protein, serine/threonine kinase p90sk and cytoskeletal proteins. 
EGF-induced nuclear transcriptional activation stimulates cell proliferation by initiating 
progression from G1 to S phase of the cell cycle. Another substrate of MAPK activation is 
phospholipase A2 (CPLA2) (Davis et al., 1994). CPLA2 catalyzes the release of arachidonic 
acid from phospholipids in membranes and is one of the rate-limiting steps in the 
synthesis of prostaglandins. In cultured rabbit corneal endothelial cells, it was shown that 
the prostaglandin PGE2 inhibits mitosis (Humblatt, 1994).
6.9.2 Myristoylated alanine-rich C kinase substrate
The major PKC substrate MARCKS may be of particular interest in relation to neural 
tube closure as the null mutant mouse displays exencephaly (Stumpo et al., 1995). 
Moreover, knockout of MARCKS family protein, MRP (also known as MARCKS-related 
protein, MacMARCK or F52) also causes NTDs, both spina bifida and exencephaly 
(Chen et al., 1996). The potential importance of these proteins is their involvement in 
cytoskeleton rearrangement and cell cycle.
6.9.3 Cyclins
Specific isoforms of PKC, such as pi and pH regulate the progression of cells through the 
G1 to S phases of the cell cycle. PKC is a potent activation of the transcriptional activity 
of the cyclin D1 promoter (Erin, 2007). PKC activation, leads to activation of c-fos and c- 
jun , which form AP-1 complexes and activate the cyclin D1 promoter. Expression of 
cyclin D1 then facilitates cell cycle progression from G1 to S phase and enhances 
proliferation. Activation of PKC also leads to activation of cyclin E expression, through 
mechanisms not fully understood. It could be interesting to determine if any of these
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downstream PKC targets contribute to the enhancement of cell proliferation in inositol- 
treated curly tail mice.
6.9.4 Shuttle proteins
A considerable number of PKC substrates are localized in defined membrane 
compartments (Parker and Parkinson, 2001). It would be interesting, as a continuation of 
this thesis, to identify how these signals get into the nucleus to regulate gene expression, a 
mechanism that is unclear at present. The discovery of shuttle proteins capable of 
carrying information from the cytoplasm into the nucleus has improved the understanding 
on how growth factors regulate gene expression (Nigg, 1995). In the absence of stimuli, 
these shuttle proteins remain in the cytoplasm in the form of macromolecular complexes 
and translocate to the nucleus in response to cell stimulation, either because they are 
small enough to pass the nuclear membrane or because they carry special nuclear target 
sequences that facilitate nuclear uptake (Silver, 1990). The NFkappa p shuttle is 
especially interesting, as it appears to be regulated by PKC. The NFkappa P system is 
widespread in a variety of cell types and regulates many genes (Gilmore 1990). It consists 
of a heterotetradimer protein complex capable of interacting with a DNA regulatory 
sequence (the kp sequence). NFkappa P is a transcriptional activator that participates in 
the induction of several genes, in particular those related to cell proliferation. NFkappa p 
is a possible PKC substrate whose translocation to the nucleus could be a possible rapid 
signalling pathway. It would be interesting to identify whether NFkappa p may be 
involved in the inositol-PKC protective effect in curly tail.
6.9.5 Lamins
Numerous studies indicate that gene transcription is regulated by the action of protein 
kinases in the nucleus. As described in Chapter 4, treatment of cells with TPA induces a
182
translocation of cytosolic PKC to nuclear fractions raising the possibility of that these 
isoforms are involved in nuclear function. Lamin B, a nuclear envelope protein, and 
topoisomerase I (Holaska et al., 2002) have been found to be substrates of PKC in vitro 
and be phsophorylated on serine or threonine in response of phorbol ester treatment of 
cells. Phosphorylation of lamin is escential for nuclear envelope disassembly during 
mitosis (Holaska et al., 2002) while phosphorylation of topoisomerase I relaxes positive 
DNA supercoiling, a crucial event for efficient gene transcription (Goss et al., 1994). 
There may be a role for nuclear PKC (31 and y in the regulation of cell growth via 
activation of nuclear lamins.
6.10 CONCLUSION AND PERSPECTIVES
Although there are still many unanswered questions about inositol lipid signaling, new 
techniques and tools are now available to study molecular cell physiology that should 
allow us to gain, in a relatively short time, a better understanding of their roles in the cell 
during the neurulation process. For example, in order to elucidate further the role of 
specific forms of PKC in modulating the expression of genes related to cellular growth 
control during neural development, it would be desirable to generate cell lines that stably 
produce elevated levels of a specific isoform of this enzyme. These cell lines would then 
provide a model system for studying cellular events occurring subsequent to activation of 
PKC y and pi, by tumor promoters and other agents in an epithelial cell system.
Although there are also many unanswered questions about NTDs, this thesis work has 
established, a clear link between inositol lipid signaling and specific isoforms of PKC, 
PKC y and pi, which together appear to integrate a complex network of signal 
transduction pathways. This PKC-related mechanism seems likely to control gene
183
expression and cell proliferation in the caudal region of inositol-treated curly embryos 
during rescue of NTDs.
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BACKGROUND: Among mouse genetic mutants that develop neural tube defects (NTDs), some respond to folic 
acid administration during early pregnancy, whereas NTDs in other mutants are not prevented. This parallels 
human NTDs, in which up to 30% of cases may be resistant to folic acid. Most spina bifida cases in the folic acid- 
resistant ‘curly tail’ mouse can be prevented by treatment with inositol early in embryonic development. Here, the 
effectiveness and safety during pregnancy of two isomers, myo- and D-c/rtro-inositol, in preventing mouse NTDs 
was compared. METHODS AND RESULTS: Inositol was administered either directly to embryos in vitro, or to 
pregnant females by s.c. or oral routes. Although D-chiro- and myo-inositol both reduced the frequency of spina 
bifida in curly tail mice by all routes of administration, D-c/nro-inositol consistently exhibited the more potent 
effect, reducing spina bifida by 73-86% in utero compared with a 53-56% reduction with myo-inositol. Pathological 
analysis revealed no association of either myo- or D-c/iiro-inositol with reduced litter size or fetal malformation. 
CONCLUSIONS: D-c/ttro-inositol offers a safe and effective method for preventing folic acid-resistant NTDs in the 
curly tail mouse. This raises the possibility of using inositol as an adjunct therapy to folic acid for prevention of 
NTDs in humans.
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Introduction
Folic acid supplementation during early pregnancy can prevent 
a proportion of neural tube defects (NTDs) (Wald et al., 1991; 
Czeizel and Dudas, 1992; Berry et al., 1999), whereas other 
cases of NTD appear resistant to folic acid. In the randomized 
controlled trial of the Medical Research Council, UK (Wald 
et al., 1991), 28% of NTD cases recurred despite supple­
mentation with 4 mg folic acid per day. Moreover, the recent 
introduction of folic acid fortification of bread flour in the 
USA resulted in only a 19% decline in the prevalence of 
NTDs (Honein et al., 2001). While these findings may indicate 
the need for increased levels of folic acid supplementation, 
they are also consistent with a proportion of NTDs exhibiting 
resistance to exogenous folic acid.
Mouse genetic models also indicate the existence of folate- 
resistant NTDs. Mutant strains including ‘splotch’, ‘crooked 
tail’ and the ‘Cartl’ knockout exhibit NTDs that can be 
prevented by folic acid treatment during early pregnancy 
(Fleming and Copp, 1998; Zhao et al., 1996; Carter et al., 
1999), whereas folic acid is ineffective in preventing NTDs 
in the mutant strains ‘curly tail’, ‘axial defects’ and the ‘ephrin-
A5’ knockout (Essien and Wannberg, 1993; Seller, 1994; 
Holmberg et al., 2000).
Previously, it was demonstrated that a proportion of the 
folate-resistant NTDs in curly tail mice can be prevented by 
treating pregnant females, or embryos in vitro, with myo­
inositol (Greene and Copp, 1997). These findings were 
consistent with earlier work showing that deficiency of 
myo-inositol in the culture medium of rat and mouse embryos 
caused a high incidence of cranial NTDs (Cockroft, 1988; 
Cockroft et al., 1992), and that NTDs developing in rat embryos 
cultured under diabetic conditions could be ameliorated by 
supplementation with myo-inositol (Baker et al., 1990; 
Hashimoto et al., 1990). Together, these findings suggest 
inositol as a potential therapeutic option for prevention of 
folate-resistant NTDs.
Here, the analysis of inositol as a primary therapeutic agent 
in preventing mouse NTDs has been extended. The study was 
intended to serve as a preliminary to a human clinical thera­
peutic trial. It was shown that inositol could prevent NTDs 
both in vitro and following administration to pregnant curly 
tail females, either by s.c. or oral routes. A detailed pathological
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analysis revealed no significant adverse effects of inositol 
therapy on mouse fetuses. Moreover, the effectiveness of 
myo-inositol was compared with that of D-c/z/ro-inositol, a 
closely related enantiomer that differs in the orientation of the 
carbon-two hydroxyl group (C2-OH) relative to the plane of 
the six carbon ring.
Materials and methods
Mice
Curly tail mice are maintained as a homozygous, random-bred stock 
in which NTDs develop in -60% of individuals (Van Straaten and 
Copp. 2001). Experimental litters were generated by timed matings, 
and the day of finding a copulation plug was designated embry onic 
day (E) 0.5.
In-vitro inositol treatment
E9.5 embryos (17-19 somite stage) were cultured for 24 h at 38°C 
in whole rat serum, as described previously (Copp et al.. 1999). At 30 
min after the start of culture, myo-inositol (Sigma, UK) or D-chiro- 
inositol (Insmed. VA. USA) was added to the medium (62.5 pi of 
inositol stock per ml rat serum) to a final concentration o f 5, 10. 20 
or 50 pg/ml inositol. Control cultures received an equal volume of 
phosphate-buffered saline (PBS). Following culture, embryos were 
scored for: (i) posterior neuropore length (the distance from the rostral 
end of the posterior neuropore to the tip o f the tail bud): (ii) crown- 
rump length; and (iii) somite number.
In-utero inositol treatment
For s.c. administration, osmotic mini-pumps (capacity 100 pi, delivery 
rate 1 pl/h; model 1003D. Alzet) were filled with solutions of 30, 75 
or 150 mg/ml inositol (delivering 29. 72 and 144 pg inositol/g body 
weight per day respectively for a 25 g mouse), or PBS as a control. 
Mini-pumps were incubated in sterile PBS at 37°C for 4 h and then 
implanted s.c. on the back of pregnant mice at E8.5. General 
anaesthesia was induced by an i.p. injection of 0.01 ml/g body weight 
of a solution comprising 10% Hypnovel® (midazolam 5 mg/ml) and 
25% Hypnorm® (fentanyl citrate 0.315 mg/ml. fluanisone 10 mg/ml) 
in sterile distilled water. For oral administration, pregnant mice were 
gavaged with 0.5 ml inositol solution in PBS twice daily intervals 
from E8.5 to E10.5 (six doses in total; 800 pg/g body weight per day).
Analysis of fetuses following inositol treatment in utero
Pregnant females were killed at E l8.5. and the total number of 
implantations, classified as viable fetuses or resorptions, was recorded. 
Fetuses were dissected from the uterus and inspected immediately 
for the presence of open lumbo-sacral spina bifida and tail flexion 
defects: the primary manifestations of the curly tail genetic defect 
(Gruneberg, 1954; Van Straaten and Copp, 2001). A randomly selected 
sample of fetuses was fixed in Bouin’s fluid and subjected to detailed 
internal pathological analysis by free-hand serial sectioning (Wilson. 
1965). Other fetuses were fixed in 95% ethanol and processed for 
skeletal examination (Whittaker and Dix, 1979).
Statistical data analysis
Continuous variables (somite number, crown-rump length, posterior 
neuropore length, litter size) were compared between treatment groups 
using analysis of variance or Kruskal-Wallis test. Ordinal regression 
was used to quantify further the effects of treatment and dosage on 
posterior neuropore length. Fisher’s exact or %2-tests were used to 
compare phenotype frequencies between groups. To evaluate possible
litter effects, multilevel ordinal logistic models were fitted to the 
data in Table III (MLwiN v l . 10.0006) (Goldstein. 1995). Logistic 
regression was used to determine whether the number of resorptions 
in utero was linked to dose and/or treatment.
Results
D-chiro-inositol is more effective than myo-inositol in 
normalizing neural tube closure in embryo culture
Curly tail embryos were cultured in the presence of inositol 
for 24 h from E9.5, the period during which the neural tube 
is closing at the posterior neuropore of the mouse embryo. In 
curly tail embryos, neuropore closure is delayed or fails to be 
completed, leading to the development of tail flexion defects 
and spina bifida, respectively (Figure 1A-C) (Copp. 1985). 
Posterior neuropore length at E l0-10.5 is positively correlated 
with the likelihood that an embryo will progress to develop a 
spinal NTD (Copp, 1985; Van Straaten et al.. 1992).
Both myo- and D-c/i/ro-inositol exhibited a dose-dependent 
normalization of posterior neuropore length in embryo 
culture, as judged by the reduction in neuropore length observ ed 
in embryos treated with higher inositol doses (Table I; Figure 
2A). Strikingly, D-c/i/ro-inositol significantly reduced neuro- 
pore length at dose levels of both 20 and 50 pg/ml, whereas 
a comparable effect was seen with myo-inositol only at 
50 pg/ml. Embryos exposed to 20 pg/ml myo-inositol (or 
5-10 pg/ml D-c/n'ro-inositol) exhibited neuropore lengths 
that were not different from PBS-treated controls.
Neither myo- nor D-chiro-inositol affect the rate of 
embryonic growth in embryo culture
In the experimental design, embry os in the different treatment 
groups were matched for somite number before culture, in 
order to avoid differences in developmental outcome (neuro- 
pore length) that might arise from comparing embryos of 
different stages. Following culture, all groups exhibited mean 
somite numbers in the range 30-31. with no difference between 
treatments (Table I). Moreover, no significant difference was 
found in crown-rump length of embryos treated with either 
myo- or D-c/i/ro-inositol compared with PBS-treated controls 
(Table I), suggesting that the effect o f inositol is specific to 
the closing posterior neuropore, and not mediated via alteration 
of embryonic growth.
D-chiro-inositol is more effective than myo-inositol in 
preventing NTDs in utero
Next, the effectiveness of s.c. and oral routes of inositol 
administration in preventing NTDs in curly tail litters was 
evaluated. Using surgically implanted osmotic mini-pumps to 
administer inositol at a constant rate over a period of 72 h of 
pregnancy, encompassing the stages of neural tube closure, a 
dose-dependent effect of both myo- and D-c/i/ro-inositol was 
observed. At 29 pg/g body weight per day, neither myo- nor 
D-c/j/ra-inositol significantly affected the frequency of fetuses 
with spina bifida (Figure 2B), whereas at dose levels o f 72 
and 144 pg/g body weight per day, both inositols reduced 
the frequency of spina bifida compared with PBS-treated 
pregnancies (Figure 2B). At these higher dose levels, inositol
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Figure 1. (A) Curly tail embryo after 24 h culture from E9.5 to E10.5. The box indicates the posterior neuropore region. (B,C) Higher 
magnification of the caudal region of cultured curly tail embryos. The posterior neuropore, a region of open neural folds, occupies the dorsal 
part of the caudal region, between the arrows in (B) and (C). Embryos with a large neuropore (C) develop spina bifida and/or a tail flexion 
defect, whereas embryos with a small neuropore (B) complete neural tube closure normally. (D-G) Skeletal preparations of E l8.5 curly tail 
fetuses in dorsal view (D,E: rostral to the top) or right lateral view (F,G: rostral to the right). Compared with the normal fetus in (D), the 
fetus with spina bifida (E) exhibits vertebral pedicles widely spaced apart and absent neural arches in the low lumbar/sacral region (long 
arrow in E). The tail (short arrow in E) is enclosed in a skin sac and appears reduced in length owing to deformation and fusion of caudal 
vertebrae. The tail flexion defect (G) comprises a 360° curl of the tail, compared with the normal fetus which exhibits a straight tail (F). 
Scale bars: A =  0.5 mm; B,C = 0.2 mm; D,E =  2 mm; F,G =  2 mm.
caused a significant shift towards the mild end of the NTD study, D-c/frro-inositol appeared most effective, causing a
phenotype spectrum, with fewer fetuses having spina bifida 73-83% decrease in spina bifida frequency relative to PBS
and more appearing normal (Table II). As with the in-vitro controls, at both 72 and 144 pig/g body weight per day.
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Table I. Comparison of growth and developmental parameters in curly tail embryos cultured in the presence 
of myo- and D-c/nro-inositol
Treatment Cone. No. of Somite Crown-rump PNP
pg/ml embryos number3 length3 length3
PBS -  16 30.3 ±  0.15 3.56 ±  0.10 0.59 ±  0.13
A/vo-inositol
20 16 30.5 ±  0.12 3.50 ±  0.12 0.62 ±  0.06
50 16 30.5 ± 0.14 3.57 ±  0.07 0.06 ±  0.03*
D-c/nro-inositol
5 15 30.6 ±  0.13 3.50 ±  0.10 0.62 ±  0.11
10 15 30.5 ± 0.13 3.39 ±  0.10 0.55 ±  0.11
20 18 30.6 ± 0.16 3.55 ± 0.10 0.09 ±  0.11*
50 15 30.3 ± 0.16 3.49 ±  0.08 0.07 ±  0.03*
3Values are mean ±  SEM.
Statistical analysis: somite number and crown-rump length do not differ significantly, whereas posterior 
neuropore (PNP) length varies significantly between treatment groups (P <  0.0001). Ordinal regression 
analysis indicates that PNP length is significantly reduced (marked with asterisk) in embryos treated with 
myo-inositol (50 pg/ml) and D-c/i/ro-inositol (20 and 50 pg/ml) compared with those exposed to phosphate- 
buffered saline (PBS) alone (P <  0.05), whereas PNP length in other inositol-treated groups does not differ 
significantly from the PBS control group.
A/w-inositol produced a consistent 54—56% reduction in 
spina bifida frequency (Figure 2B).
Inositol was administered orally to pregnant females, using 
a twice-daily dosing regime, from E8.5 to E10.5, that delivered 
800 pg/g body weight per day, equivalent to the i.p. dose used 
in a previous study (Greene and Copp, 1997). As with 
s.c. administration, a marked reduction was detected in the 
frequency of spina bifida among the offspring o f mice treated 
with either myo- or D-chiro-inositol (Figure 2B), and a 
significant shift in the distribution o f fetuses between the three 
phenotype categories (Table II). D-chiro-inositol was most 
effective, causing a 86% reduction in the frequency of spina 
bifida, while a 53% reduction was observed for myo-inositol.
An ordinal multilevel regression analysis confirmed that 
fetuses treated s.c. with D-c/i/ro-inositol (P  <  0.0005) and 
myo-inositol (P  <  0.002) were significantly less likely to have 
spina bifida than those treated with PBS. In the oral dosing 
study, fetuses treated with D-c/nro-inositol were less likely to 
have spina bifida than PBS-treated controls (P  <  0.01), whereas 
the trend towards reduced spina bifida frequency in fitters 
treated with myo-inositol did not reach statistical significance.
A further investigation was made to determine whether 
clustering of fetuses o f particular phenotypes within fitters 
may have affected the outcome of the comparison between 
myo-inositol, D-c/nro-inositol and PBS. The multilevel analysis 
(which took into account the potential non-independence of 
fetuses within fitters) showed that the difference between 
treatment groups is unaffected when possible fitter effects are 
taken into account.
No evidence of an adverse effect of inositol on pregnancy 
success or fetal outcome
One possible explanation for a decrease in spina bifida 
frequency following maternal inositol administration could be 
an increase in loss of affected fetuses during pregnancy. 
When both resorption rate and fitter size were examined in 
pregnancies receiving either s.c. or oral inositol, no significant
difference was found between pregnancies treated with inositol 
and those receiving PBS alone (Table III).
To identify any adverse effects of inositol treatment on fetal 
outcome, fetal crown-rump length was measured, but no 
significant differences were found between treatment groups 
(Table III). An extensive pathological analysis o f treated 
fetuses was performed using both free-hand serial sectioning 
and skeletal preparation. This analysis confirmed the occur­
rence of spina bifida and tail defects in a proportion of fetuses 
(Figure 1D-G), as also scored by external fetal inspection. 
Additionally, exencephaly. a failure of cranial neural tube 
closure, was observed in a small proportion of fetuses (Table 
IV). Exencephaly is a recognized, infrequent defect in curly 
tail homozygotes (Embury et al., 1979). No overall increase or 
decrease in this defect was observed in inositol-treated fetuses 
compared with PBS controls, although the low frequency of 
affected fetuses may have obscured any treatment effect.
Internal and skeletal examination revealed almost no major 
structural defects, apart from NTDs (Table IV). For instance, 
no major malformations of the heart, lungs, kidney, gut, limbs 
or skeleton were identified. Of the morphological changes 
observed in the analysis, most were minor (e.g. small additional 
liver lobe) and the great majority occurred as frequently in 
PBS controls as in fetuses treated with inositol. D-chiro- 
inositol-treated fetuses (144 pg/g body weight per day) showed 
a somewhat elevated frequency of enlargement of the renal 
pelvis/ureter, rudimentary ribs on the seventh cervical vertebra 
and occurrence of anomalous cervical vertebrae (Table IV). 
although these trends were not statistically significant. Anomal­
ous cervical vertebrae was associated with exencephaly in 
several fitters, suggesting that cervical anomalies may form 
part of the spectrum of vertebral column defects present in the 
curly tail mouse.
Discussion
In the present study, the ability of exogenous inositol to prevent 
spinal NTDs in the folate-resistant curly tail mouse genetic
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F ig u re  2. (A) Exposure of curly tail embryos in culture to myo- (dark 
grey bars) or D-c/nro-inositol (black bars) causes a dose-dependent 
reduction in posterior neuropore length. Embryos treated with 
phosphate-buffered saline (PBS) (light grey bar; n = 16), 20 pg/ml 
myo-inositol (n = 16), or 5-10 pg/ml D-c/i/ro-inositol (n = 15 in 
each group) all exhibit mean neuropore lengths of -0 .6  mm, evidence 
of delayed posterior neuropore closure. Treatment with 50 pg/ml 
myo-inositol (n =  16) or 20-50 pg/ml D-c/nro-inositol (n = 18 and 
15 respectively) significantly reduced (P <  0.05) mean neuropore 
length to values typical of non-mutant embryos at this somite stage. 
(B) Administration of myo- or D-c/nro-inositol to pregnant curly tail 
females by slow release from s.c. implanted minipumps reduces the 
frequency of spina bifida at doses of 72 and 144 pg/g body weight per 
day, but not at 29 pg/g body weight per day. A similar preventive 
effect of inositol is seen with oral dosing at 800 pg/g body weight per 
day. For results of statistical analysis, see text.
model was evaluated. Maternal inositol administration signi­
ficantly reduced the frequency of spina bifida in curly tail 
mice and normalized closure of the posterior neuropore in 
whole cultured embryos. A striking finding was the increased 
potency of D-c/iiro-inositol compared with myo-inositol— two 
closely related enantiomers that differ only in the orientation 
of the carbon-two hydroxyl group (C2-OH) relative to the 
plane of the six carbon ring. At identical dosage levels, s.c. 
administered D-c/iiro-inositol caused a consistently greater 
reduction in frequency of spina bifida than myo-inositol. 
Moreover, in vitro, D-c/nro-inositol was effective in normaliz­
ing neural tube closure at a concentration at which myo-inositol 
had no effect.
Reasons fo r the differing potency o f myo- and D-chiro- 
inositol in preventing NTD
It was shown previously that the protective effect of myo­
inositol is mediated via the phosphoinositide cycle (Greene 
and Copp, 1997), which generates the second messengers 
inositol triphosphate and diacylglycerol (DAG) (Majerus, 
1992). Among the downstream events of this signalling path­
way, activation of protein kinase C (PKC) by DAG appears 
critical for normalization of neuropore closure in curly tail 
embryos. For instance, activation of PKC by phorbol esters 
mimics the effect of inositol supplementation, whereas PKC 
inhibitors abrogate the protective effect (Greene and Copp, 
1997).
It is possible that D-c/nro-inositol also acts through a PKC- 
dependent pathway, in which case the greater preventive 
effect of D-c/u'ro-inositol may result from its differential 
incorporation and metabolism within the phosphoinositide 
cycle. Insulin stimulation of rat fibroblasts expressing the 
human insulin receptor leads to a significant increase in the 
incorporation of D-c/nro-inositol into phospholipids, whereas 
the effect on myo-inositol incorporation is only marginal (Pak 
et al., 1993). Moreover, D-chiro-inositol induces a much larger 
reduction in plasma glucose level in rats rendered diabetic by 
streptozotocin administration compared with exogenous myo­
inositol (Ortmeyer et al., 1993). In humans, D-c/n'ro-inositol 
can increase the action of insulin in patients with polycystic 
ovarian syndrome, improving ovulatory function, reducing 
blood pressure, and decreasing blood androgen and triglyceride 
concentrations (Nestler et al., 1999). These findings suggest 
an inherently greater potency or bioactivity of D-chiro-inositol 
than mvo-inositol, perhaps as a result of incorporation into 
different phosphatidylinositol species (Pak and Lamer, 1992). 
It is striking, however, that these differences of in-vivo potency 
are maintained in the face of the demonstrated interconversion 
of the two inositol isomers (Pak et al., 1992). Perhaps the rate 
of interconversion is too low to obscure the inherently greater 
potency of D-chiro-inositol in short-term effects on embryonic 
development.
How does inositol normalize neural tube closure in curly 
tail mice?
Although the causative gene responsible for the curly tail 
defect is unknown (Van Straaten and Copp, 2001), the primary 
cellular abnormality leading to the development of spina bifida 
has been identified as a reduced rate of cell proliferation in 
the hindgut endoderm and notochord (Copp et al., 1988). The 
resultant growth imbalance between dorsal and ventral tissues 
causes excessive ventral curvature of the caudal embryonic 
region, which mechanically opposes closure of the posterior 
neuropore (Brook et al., 1991). Exogenous inositol treatment 
may correct the underlying cell proliferation defect in curly 
tail embryos. In support of this idea, inositol metabolism is 
known to be intimately involved with cell cycle progression 
in a variety of cell types. For instance, a nuclear polyphospho­
inositide cycle exists in which phosphatidylinositol-specific
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Table II. Frequency of neural tube and tail defects among curly tail fetuses treated in utero with myo- and 
D-c/u'ro-inositol
Dose
route
Treatment Inositol
dose3
No. of 
fetuses
Phenotype of fetuses*5"
Spina bifida Curly 
±  curly tail tail
Normal
s.c. PBS _ 25 6 (24.0) 14 (56.0) 5 (20.0)
myo 29 29 6 (20.7) 12 (41.4) 11 (37.9)
D-chiro 29 26 3 (11.5) 17 (65.4) 6(23.1)
PBS - 104 14 (13.5) 63 (60.6) 27 (25.9)
myo 72 67 4 (6.0) 37 (55.2) 26 (38.8)
D-chiro 72 86 2 (2.3) 39 (45.4) 45 (52.3)
PBS - 102 19 (18.6) 49 (48.0) 34 (33.3)
myo 144 94 8 (8.5) 52 (55.3) 34 (36.2)
D-chiro 144 99 5 (5.0) 46 (46.5) 48 (48.5)
Oral PBS - 44 8 (18.2) 21 (47.7) 15 (34.1)
myo 800 35 3 (8.6) 15 (42.9) 17 (48.6)
D-chiro 800 39 1 (2.6) 12 (30.8) 26 (66.7)
a|ig inositol/g body weight per day.
"Phenotype frequencies expressed as number of fetuses (% of total for treatment group).
"Statistical analysis: distribution of embryos among the three phenotype categories varies significantly with
treatment group at 72, 144 and 800 |ig inositol/g body weight per day (x* -tests, P = 0.0005, 0.0051 and
0.026 respectively) but not at 29 pg inositol/g body weight per day (P = not significant).
PBS =■ phosphate-buffered saline.
Table III. Survival of embryos and fetuses among curly tail litters treated in utero with myo- and D-c/u'ro-inositol
Dose route Treatment Inositol No. of No. of viable Mean fetal No. of uterine Mean litter
dose3 litters fetuses crown— rump resorptions" size3
length*5
s.c. PBS 4 25 22.3 ± 0.3 3 (10.7) 6.3 -  1.0
myo 29 4 29 21.8 ±  0.3 2 (6.5) 7.3 r  1.8
D-chiro 29 3 26 22.0 ±  0.3 1 (3.7) 8.7 ±  1.8
PBS - 12 104 21.4 ±  0.6 10 (8.8) 8.7 ±  0.5
myo 72 8 67 21.9 ±  0.2 7 (9.5) 8.4 ±  0.8
D-chiro 72 12 86 21.8 ±  0.2 8 (8.5) 7.2 ±  0.9
PBS 12 102 20.9 ±  0.3 9 (8 .1) 8.5 r  0.8
myo 144 12 94 21.4 ±  0.5 9 (8.7) 7.8 ±  0.4
D-chiro 144 14 99 21.6 ±  0.4 6 (5.7) 7.1 ±  0.8
Oral PBS - 7 44 22.3 ±  0.4 5 (10.2) 6.3 ±  0.4
myo 800 6 35 22.0 ±  0.3 3 (7.9) 5.8 ±  0.5
D-chiro 800 6 39 21.7 ±  0.2 3 (7.1) 6.5 ±  1.1
a|ig inositol/g body weight per day.
bCrown-rump length (mm; mean ±  SEM) measured on a subset of fetuses {n = 6-9 per group). Values do not differ significantly between treatments or dose 
levels.
cValues in parentheses are resorptions as % of total number of implantations (i.e. viable fetuses +  resorptions). Logistic regression analysis: the proportion of 
resorptions does not differ significantly between myo-inositol and PBS litters, between D-c/u'ro-inositol and PBS litters, or between inositol dose levels. 
dLitter size (mean no. of viable fetuses per litter ±  SEM) does not vary significantly with treatment group or inositol dose level. Although not statistically 
significant, litters treated with oral inositol contain an average of 1.6 (95% confidence intervals: 0.4—2.8) fewer fetuses than litters treated with s.c. inositol.
phospholipase C generates elevated levels of nuclear DAG 
specifically during G2 phase of the cell cycle (Sun et al., 
1997). This DAG production is required for the G2/M transition, 
perhaps by attracting specific activated PKC isozymes to the 
nucleus, where they are stabilized by binding to nuclear 
proteins including lamins A, B and C. The elevation of DAG 
levels is transient, as DAG is rapidly converted to phosphatidic 
acid by nuclear DAG kinases, enzymes that are also induced 
by growth-promoting agents (Martelli et al., 2000). It is 
possible that inositol treatment of curly tail embryos stimulates
this nuclear DAG cycle leading, via the activation of specific 
PKC isozymes, to the increased proliferation of hindgut and 
notochordal cells, so normalizing neural tube closure.
Relevance of the findings for clinical application of inositol 
therapy
In order for these experimental findings to be translated into 
a clinical application, inositol supplementation must be not 
only effective in preventing NTDs, but also safe for use during 
human pregnancy. The current demonstration of a protective
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Table IV. Pathological analysis of curly tail fetuses treated in utero with myo- and D-c/»'ro-inositola
Pathology Inositol dose (pg/g body weight per day)
PBSb myo D-chiro
72 144 72 144 72 144
Serial section analysis
No. of fetuses examined 27 17 11 21 24 19
Exencephaly ± open eye 1 (3.7) 2 (11.8) - 2 (9.5) - 1 (5.3)
Hydrocephaly 1 (3.7) - - 1 (4.8) - 1 (5.3)
Haemorrhage in/around brain - 2 (11.8) - 2 (9.5) - 1 (5.3)
Microphthalmia/macrophthalmia 1 (3.7) 1 (5.9) - - - -
Bleeding in thorax/abdomen 6 (22.2) 4 (23.6) 2 (18.2) - 2 (8.4) 1 (5.3)
Thyroid lobe reduction 1 (3.7) - - 1 (4.8) - -
Intrahepatic bleeding - 1 (5.9) 1 (9.1) 1 (4.8) - -
Small additional liver lobe 9 (33.3) 4 (23.5) 6 (54.5) 4 (19.0) 6 (25.0) 4(21.1)
Fissure in liver lobe - 2 (11.8) 1 (9.1) - - 1 (5.3)
Renal pelvis/ureter enlarged 1 (3.7) - - - 1 (4.2) 3 (15.8)c
Skeletal analysis
No. of fetuses examined 29 18 16 18 22 21
Exencephaly - - - 2 (11.1) - 2 (9.5)
Bony plaque in frontonasal suture 1 (3.4) - 1 (6.3) - - 1 (4.8)
Anomalous cervical vertebra(e) - - - - 1 (5.6) 4 (19.0)c
Rudimentary ribs on 7th cervical vertebra 4 (13.8) 2(11.1) 1 (6.3) 3 (16.7) 1 (4.5) 7 (33.3)c
Anomalous thoracic vertebrae and/or ribs - - - - - 2 (2.5)c
Rudimentary 14th ribs - 1 (5.6) - 1 (5.6) - 1 (4.8)
Sternal fusions 1 (3.4) - - - - 2 (9.5)
aSummary of most prevalent findings only are listed. A single fetus may have more than one morphological finding. Values are number of fetuses with defect 
(% of total for treatment group). A dash (-) indicates that no fetuses exhibited that finding.
bPBS dose levels 72 and 144 refer to saline controls performed contemporaneously with the stated dose levels of myo- and D-c/nro-inositol.
cProportion with defect does not differ significantly between fetuses treated with D-c/uro-inositol and PBS controls (144 pg/g body weight per day; Fisher’s
exact test; P >  0.05).
effect of inositol by s.c. and oral administration is supported 
by the results of previous studies in which myo-inositol was 
injected i.p. (Greene and Copp, 1997). Further support for the 
effectiveness of oral supplementation with myo-inositol comes 
from the finding of a reduction in the incidence of diabetes- 
induced abnormalities in rats by oral administration of myo­
inositol (Khandelwal et al., 1998). The efficacy of inositol in 
preventing human NTDs has not yet been tested in a clinical 
trial. Nevertheless, a recent case study has documented inositol 
supplementation in association with a normal outcome in the 
third pregnancy of a woman who had two previous consecutive 
NTD pregnancies despite taking 4 mg folic acid throughout 
the periconceptional period (Cavalli and Copp, 2002). The 
empirical recurrence risk of NTD following two previous 
affected fetuses is ~1 in 9 (Seller, 1981), so the association of 
inositol therapy with normal pregnancy outcome in this case 
may have been a chance association. A larger study of 
pregnancies at risk of ‘folate-resistant’ NTDs is needed, to 
test the idea that inositol may be as effective in humans as 
in mice.
With regard to the safety of inositol therapy during preg­
nancy, the present pathological study revealed no major defects, 
apart from NTDs, and no increase in the frequency of embry­
onic or fetal loss in utero in inositol-treated mice. The present 
study was limited, however, and in particular the effects of 
inositol administration during the periconceptional period—  
when inositol would be taken during a clinical trial—were not 
assessed. The reproductive toxicology of D-chiro-inositol has
been the subject of studies in rats and rabbits, with more 
extensive administration at doses up to 2000 mg/kg per day, 
and no adverse effects on mating, fertility or embryo/fetal 
development have been found (Insmed Inc., data on file). 
There is much less information available on the safety of 
inositol therapy in human pregnancy. In the case of the mother 
who took inositol in her third pregnancy following two 
apparently ‘folate-resistant’ NTD pregnancies, a dose of 0.5 g 
inositol per day was used, with no known side-effects for 
either mother or baby (Cavalli and Copp, 2002). In particular, 
there was no evidence of abnormal uterine contractions, such 
as have been suggested as a possible adverse effect of inositol 
therapy (Colodny and Hoffman, 1998). Myo-inositol has also 
been tested in adults for prevention of depression, panic 
disorder and obsessive compulsive disorder (Benjamin et al., 
1995; Levine et al., 1995; Fux et al., 1996) and in children 
for treatment of autism (Levine et al., 1997). No significant 
side-effects were reported in these studies, which employed 
relatively high inositol doses of up to 18 g per day in adults 
and 200 mg/kg in children.
In conclusion, D-c/u'ro-inositol has been shown to be highly 
effective in preventing folate-resistant mouse NTDs. A clinical 
trial could next evaluate the effectiveness of peri-conceptional 
inositol supplementation, as an adjunct to folic acid therapy, 
in preventing human NTDs. If folate-resistant NTDs can be 
prevented, in addition to those cases already prevented by 
folic acid, this could lead to a significant further reduction in 
the frequency of this birth defect.
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Specific isoform s of protein kinase C are 
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A proportion of neural tube defects (NTDs) can be prevented by maternal folic acid supplementation, although 
some cases are unresponsive. The curly tail mutant mouse provides a model of folate-resistant NTDs, in which 
defects can be prevented by inositol therapy in early pregnancy. Hence, inositol represents a possible novel 
adjunct therapy to prevent human NTDs. The present study investigated the molecular mechanism by which 
inositol prevents mouse NTDs. Activation of protein kinase C (PKC) is known to be essential, and we examined 
neurulation-stage embryos for PKC expression and applied PKC inhibitors to curly tail embryos developing in 
culture. Although all known PKC isoforms were detected in the closing neural tube, use of chemical PKC 
inhibitors identified a particular requirement for ‘conventional’ PKC isoforms. Peptide inhibitors offer selective 
inhibition of individual PKCs, and we demonstrated isoform-specific inhibition of PKC in embryonic cell 
cultures. Application of peptide inhibitors to neurulation-stage embryos revealed an absolute dependence on 
the activity of PKCpi and y for prevention of NTDs by inositol, and partial dependence on PKC£, whereas other 
PKCs (a, pll 5, and s) were dispensable. To investigate the cellular action of inositol and PKCs in NTD 
prevention, we examined cell proliferation in curly tail embryos. Defective proliferation of hindgut cells is a key 
component of the pathogenic sequence leading to NTDs in curly tail. Hindgut cell proliferation was stimulated 
specifically by inositol, an effect that required activation of PKCpl. Our findings reveal an essential role of 
specific PKC isoforms in mediating the prevention of mouse NTDs by inositol.
INTRODUCTION
Neural tube defects (NTDs) are common, severe birth defects 
with a multifactorial aetiology involving both genetic and 
environmental factors. In a proportion of cases, NTDs can be 
prevented by maternal peri-conceptional supplementation with 
folic acid (1,2). Around 30% of NTDs appear unresponsive to 
folic acid, however, and there is currently no preventive therapy 
available for these ‘folate-resistant’ defects. A large number of 
mouse genetic mutants exhibit NTDs and, as in humans, some 
of these are responsive to folic acid treatment whereas others 
are not (3,4). Mice homozygous for the curly tail mutation 
develop spina bifida that exhibits many similarities to the 
corresponding human NTD (5). NTDs in curly tail mice are 
folate-resistant (6), but we showed that the majority of NTDs in 
curly tail mice can be prevented by both myoinositol and its
D-chiro- enantiomer, either administered to pregnant females 
or directly to embryos in vitro (7,8). Our findings raise the 
possibility of developing a novel clinical therapy based on 
inositol. The recent observation that inositol therapy is well 
tolerated during human pregnancy at high risk o f NTD 
recurrence (9), encourages progress towards a clinical trial o f  
inositol.
The mechanism of action of inositol in preventing NTDs in 
curly tail mice involves activation o f PKC, a family of serine/ 
threonine kinases (7). The effect o f inositol can be mimicked 
by brief treatment of embryos with TPA (12-O-tetradecanoyl- 
phorbol-13-acetate), an agonist o f PKC. Moreover, the effect of 
inositol is blocked by co-administration o f a broad-spectrum 
chemical inhibitor of PKC (7). At least 10 isoforms o f PKC are 
known, grouped according to their dependence on diacylgly- 
cerol (DAG) and Ca2+ for activation (10). Conventional PKCs
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(cPKCs; a, (31, pil, y) require DAG and Ca2+, novel PKCs 
(nPKCs; 5, e, r|, 0) are DAG-sensitive but Ca2+-insensitive, 
and atypical PKCs (aPKCs; £» X and the related PKCp) are 
activated by neither DAG or Ca2+ (10).
To elucidate the molecular mechanism by which inositol 
normalizes neural tube closure, we determined which of the 
PKC isoforms mediate this effect. All known PKC isoforms 
could be detected during mouse neural tube closure, but culture 
of intact curly tail embryos in the presence o f isoform-specific 
PKC inhibitors identified PKCpi and y as essential for the 
normalizing action of inositol. Other PKC isoforms were not 
required. At the cellular level, inositol treatment was found to 
correct the deficit of cell proliferation that underlies NTD 
development in curly tail embryos (11), an effect that is 
blocked by inhibition of PKC (31. Moreover, treatment of 
cultured cells with either the PKC activator TPA or inositol 
itself, could induce translocation of PKC isoforms, including 
PKCpi and y to the nucleus. We conclude that PKCpi and y are 
essential components of the molecular mechanism underlying 
the preventive effect o f inositol on mouse NTDs.
RESULTS
cPKCX P
nPKO
aPKC< X.
Figure I. Developmental regulation of PKC isoform expression in mouse 
embryos from E9.5 to E l6.5. Sub-cellular protein fractions of whole embry-o 
homogenates were western blotted using isoform-specific anti-PKC antibodies. 
PKC isoforms exhibit varying patterns of developmental regulation ranging from 
limited expression in only the C fraction, at only the most advanced developmen­
tal stages (PKCa and P) to constitutive expression in all three fractions, through­
out the developmental period studied (PKCr|, C, X. and p). Abbreviations: A, 
P-actin control; C. cytoplasmic fraction: Co, Coomassie Blue stained loading 
control; MBr, mouse brain standard; Ps, soluble pelleted fraction (membrane 
associated); Pi, insoluble pelleted fraction. Experiment performed on two 
occasions with same result
PKC isoform expression during mouse embrvogenesis
In order to identify the isoforms that might play a role in 
prevention of NTD, we initially determined which PKC 
isoforms are expressed in mouse embryos undergoing 
organogenesis (E9.5 to E l6.5). Western blot analysis o f 
cytoplasmic (C), membrane-associated (Ps) and insoluble (Pi) 
fractions of embryonic cell extracts indicated the degree to 
which PKC isoforms are activated (i.e. associated with 
membrane or insoluble cellular compartments). All PKC 
isoforms could be detected, but their relative abundance varied 
with stage and cellular fraction (Fig. 1). cPKCs (a, P, y) were 
weak or undetectable in the cytoplasmic fraction at E9.5 and 
E10.5, although expression increased from El 1.5 onwards. 
Among the cPKCs, only PKCy was present in the Ps fraction 
from El 1.5 and in the Pi fraction at the latest stages. nPKCs 
(5, e, 0, r|) were expressed throughout the developmental 
period in both C and Ps fractions, whereas expression in the Pi 
fraction was more variable. aPKCs (X, £ and the related PKCp) 
were abundant from E9.5 onwards in all cellular fractions, with 
a fairly constant level o f expression. All PKC isoforms were 
also detected in mutant curly tail embryos with no consistent 
differences in abundance compared with non-mutant CD 1 mice 
(data not shown). Hence, the DAG-responsive cPKCs and 
nPKCs, which are likely to mediate the normalizing effect of 
inositol (6), exhibit evidence of stage-dependent activation 
unlike the aPKCs which appear ubiquitous and constitutively 
activated, as also described in other systems (12).
Western blot analysis was insufficiently sensitive to detect 
PKC isoform expression in specific embryonic regions, such as 
the posterior neuropore (PNP), the site o f spinal neurulation 
(13). We performed immunohistochemistry on histological 
sections through the PNP region, and detected expression of 
PKCs a, pi, pil, y and e in the closing neural tube, hindgut, 
notochord and presomitic mesoderm, at both E9.5 and E l0.5 
(Fig. 2). We conclude that although cPKCs, in particular, are
variably expressed in whole neurulation-stage embryos by 
immunoblotting, they can be detected in all tissues of the PNP 
region by immunohistochemistry and, therefore, are candidates 
for a role in mediating the preventive effect o f inositol on 
NTDs. Immunostaining was not carried out for the remaining 
isoforms as they were clearly detectable by western blot (Fig. 1).
Chemical PKC inhibitors block the protective effect 
of inositol on NTDs
We used PKC inhibitors to block the effect o f inositol on neural 
tube closure. Curly tail embryos were cultured from E9.5 to 
E l0.5, and the length o f unclosed neural folds at the PNP was 
then measured to indicate predisposition to spina bifida (13). 
Embryos exposed to PBS (vehicle) alone had enlarged PNPs 
(Fig. 3A), reflecting the in vivo development of spinal NTDs 
by 50-60% of curly tail embryos (5), whereas treatment with 
myo-inositol decreased PNP length significantly (first grey bar, 
Fig. 3A), to a value characteristic of normally developing 
embryos (5). Hence, inositol normalizes PNP closure in vitro, 
confirming previous findings (7,8). Curly tail embryos were 
exposed in culture to chemical inhibitors that block different 
combinations o f PKC isoforms. Bisindolylmaleimide I (BisI) 
inhibits PKC a, pi, pil, y and e (14), Go6976 inhibits solely 
cPKCs (15), HBDDE inhibits PKCa and y in vitro (16) and 
LY294002 is an inhibitor of phosphatidylinositol-3-kinase (17), 
an activator o f PKCC (18). When added alone, none o f the 
inhibitors significantly altered PNP length (white bars. Fig. 3A). 
Moreover, BisV, an inactive control, did not prevent the 
reduction in PNP length caused by co-administration o f inositol 
(second grey bar, Fig. 3A). In contrast, BisI, Go6976, HBDDE 
and LY294002 all partially blocked the normalizing effect of 
inositol, such that PNP length was reduced to a significantly 
lesser degree than in the presence o f inositol alone (black bars, 
Fig. 3A). Hence, use o f chemical inhibitors highlights the
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Figure 2. Ubiquitous expression of PKC isoforms during mouse spinal neuru­
lation, detected by immunohistochemistry. Transverse histological sections 
through the posterior neuropore region of curly tail mouse embryos at E9.5 
(A. D, G. J. M) and E10.5 (B. E. H. K. N) stained with antibodies specific 
for PKCat, pi, pil, y and c. All PKCs exhibit ubiquitous expression in the neural 
plate, notochord, hindgut and presomitic mesoderm of the posterior neuropore 
region. Sections of adult mouse cerebellum (C. F. I, L. O) provide a positive 
control for the isoform-specific PKC antibodies: anti-PKCa, y and c stain only 
Purkinje cells, whereas anti-PKCpi and pil stain only granule cells, as 
described previously for the rat cerebellum (46). Abbreviations: G. granule 
cells; H. hindgut; M, presomitic mesoderm; N, notochord; Np, neural plate; 
P. Purkinje cells. Scale bar represents 20 pm.
potential importance of PKCa, p, y ,  e and C in mediating NTD 
prevention by inositol.
Treatment Groups
Figure 3. Normalization of spinal neural tube closure by inositol in curlv tail 
embryos is abrogated by inhibition of specific PKC isoforms. (A) Chemical 
and (B) isoform-specific peptide PKC inhibitors were applied to curlv tail 
mouse embryos cultured from E9.5 for 24 h. followed by measurement of 
posterior neuropore (PNP) length, an indicator of predisposition to spinal 
NTD (13). White bars: PNP length of embryos exposed to PKC inhibitors 
in the absence of inositol; grey bars: PNP length of embryos exposed to 
PKC inhibitors in the presence of inositol; black bars: PNP length in the pre­
sence of PKC inhibitor plus inositol as a % of the value in the presence of 
PKC inhibitor alone (right axis). (A) Inositol significantly reduces PNP length 
in the absence of inhibitor (PBS; P< 0.001) and in the presence of inactive 
BisV (P< 0.002), whereas the inositol effect is abrogated in the presence of 
chemical inhibitors BisI. Go6976, HBDDE and LY294002 (/>>0.05). (B) 
Inositol significantly reduces PNP length in the absence of inhibitor (PBS; 
P<  0.001) and in the presence of inactive peptide (Pept) or peptide inhibitors 
to PKC % fill I. 6 (P< 0.005) and f: (/>< 0.05), whereas the inositol effect is 
abrogated by inhibitors to PKCpi, y and C (P > 0.05). There is no effect on 
PNP length of either chemical or peptide inhibitors in the absence of inositol 
(analysis of variance, P > 0.05).
Peptide inhibitors identify a critical role for PKCpi, 
y and £ in the inositol effect
Because of the relatively broad spectrum activity of chemical 
PKC inhibitors, we next applied isoform-specific peptide PKC 
inhibitors to cultured curly tail embryos, to more precisely 
define the PKC isoform requirement for the inositol effect. 
Each peptide inhibitor was designed to the amino acid
sequence corresponding to the isoform-specific RACK (recep­
tor for activated C kinase) binding site on PKC. Inhibitors of 
this type prevent PKC translocation and/or activation in an 
isoform-specific manner (19,20). Peptide inhibitors were 
coupled to a sequence derived from the Drosophila 
Antennapedia homeodomain, ensuring cell permeability.
As with the chemical inhibitors, peptide PKC inhibitors 
alone had no significant effect on PNP length. Moreover,
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the normalizing effect of inositol on PNP length persisted in the 
presence of inhibitors for PKCa, (311, 5 and e, as well as an 
inactive peptide (Fig. 3B). Strikingly, however, the co-addition 
with inositol of inhibitors for PKC(31 or y largely abolished the 
normalizing effect of inositol (black bars in Fig. 3B). Inhibition 
of PKCC also partially blocked the normalizing action of 
inositol. These findings are consistent with the results from use 
of the chemical inhibitors, and indicate that the cPKCs, pi and 
y, and additionally PKCC, are critical for mediating the 
preventive effect of inositol.
Activation of PKC isoforms in embryonic mouse cells 
is blocked by peptide inhibitors
One possible explanation for the apparently isoform-specific 
PKC requirement for inositol action is that (31, y and C are the 
only isoforms whose activation is blocked by peptide inhibitors 
in curly tail embryonic cells. To test this idea, primary 
fibroblastic cell cultures, prepared from caudal regions of E9.5 
curly tail embryos were serum-starved, and then treated with 
the PKC agonist, TPA, in the presence or absence of peptide 
PKC inhibitors. Prior to TPA treatment, each PKC isoform 
exhibited cytoplasmic localization (Fig. 4A, D, G, J and M) 
but, following TPA treatment, all isoforms translocated to the 
nucleus (Fig. 4B, E, H, K and N), indicative o f activation. In 
every case, addition of the appropriate peptide inhibitor 
blocked this TPA-induced translocation indicating that PKC 
activation had been prevented (Fig. 4C, F, I, L and O). Closely 
similar results were obtained with the mouse 3T3 cell line (data 
not shown).
In view of the close relationship between PKCpi and its 
alternatively spliced variant PKC (311, we tested whether 
abrogation o f the inositol effect by the PKCpi inhibitor might 
have resulted from antagonism of both PKCpi and pil 
activation. PKCpi translocated to the nucleus following TPA 
stimulation, and this translocation was blocked by the pi 
inhibitor, but not by the pil inhibitor (Fig. 5A-C). Conversely, 
translocation of PKC (311 was blocked by the pil inhibitor but 
not the pi inhibitor (Fig. 5D-F). This finding confirms that the 
peptide inhibitors of PKCpi and pH are indeed isoform-specific 
and suggests separate roles for these splice variants. We 
conclude that the requirement for specific PKC isoforms is 
unlikely to reflect differential activity of the peptide inhibitors, 
but may reflect a difference in participation of PKC isoforms in 
the action of inositol in preventing mouse NTDs.
To determine whether the PKC stimulation observed after 
TPA treatment also follows inositol administration, we studied 
PKC localization after inositol treatment. Inositol treatment 
was capable of inducing the translocation of PKCa from the 
cytoplasm, as in serum-starved cells, to the nucleus (Fig. 5G 
and H). Similarly, PKCpi and y, isoforms whose activity is 
essential for prevention of NTD, were also found to exhibit 
nuclear localization in inositol-treated but not in untreated cells 
(data not shown). No difference in the localization o f PKCC 
could be detected after 6 h inositol treatment (50 pg/ml), but we 
cannot rule out the possibility that PKCC is activated at a 
different dose or at a different time point. This observation 
suggests that PKCa, pi and y can be activated by inositol 
treatment. However, PKCa is not required for prevention of 
NTD whereas PKCpi and y are essential.
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Figure 4. Inhibition of PKC isoform translocation by peptide inhibitors in TPA- 
treated mouse embryonic cells. Immunocytochemistry using isoform-specific 
antibodies to PKC (as in Fig. 2) in curly tail primary embryonic cell cultures. 
Cells cultured for 18 h in growth medium containing l0/o FCS were either fixed 
with no additional treatment ('serum starved': A. D. G. J. M), exposed to 
lOOpM TPA for lOmin prior to fixation (+TPA; B, E, H. K. N), or exposed 
to 1 mM isoform-specific PKC inhibitor for 20min and to TPA for lOmin prior 
to fixation (TPA +  Inhib; C. F. I. L. O). PKCs are uniformly located in the 
cytoplasm of serum starved cells whereas a lOmin treatment with TPA induces 
translocation to the nucleus in all cases. Pre-treatment with isoform-specific 
PKC inhibitors prevents TPA-induced translocation and all PKC isoforms exhi­
bit cytoplasmic staining. Inset in (O) shows same field stained with DAPI to 
demonstrate nuclei. Scale bar represents 20 pm.
Embryonic cell proliferation is stimulated by inositol, 
in a PKC(31-sensitive manner
Delayed closure of the PNP in curly tail embryos results from a 
reduced rate of cell proliferation, specifically in the embryonic 
hindgut, within the caudal region (3,11,21,22). The resulting 
proliferation imbalance causes ventral curvature of the caudal 
region, counteracting the apposition of the neural folds, and 
leading to spina bifida (23,24). The effect of inositol on cell 
proliferation was examined by immunohistochemistry for 
PCNA (proliferating cell nuclear antigen) and phospho-histone 
H3, markers o f S-phase and M-phase of the cell cycle 
respectively. A significant stimulatory effect o f inositol on
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Figure 5. Inositol stimulates PKC translocation, whereas peptide inhibitors to 
PKCPI and pil exhibit isoform-specificity in blocking translocation. PKC 
isoforms were localized by immunocytochemistry on primary cell cultures 
established from curly tail mouse embryos. Serum starved cells exhibit 
PKCpi and pil immunoreactivity in the cytoplasm. TPA-induced translocation 
to the nucleus of PKCpi can be blocked by the pi inhibitor (C) but not by the 
pil inhibitor (B). Conversely, translocation to the nucleus of PKCpiI can be 
blocked by die inhibitor to pil (E) but not by the inhibitor to pi (F). 
Addition of 50 pg/ml myo-inositol to serum starved cells 6 h prior to fixation 
induces translocation of PKCa to the nucleus (H) whereas PKCa is cytoplas­
mic in untreated cells (G). This effect of inositol is not unique to curly tail cells 
as similar results were obtained in 3T3 cells. Scale bar represents 20 pm.
the percentage of PCNA-positive (Fig. 6A) and histone 
H3-positive (Fig. 6B) cells was detected in the hindgut, 
whereas inositol treatment had no effect on either proliferation 
marker in the neuroepithelium or notochord (Fig. 6A and B). 
Co-administration of the PKCpi peptide inhibitor blocked the 
stimulatory effect of inositol on hindgut proliferation, whereas 
the PKCs inhibitor had no effect. Neither inhibitor significantly 
altered proliferation in neuroepithelium or notochord. Hence, 
inositol overcomes the genetically-determined defect of cell 
proliferation in curly tail embryos, an effect that requires 
activation of PKCpi.
DISCUSSION
Inositol normalizes neural tube closure in the spinal region of 
curly tail mouse embryos destined to develop spina bifida (7), 
whereas folic acid has no preventive effect (6). Brief treatment 
with the PKC agonist TPA mimics the inositol effect, whereas 
the PKC inhibitor BisI abrogates inositol-mediated prevention 
(7). Here, we used other chemical PKC inhibitors, with 
reportedly narrower spectra of action, and showed that these are
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Figure 6. Inositol stimulates hindgut cell proliferation during NTD prevention, 
an effect requiring activation of PKCpi but not PKCe. Cell proliferation 
was measured in tissues of the posterior neuropore region of cultured curly 
tail embryos by (A) PCNA labelling, a measure of cells in S-phase and (B) 
phospho-histone H3 labelling, a marker of mitotic cells. Cell proliferation is 
most rapid in neuroepithelium, less intense in hindgut endoderm and slowest 
in notochord, as described previously (11). Inositol significantly stimulates 
PCNA labelling (P  < 0.005) and histone H3 labelling (P < 0.02) in hindgut 
endoderm, whereas inositol has no significant effect on PCNA or histone H3 
labelling in either neuroepithelium or notochord (P > 0.05). In hindgut endo­
derm, inhibition of PKCpi significantly reduces histone H3 labelling compared 
with inositol alone (P < 0.05), whereas inhibition of PKCe has no significant 
effect (P > 0.05). Blocking PKCpi or e has no significant effect on histone 
H3 labelling in neuroepithelium or notochord (P > 0.05). No cells were positive 
for histone H3 in the presence of inositol and the PKCpi inhibitor (Fig. 6B, 
notochord data, bar 5). Labelling indices are mean ±  SEM of at least 10 
embryos per treatment.
also able to block the inositol effect. However, the precise 
specificity of chemical PKC inhibitors may vary between cell 
types. For example, HBDDE is specific for PKCa and y in vitro 
(16), but acts on other molecular targets in cerebellar granule 
neurons (25). This prompted the use of peptide PKC inhibitors 
which were able to block the translocation of specific PKC 
isoforms. Isoform-by-isoform analysis using these inhibitors 
revealed a requirement for PKCpi, y and £, but not other PKCs 
in the normalization of neural tube closure in curly tail 
embryos.
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Developmental regulation of PKC isoform expression
We detected all PKC isoforms, during mouse development 
from E9.5 to E l7.5, in agreement with previous analysis o f  
PKCs in E l5-17 fetuses (26). Our findings contrast with a 
study o f E l0.5 embryos that detected PKCa, 6 and £, but not 
pi, pil, y and s (27). This difference may reflect the 
low abundance o f cPKCs on western blot, at early stages 
(E9.5-11.5) in particular, although all isoforms were clearly 
detectable in the PNP region by immunohistochemistry. Each 
PKC isoform exhibited a distinct distribution between 
sub-cellular fractions, which likely reflects the degree of  
activation. For instance, cPKCs were confined to the cytoplas­
mic fraction, suggesting minimal activation during undisturbed 
development, whereas aPKCs were present in membrane- 
associated and insoluble fractions throughout development, 
suggesting constitutive activation, as described in other systems 
(12). This finding is consistent with a role for the cPKCs, pi 
and y, in mediating the preventive effect o f inositol, since 
activation o f these isoforms may be limiting in the absence of 
inositol, providing capacity for activation after treatment.
PKC isoforms and cell cycle regulation
We have demonstrated that inositol stimulates cell proliferation 
in the hindgut o f curly tail embryos, reversing the imbalance of 
cell proliferation that is known to lead, via enhanced ventral 
curvature o f the caudal region, to delay or failure o f PNP 
closure (11,23,24,28). Moreover, PKCpi but not PKCe is 
required for this stimulation o f cell proliferation. PKCpi has 
been previously associated with increased cell cycle entry. 
Its over-expression leads to increased proliferation o f aortic 
endothelial cells, in contrast to PKCa which has an inhibitory 
effect (29). Similarly, proliferation o f vascular smooth muscle 
cells is stimulated by PKCpi, through increased S-phase entry, 
but inhibited by PKCpiI, through extension o f S-phase (30). 
S-phase entry/progression has been suggested to be defective in 
hindgut cells o f curly tail embryos (11), raising the possibility 
that activation o f PKCpi may reverse this defect, leading to 
‘rescue’ o f the mutant phenotype. Interestingly, inositol 
treatment o f cells for 6h  resulted in nuclear translocation o f  
PKCpi and y in some cells, as observed for short-term 
exposure to TPA. This nuclear localization suggests that a role 
o f PKCpi in cell cycle regulation is plausible. PKCa also 
exhibits nuclear translocation in inositol-treated cells (both 
curly tail and non-mutant), but does not play an essential role in 
the prevention o f NTD.
Molecular basis of the requirement for PKC£ 
and PI3-kinase
The normalizing effect o f inositol on PNP closure was partially 
blocked by inhibition o f PKCC or PI3-kinase. The requirement 
for PKCC may reflect a role in regulating other PKC isoforms 
(31). PKCC is activated downstream o f PI3-kinase (18), whose 
activity in turn depends on availability o f phosphatidylinositol 
species. Hence, inositol administration may activate both 
PI3-kinase and PKCC, by increasing flux through intracellular 
phosphoinositide metabolism. Indeed, inhibition o f the inositol 
phosphate cycle by lithium blocks the preventive effect o f
inositol (7). The requirement for PI3-kinase may also be 
explained by its participation, with 3-phosphoinositide- 
dependent protein kinase-1 (PDK1) (32), in phosphorylation 
o f the T-loop o f  the kinase domain, a requirement for activity 
o f PKCs (33). Although we detected nuclear translocation o f  
PKCa, pi and y following treatment o f cells with inositol for 
6 h, altered localization o f  PKCC was not detected. This could 
be simply due to suboptimal dose or period o f  treatment 
(activation could be short-lived), but it is also likely that PKCC 
activation occurs by a different mechanism to the classical 
isoforms as PKCC is not diacylglycerol-responsive. Moreover, 
the partial requirement for PKCC in the protective effect o f  
inositol may reflect a permissive role for PKCC activity that 
does not involve translocation to the nucleus.
Is PKC implicated in the mechanism of 
neural tube closure?
Several lines o f  evidence suggest that spinal neurulation per se 
does not depend on PKC activation and that defective closure 
in curly tail embryos is unlikely to result from an intrinsic 
deficiency in specific PKC isoforms. First, exposure o f  curly 
tail embryos to PKC inhibitors, in the absence o f  inositol, did 
not affect PNP closure. Similar findings were obtained with 
non-mutant CD 1 embryos (data not shown). Second, there is no 
difference in abundance o f PKC isoforms between affected and 
unaffected curly tail embryos (data not shown). Third, uptake 
and incorporation o f 3H-inositol occurs similarly in cultured 
curly tail and non-mutant embryos, while inositol deficiency 
in vitro does not increase the penetrance o f  spinal NTDs in 
curly tail embryos (7). Finally, mice with targeted inactivation 
o f the genes encoding PKCa, p, y, 5, e and C do not exhibit 
neurulation defects (34-39). We suggest, therefore, that 
prevention o f  NTDs in curly tail mice by exogenous inositol 
operates via stimulation o f the cell cycle in the embryonic 
hindgut, an effect that requires activation o f specific PKC 
isoforms. Inositol is also reported to prevent NTDs in animal 
models o f diabetes (40), whereas inositol deficiency causes 
cranial NTD, even in non-mutant mice (41). It remains to be 
determined whether the protective action o f  inositol also 
involves stimulation o f cell proliferation in these cases.
MATERIALS AND METHODS
Mouse strains and embryo culture
Curly tail mice were maintained as described (5). Non-mutant 
random-bred CD1 mice were purchased from Charles River, 
UK. Mice were paired overnight and females checked for 
copulation plugs the following morning, designated embryonic 
day (E) 0.5. Embryos were explanted at E9.5 and those with 
17-19 somites were cultured for 24 h in rat serum (6). Embryos 
were randomly allocated to treatment groups to minimize the 
effect o f  litter-to-litter variation. Cultures were supplemented 
with 1% (v/v) additions o f phosphate buffered saline (PBS) or 
mvo-inositol (50 pg/ml, final concentration). PKC inhibitors 
were added as 1% (v/v) additions. Bisindolylmaleimide (Bis) I 
and V, Go6976, HBDDE and LY294002 (all from Calbiochem) 
were diluted in minimal volumes o f DM SO, further diluted in
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PBS, and added to cultures at final concentrations correspond­
ing to their IC50 values (14-17): 10 pM (BisI, BisV, Go6976), 
50 pM (HBDDE) or 1.4 pM (LY294002). DMSO diluted in PBS 
was added to control cultures. Peptide PKC inhibitors (supplied 
by Dr D. Mochly-Rosen) were added to embryo cultures to 
final concentrations o f 1 pM: PKCaC2-4, PKCPIV5-3, 
PKCPIIV5-3, PKCyC2-4, PKC5V1-1; PKCeVl-2 and PKCC 
(pseudosubstrate region) (19,42^45). An Antennapedia peptide 
dimer served as an inactive control.
Statistical analysis
Comparison of multiple experimental groups was carried out 
by one way analysis o f variance or by Kruskal-Wallis test (for 
data that were not normally distributed). Where significant 
variation was detected, multiple pairwise comparisons were 
performed by Tukey t-test or by Dunn’s test. A value of 
P  < 0.05 was considered significant where the power of the test 
exceeded 0.8. Statistical tests were computed using SigmaStat 
2.03 software.
Western blot of PKC isoforms
Embryos were homogenized in ice cold buffer (60 mM Tris/ 
HC1, pH 7.5, 0.25 m sucrose, 10 mM EGTA, 5mM EDTA, 
500 pM leupeptin, 1 mM PMSF, 0.1 U/ml aprotinin, 1 mM 
dithiothreitol, lOOpM sodium vanadate, 50 pM sodium fluor­
ide) and prepared as sub-cellular fractions: centrifugation at 
lOOOOOg for 30min yielded a supernatant (C fraction). The 
pellet was resuspended in homogenization buffer containing 
1% Triton X-100, and spun at 40000g for 15min., yielding a 
second supernatant (Ps-fraction) and a pellet (Pi-ffaction). 
Samples were western blotted with mouse monoclonal IgGs for 
specific PKC isoforms (Transduction Laboratories), diluted as: 
a, 1 :1000; P, 1 :250; y, 1:5000; 5, 1 :500; e, 1:1000; i l l ,
1 :250; p, 1 :250; 0, 1 :250; £, 1: 1000, or rabbit polyclonal 
anti-PKC r\ (1:2000; Sigma). Constant protein loading was 
confirmed in parallel blots probed with rabbit anti-P-actin 
(1:5000; Sigma). Blots were exposed to horseradish 
peroxidase-linked rabbit secondary antibodies and visualized 
by ECL detection system (Amersham Bioscience). Positive 
controls were C-fraction from adult male CD1 mouse brain or 
spleen.
Immunohistochemistry
E9.5-10.5 embryos were fixed in 4% paraformaldehyde (PFA), 
embedded in paraffin wax and sectioned at 6 pm. Sections were 
re-fixed in 4% PFA then exposed to rabbit IgG primary antibodies 
to PKCa, pi, pil, y or e (1:200; Santa Cruz Biotechnology), anti- 
PCNA (1 :100; Santa Cruz Biotechnology) or anti-phospho- 
histone H3 (1: 100; Upstate Biotechnology). After washing in 
PBS, 0.1% BSA, 0.05% Triton X-100, sections were exposed to 
FITC-linked secondary antibodies (1:40; Jackson Immuno 
Research). Controls included non-specific rabbit IgG [R&D 
Systems, 1 : 100 dilution in 10% foetal calf semm (FCS) in PBS] 
in place of primary antibody or pre-absorption o f primary 
antibody with blocking peptides. Both yielded no signal. 
Labelling indices (number of labelled cells/total cell 
number x 100) were obtained from alternate transverse sections
through the rostral end of the PNP (i.e. the region o f maximal 
neural fold elevation) stained for PCNA or histone H3. 
Experiments were carried out in triplicate by an observer blinded 
to treatment type.
Primary embryonic cell cultures
The trunk distal to the forelimb bud was removed from 15 
curly tail embryos (average stage: 27 somites), disrupted 
mechanically and dissociated by 20min incubation at room 
temperature in F10 medium containing 0.12% w/v sodium 
bicarbonate, 10 mM HEPES, pH 7.4, 1 mg/ml trypsin, 1.5 mg/ml 
collagenase. After trituration, the suspension was passed through 
a Nitex filter and centrifuged for 5 min at 1000g. Pelleted cells 
were resuspended in 5 ml growth medium (Dulbecco’s Modified 
Eagle’s Medium, 100 units/ml penicillin, lOOpg/ml streptomy­
cin) containing 10% v/v FCS, then seeded onto tissue culture 
dishes and cultured at 37°C in 5% C 0 2. For experiments, 104 
cells (passage 5) were seeded onto glass cover slips coated with 
poly-L-lysine and fibronectin, cultured for 5 h in growth medium 
containing 10% FCS, and transferred to growth medium 
containing 1% FCS for 18 h (‘semm starvation’). Cells received 
either: (i) lOOmM TPA, 10 min prior to fixation in 4% PFA; (ii) 
lOOmM isoform-specific peptide PKC inhibitor, 20 min prior to 
fixation, then 100mM TPA, 10 min prior to fixation; (iii) 50 pg/ 
ml myo-inositol, 6 h prior to fixation; or (iv) no treatment. For 
analysis o f the effect of inositol, parallel experiments were 
carried using 3T3 cells. Cells were processed for immunohis­
tochemistry as above and analysed in triplicate by an observer 
blinded to treatment type.
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